<!DOCTYPE html>

<html lang="fa">
<meta content="text/html;charset=utf-8" http-equiv="content-type"/>
<head><title>Fentanyl: Pediatric drug information</title><link href="/d/css/bootstrap.min.css" rel="stylesheet"/><link href="/d/css/icofont.min.css" rel="stylesheet"/><link href="/d/css/classy-nav.min.css" rel="stylesheet"/><link href="/d/css/animate.css" rel="stylesheet"/><link href="/d/css/owl.carousel.css" rel="stylesheet"/><link href="/d/css/magnific-popup.css" rel="stylesheet"/><link href="/d/css/owl.theme.default.min.css" rel="stylesheet"/><link href="/d/css/style.css" rel="stylesheet"/><link href="/d/css/rtl_edited.css" rel="stylesheet"/><link href="/d/css/responsive.css" rel="stylesheet"/><link href="https://medilib.ir/uptodate_assets/main.css" rel="stylesheet">
<style>

#myUL {
  list-style-type: none;
  padding: 0;
  margin: 0;
}

#myUL li a {
  border: 1px solid #ddd;
  margin-top: -1px; /* Prevent double borders */
  background-color: #f6f6f6;
  padding: 12px;
  text-decoration: none;
  font-size: 16px;
  color: black;
  display: block
}

#myUL li a:hover:not(.header) {
  background-color: #eee;
}

#searchResult {

  list-style-type: none;
  padding: 0;
  padding-right: 20px;
}

#searchResult li a {
  border: .5px solid #ddd;
  margin-top: -1px; /* Prevent double borders */
  background-color: #79bc21;
  padding: 7px;
  text-decoration: none;
  font-size: 14px;
  color: white;
  display: block
}

#searchResult li a:hover:not(.header) {
  background-color: #222;
}


#txtHint   {
  position: absolute;
  text-shadow: none;
  width: 100%;
  margin-top: -15px;
  padding-right: 10px;

  filter: alpha(opacity=95);
  -moz-opacity: 0.95;
  opacity: 1;
  z-index: 200;
}
.countBubl {
  background:#eb0029;
  color:#fff;
  padding:5px;
  margin-top: 50%;

}
.uptodate-area > div:nth-child(1) > div:nth-child(1) > div:nth-child(1) > span:nth-child(1) > img:nth-child(2) {
 width: 55%;
 padding-left: 20px;
}
.uptodate-area > div:nth-child(1) > div:nth-child(1) > div:nth-child(1) > span:nth-child(1) > img:nth-child(3) {
 width: 20%;
}
 #Uptodate_image {
      width: 50%;
  }#uptodate-area {
      /*z-index: 99;*/
  }
#uptodate-area > div:nth-child(1) > div:nth-child(1) > div:nth-child(1) > div:nth-child(2) {
 margin-left: 10px;
 margin-bottom: 6%;
}
@media (max-width: @screen-xs) {
    .countBubl {
        font-size: 4px ;
    }
    #uptodate_version {
        font-size: 4px ;
    }
}

@media (max-width: @screen-sm) {
    .countBubl {
        font-size: 14px ;
    }
}
@media  all and(max-width: 820) {
    #Uptodate_image {
        width: 80% ;
    }#uptodate-area {
        z-index: 99;
    }
}@media  all and (min-width: 820) and(max-width: 88820){
    #Uptodate_image {
        width: 100% !important;
    }
    .countBubl {
        font-size: 4px ;
    }
}
div.col-md-3:nth-child(3) {
 margin-top: 6%;
}

div.col-md-3:nth-child(3) > img:nth-child(1) {
 width: 100%;
 margin-left: 11px;
}

</style>
<style media="screen" type="text/css">
  .goback {
    width: 200px;
    height: 40px;
    line-height: 40px;
    position: fixed;
    display: none;
    font-size: 15px;
    background: #71c0fa;
    z-index: 1000;
    text-align: center;
    color: #ffffff;
    -webkit-border-radius: 1px;
    -moz-border-radius: 1px;
    border-radius: 50px;
    bottom: 3.8%;
    right: 2%;
}
  .buyPackage {
  width: 100px;
  height: 100px;
  line-height: 40px;
  position: fixed;
  display: none;
  font-size: 10px;
  background: #fa759e;
  z-index: 1000;
  text-align: center;
  color: #ffffff;
  -webkit-border-radius: 1px;
  -moz-border-radius: 1px;
  border-radius: 10px;
  top: 150px;
  right: 2%;
  text-align: center;
}
.uptodate-area {
  /*background-image: url(../../assets/img/news-letter-bg.jpg);*/
  background-position: center center;
  background-size: cover;
  background-repeat: no-repeat;
    background-attachment: fixed;
  position: relative;
}
.uptodate-area::before {
  content: '';
  position: absolute;
  left: 0;
  padding-top: 100px;
  width: 100%;
}
#references{
  display: none;
}
</style>
<style>
section.sticky {
  position: sticky;
  top: 0;
  background-color: #fff !important;
  /*z-index: 100;*/
  /*padding-top: 80px;*/

}
.m4inb{
    border: solid !important;
  }

  .newsletter-area::before {
       background: unset !important;
  }
p {
    color: #555;
}
</style>

<meta content="" name="description"/>
<link href="/d/img/favicon.png" rel="icon" type="image/png"/>
</link></head>
<body>
<!-- Start Main Menu Area -->

<br/>
<br/>
<br/>
<br/>
<div class="container">
<div class="row">
</div>
</div>




<section class="teacher-area ptb-10">
<div class="container">
</div>

<section class="course-details-area ptb-60">
<div class="container">
<div class="uptodate2" style="padding:50px 0px 50px 0px;direction: ltr;text-align: left;">
<h1 style="text-align:center">Fentanyl: Pediatric drug information</h1>
<div class="utdArticleSection utdStyle" id="topicContent"><div id="drugTitle">Fentanyl: Pediatric drug information</div><div class="clear"></div><div id="topicText">(For additional information <a class="drug drug_general" data-topicid="8441" href="/d/html/8441.html" rel="external">see "Fentanyl: Drug information"</a> and <a class="drug drug_patient" data-topicid="12468" href="/d/html/12468.html" rel="external">see "Fentanyl: Patient drug information"</a>)<br/><br/>For abbreviations, symbols, and age group definitions used in Lexicomp (<a class="graphic graphic_table" href="/d/html/57469.html" rel="external">show table</a>)<div class="block spa drugH1Div" id="F58073952"><span class="drugH1">Special Alerts</span>
<div class="collapsible">
<span class="collapsible-title">FDA Requiring Updates to Opioid Prescribing Information</span>
<span class="collapsible-date">April 2023</span>
<div class="collapsible-wrap">
<p style="text-indent:0em;">The FDA has issued a drug safety communication to announce safety-related updates to the prescribing information for immediate-release (IR) and extended-release (ER)/long-acting (LA) opioid analgesics, including updates to Boxed Warnings, Indications and Usage, Dosage and Administration, Warnings and Precautions, and the Medication Guide. These safety labeling changes are intended to provide clarity on appropriate patient populations for opioid treatment, appropriate dosage and administration, and updated information on the risks associated with opioid use. The required safety labeling changes include stating:</p>
<ul>
<li>
<p style="text-indent:0em;">the risk of overdose increases as the dosage increases for all opioid pain medicines;</p></li>
<li>
<p style="text-indent:0em;">IR opioids should not be used for an extended period of time unless a patient's pain remains severe enough to require them and alternative treatment options continue to be inadequate;</p></li>
<li>
<p style="text-indent:0em;">many acute pain conditions treated in the outpatient setting require no more than a few days of an opioid pain medicine;</p></li>
<li>
<p style="text-indent:0em;">it is recommended to reserve ER/LA opioid pain medicines for severe and persistent pain that requires an extended treatment period with a daily opioid pain medicine and for which alternative treatment options are inadequate; and</p></li>
<li>
<p style="text-indent:0em;">a warning about opioid-induced hyperalgesia (OIH), including information on differentiating OIH symptoms from those of opioid tolerance and withdrawal.</p></li></ul>
<p style="text-indent:0em;">Further information may be found at <a href="/external-redirect?target_url=https%3A%2F%2Fwww.fda.gov%2Fdrugs%2Fdrug-safety-and-availability%2Ffda-updates-prescribing-information-all-opioid-pain-medicines-provide-additional-guidance-safe-use&amp;token=W5X7myh%2Fi%2FQGr76L%2FoSZbu%2BwYKvRHJDB8O4e79tNg%2FJelrlNqz4gv2DJCwSZVkI3gE10g96a4t1z3Z59rSO%2Fb6izsjmacse6U4o7Ho29jYziQVHf0MYzW7j8%2B8LrQ2%2B4Ru4vvCtWrdS3FrWL%2B0kz4ajIBlnws%2B6VB3AxZWaliq8%3D&amp;TOPIC_ID=13298" target="_blank">https://www.fda.gov/drugs/drug-safety-and-availability/fda-updates-prescribing-information-all-opioid-pain-medicines-provide-additional-guidance-safe-use</a>.</p></div>
</div>
</div>
<div class="block black-box-warn drugH1Div" id="F5708780"><span class="drugH1">ALERT: US Boxed Warning</span>
<div class="collapsible">
<span class="collapsible-title">Life-threatening respiratory depression:</span>
<div class="collapsible-wrap">
<p style="text-indent:-2em;margin-left:2em;">Buccal, intranasal, lozenge, sublingual, transdermal iontophoretic system: Serious, life-threatening, or fatal respiratory depression has occurred with use of fentanyl, including following use in opioid non-tolerant patients and improper dosing. Evaluate patients for respiratory depression, especially during initiation of fentanyl or following a dosage increase. To reduce the risk of respiratory depression, proper dosing and titration of fentanyl are essential. The substitution of fentanyl buccal, intranasal, lozenge, or sublingual for any other fentanyl product may result in fatal overdose. Due to the risk of respiratory depression, fentanyl buccal, intranasal, lozenge, and sublingual are contraindicated in the management of acute or postoperative pain including headache/migraine and in opioid non-tolerant patients. Only the patient should activate Ionsys dosing.</p>
<p style="text-indent:-2em;margin-left:2em;">Parenteral, transdermal (Duragesic): Serious, life-threatening, or fatal respiratory depression may occur with use of fentanyl, especially during initiation or following a dosage increase. To reduce the risk of respiratory depression, proper dosing and titration of fentanyl parenteral and transdermal system are essential.</p></div>
</div>
<div class="collapsible">
<span class="collapsible-title">Addiction, abuse, and misuse:</span>
<div class="collapsible-wrap">
<p style="text-indent:-2em;margin-left:2em;">Because the use of fentanyl exposes patients and other users to the risks of opioid addiction, abuse, and misuse, which can lead to overdose and death, assess each patient's risk prior to prescribing and reassess all patients regularly for the development of these behaviors and conditions.</p></div>
</div>
<div class="collapsible">
<span class="collapsible-title">Accidental exposure:</span>
<div class="collapsible-wrap">
<p style="text-indent:-2em;margin-left:2em;">Accidental exposure of even one dose of fentanyl, especially by children, can result in a fatal overdose of fentanyl. Death has been reported in children who have accidentally ingested transmucosal immediate-release fentanyl products. Deaths due to an overdose of fentanyl have occurred when children and adults were accidentally exposed to fentanyl transdermal system. Strict adherence to the recommended handling and disposal instructions is of the utmost importance to prevent accidental exposure. Fentanyl must be kept out of reach of children.</p></div>
</div>
<div class="collapsible">
<span class="collapsible-title">Cytochrome P450 3A4 interaction:</span>
<div class="collapsible-wrap">
<p style="text-indent:-2em;margin-left:2em;">The concomitant use of fentanyl with all cytochrome P450 3A4 inhibitors may result in an increase in fentanyl plasma concentrations, which could increase or prolong adverse reactions and may cause potentially fatal respiratory depression. In addition, discontinuation of a concomitantly used cytochrome P450 3A4 inducer may result in an increase in fentanyl plasma concentration. Evaluate patients at frequent intervals receiving fentanyl and any CYP3A4 inhibitor or inducer.</p></div>
</div>
<div class="collapsible">
<span class="collapsible-title">Neonatal opioid withdrawal syndrome:</span>
<div class="collapsible-wrap">
<p style="text-indent:-2em;margin-left:2em;">If opioid use is required for an extended period of time in a pregnant woman, advise the patient of the risk of neonatal opioid withdrawal syndrome (NOWS), which may be life-threatening if not recognized and treated. Ensure the management by neonatology experts will be available at delivery.</p></div>
</div>
<div class="collapsible">
<span class="collapsible-title">Risks from concomitant use with benzodiazepines or other CNS depressants:</span>
<div class="collapsible-wrap">
<p style="text-indent:-2em;margin-left:2em;">Concomitant use of opioids with benzodiazepines or other CNS depressants, including alcohol, may result in profound sedation, respiratory depression, coma, and death. Reserve concomitant prescribing of fentanyl and benzodiazepine or other CNS depressants for use in patients for whom alternative treatment options are inadequate.</p></div>
</div>
<div class="collapsible">
<span class="collapsible-title">Risk of medication errors (buccal, intranasal, lozenge, sublingual):</span>
<div class="collapsible-wrap">
<p style="text-indent:-2em;margin-left:2em;">Substantial differences exist in the pharmacokinetic profile of fentanyl buccal, intranasal, lozenge, and sublingual compared with other fentanyl products that result in clinically important differences in the extent of absorption of fentanyl that could result in fatal overdose. When prescribing, do not convert patients on a mcg-per-mcg basis from any other fentanyl products to fentanyl buccal, intranasal, lozenge, or sublingual. When dispensing, do not substitute a fentanyl buccal, intranasal, lozenge, or sublingual prescription for other fentanyl products.</p></div>
</div>
<div class="collapsible">
<span class="collapsible-title">REMS program:</span>
<div class="collapsible-wrap">
<p style="text-indent:-2em;margin-left:2em;">Buccal, intranasal, lozenge, sublingual: Because of the risk for accidental exposure, misuse, abuse, addiction, and overdose, fentanyl buccal, intranasal, lozenge, and sublingual are available only through a restricted program required by the FDA, called a Risk Evaluation and Mitigation Strategy (REMS). Under the Transmucosal Immediate Release Fentanyl (TIRF) REMS, pharmacies, outpatients, and health care professionals who prescribe to outpatients must enroll in the program. Inpatient pharmacies must develop policies and procedures to verify opioid tolerance in inpatients who require fentanyl buccal, intranasal, lozenge, and sublingual while hospitalized. Further information is available at http://www.TIRFREMSaccess.com or by calling 1-866-822-1483.</p>
<p style="text-indent:-2em;margin-left:2em;">Transdermal iontophoretic system (Ionsys): For use only in patients in the hospital. Discontinue treatment with before patients leave the hospital. Because of the risk of respiratory depression from accidental exposure, Ionsys is available through a restricted program called the Ionsys REMS Program. Healthcare facilities that dispense Ionsys must be certified in this program and comply with the REMS requirements.</p>
<p style="text-indent:-2em;margin-left:2em;">Transdermal (Duragesic): Health care providers are strongly encouraged to complete a REMS-compliant education program and to counsel patients and caregivers on serious risks, safe use, and the importance of reading the Medication Guide with each prescription.</p></div>
</div>
<div class="collapsible">
<span class="collapsible-title">Exposure to heat (Duragesic only):</span>
<div class="collapsible-wrap">
<p style="text-indent:-2em;margin-left:2em;">Exposure of the fentanyl application site and surrounding area to direct external heat sources, such as heating pads or electric blankets, heat or tanning lamps, sunbathing, hot baths, saunas, hot tubs, and heated water beds may increase fentanyl absorption and has resulted in fatal overdose of fentanyl. Warn patients to avoid exposing the application site and surrounding area to direct external heat sources.</p></div>
</div>
</div>
<div class="visuallyHidden drugH1Div" id="formulinkBodyPlaceholder"><span class="drugH1"></span></div>
<div class="list ubnlist drugH1Div drugBrandNames" id="F170610"><span class="drugH1">Brand Names: US</span>
<ul>
<li>Abstral [DSC];</li>
<li>Actiq [DSC];</li>
<li>Duragesic-100 [DSC];</li>
<li>Duragesic-12 [DSC];</li>
<li>Duragesic-25 [DSC];</li>
<li>Duragesic-50 [DSC];</li>
<li>Duragesic-75 [DSC];</li>
<li>Fentora;</li>
<li>Ionsys [DSC];</li>
<li>Lazanda [DSC];</li>
<li>Subsys [DSC]</li></ul></div>
<div class="list canbnlist drugH1Div drugBrandNames" id="F52912014"><span class="drugH1">Brand Names: Canada</span>
<ul>
<li>FentaNYL Citrate SDZ;</li>
<li>Fentora;</li>
<li>PMS-FentaNYL MTX [DSC];</li>
<li>SANDOZ FentaNYL;</li>
<li>TEVA-FentaNYL</li></ul></div>
<div class="list_set htclist drugH1Div drugBrandNames" id="F1052734"><span class="drugH1">Therapeutic Category</span>
<ul>
<li>
<span class="list-set-name">Analgesic, Opioid</span>;</li>
<li>
<span class="list-set-name">General Anesthetic</span></li></ul></div>
<div class="block don drugH1Div" id="F53462449"><span class="drugH1">Dosing: Neonatal</span>
<p style="text-indent:-2em;margin-left:2em;">
<b>Dosage guidance:</b></p>
<p style="text-indent:-2em;margin-left:4em;">
<b>Dosing:</b> Titrate dose to appropriate effects; wide range of doses exist, dependent upon desired degree of analgesia/anesthesia, clinical environment, patient's status, and presence of opioid tolerance. Lower initial doses are recommended for nonventilated patients (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-23720867']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-23720867'])">Ref</a></span>).</p>
<div class="collapsible-indication">
<span class="collapsible-indication-title" data-indication-id="b39f70aa-4cba-40b7-9987-46b6d87bfe98">Acute pain in opioid-naive patients</span>
<div class="collapsible-indication-wrap">
<p style="text-indent:-2em;margin-left:2em;">
<b>Acute pain in opioid-naive patients:</b> Limited data available: <b>Note:</b> Lower initial doses are recommended for patients who are preterm, low birth weight, younger age, or nonventilated (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-30290021','lexi-content-ref-23720867']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-30290021','lexi-content-ref-23720867'])">Ref</a></span>).</p>
<p style="text-indent:-2em;margin-left:4em;">Intermittent IV doses: Preterm and term neonates: IV: Initial: 1 to 3 mcg/kg/dose over at least 5 minutes; may repeat every 2 to 4 hours as needed (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-11177093','lexi-content-ref-23582138','lexi-content-ref-30290021','lexi-content-ref-Domonoske.1','lexi-content-ref-23720867']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-11177093','lexi-content-ref-23582138','lexi-content-ref-30290021','lexi-content-ref-Domonoske.1','lexi-content-ref-23720867'])">Ref</a></span>).</p>
<p style="text-indent:-2em;margin-left:4em;">Continuous IV infusion: <b>Note:</b> Some experts recommend a loading dose of to achieve analgesic effects more rapidly (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-30290021','lexi-content-ref-Domonoske.1','lexi-content-ref-23720867']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-30290021','lexi-content-ref-Domonoske.1','lexi-content-ref-23720867'])">Ref</a></span>).</p>
<p style="text-indent:-2em;margin-left:6em;">Preterm and term neonates: Loading dose (optional): 1 to 2 mcg/kg once over 5 to 30 minutes, followed by continuous IV infusion: 0.5 to 1 mcg/kg/<b>hour</b>; titrate to desired effect; usual initial range: 1 to 3 mcg/kg/<b>hour</b>; some patients require higher doses especially in the presence of opioid tolerance (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-11177093','lexi-content-ref-Domonoske.1','lexi-content-ref-23720867']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-11177093','lexi-content-ref-Domonoske.1','lexi-content-ref-23720867'])">Ref</a></span>).</p></div>
</div>
<div class="collapsible-indication">
<span class="collapsible-indication-title" data-indication-id="7792910a-1470-48f6-ac51-a80bb9b156ba">Endotracheal intubation, premedication</span>
<div class="collapsible-indication-wrap">
<p style="text-indent:-2em;margin-left:2em;">
<b>Endotracheal intubation, premedication:</b> Limited data available:</p>
<p style="text-indent:-2em;margin-left:4em;">Preterm and term neonates:</p>
<p style="text-indent:-2em;margin-left:6em;">IV, IM: 1 to 4 mcg/kg over 3 to 5 minutes (preferred); may be used in combination with other medications. <b>Note: </b>Risk of chest wall rigidity is minimized when doses are administered over at least 1 to 2 minutes (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-20176672','lexi-content-ref-Eichenwald.1']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-20176672','lexi-content-ref-Eichenwald.1'])">Ref</a></span>).</p>
<p style="text-indent:-2em;margin-left:6em;">Intranasal (using parenteral preparation): 1 to 2 mcg/kg/dose usually 5 minutes prior to procedure; administration with a mucosal atomizer device (MAD) is preferred but use may be limited by the size of the patient and/or dose, in such cases administration without a MAD is appropriate (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-32214447','lexi-content-ref-30562908','lexi-content-ref-35231912']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-32214447','lexi-content-ref-30562908','lexi-content-ref-35231912'])">Ref</a></span>); one study which used an initial dose of 1.5 mcg/kg allowed for a repeat dose after 5 minutes based on nursing’s clinical assessment with a maximum of 2 doses/procedure (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-35295509']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-35295509'])">Ref</a></span>).</p></div>
</div>
<div class="collapsible-indication">
<span class="collapsible-indication-title" data-indication-id="85d73d94-6e37-4052-a7e8-682734851b09">Pain and sedation; critically ill patients in the ICU</span>
<div class="collapsible-indication-wrap">
<p style="text-indent:-2em;margin-left:2em;">
<b>Pain and sedation; critically ill patients in the ICU (including extracorporeal membrane oxygenation [ECMO]):</b> Limited data available: <b>Note:</b> A multimodal approach (eg, a combination of pharmacologic and non-pharmacologic interventions) should typically be employed for pain control. Pain should be monitored using validated neonatal pain assessment tools (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-26810788','lexi-content-ref-11177093']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-26810788','lexi-content-ref-11177093'])">Ref</a></span>).</p>
<p style="text-indent:-2em;margin-left:4em;">Preterm and term neonates: Initial IV bolus: 1 to 2 mcg/kg, then continuous IV infusion of 0.5 to 3 mcg/kg/<b>hour</b>; titrate carefully to effect; higher doses may be needed if tolerance develops or if patient is on ECMO (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-11177093','lexi-content-ref-27729502','lexi-content-ref-Domonoske.1','lexi-content-ref-31552205','lexi-content-ref-23720867']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-11177093','lexi-content-ref-27729502','lexi-content-ref-Domonoske.1','lexi-content-ref-31552205','lexi-content-ref-23720867'])">Ref</a></span>). A pharmacokinetic study in neonates &lt;32 weeks GA showed low clearance in the first few days of life followed by a rapid increase in clearance and recommended lower initial doses in the first few days of life to prevent accumulation; the authors suggested administering 50% of the recommended dose during the first 4 days of life, 75% of the recommended dose on day of life 5 to 9, then the full recommended dose on day of life ≥10 (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-31498775']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-31498775'])">Ref</a></span>).</p></div>
</div>
<div class="collapsible-indication">
<span class="collapsible-indication-title" data-indication-id="40e16593-2d0a-4cbe-892d-c29fb3c5ec97">Pain and sedation, hypoxic ischemic encephalopathy undergoing therapeutic hypothermia</span>
<div class="collapsible-indication-wrap">
<p style="text-indent:-2em;margin-left:2em;">
<b>Pain and sedation, hypoxic ischemic encephalopathy (moderate to severe) undergoing therapeutic hypothermia:</b> Limited data available:</p>
<p style="text-indent:-2em;margin-left:4em;">Term neonates: Initial IV bolus: 1 to 2 mcg/kg, then continuous IV infusion of 0.5 to 1 mcg/kg/<b>hour</b>; increase dose by 0.5 mcg/kg/<b>hour</b> as needed to clinical effect; maximum reported dose: 3 mcg/kg/<b>hour</b> (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-30290021','lexi-content-ref-34334427','lexi-content-ref-34486466','lexi-content-ref-35558346','lexi-content-ref-30186671']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-30290021','lexi-content-ref-34334427','lexi-content-ref-34486466','lexi-content-ref-35558346','lexi-content-ref-30186671'])">Ref</a></span>).</p></div>
</div>
<div class="collapsible-indication">
<span class="collapsible-indication-title" data-indication-id="e7c6b4ca-1d21-470a-8206-202d28244777">Procedural pain and sedation</span>
<div class="collapsible-indication-wrap">
<p style="text-indent:-2em;margin-left:2em;">
<b>Procedural pain and sedation:</b> Limited data available:</p>
<p style="text-indent:-2em;margin-left:4em;">Preterm and term neonates:</p>
<p style="text-indent:-2em;margin-left:6em;">IV: Usual dosage range: 1 to 3 mcg/kg/dose over at least 5 minutes; may repeat every 2 to 4 hours as needed; lower doses (0.5 to 1 mcg/kg/dose) have been recommended for patients not on mechanical ventilation (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-23582138','lexi-content-ref-30290021','lexi-content-ref-Domonoske.1','lexi-content-ref-29740192','lexi-content-ref-32640456']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-23582138','lexi-content-ref-30290021','lexi-content-ref-Domonoske.1','lexi-content-ref-29740192','lexi-content-ref-32640456'])">Ref</a></span>).</p>
<p style="text-indent:-2em;margin-left:6em;">Intranasal (using parenteral preparation): 1 to 2 mcg/kg/dose prior to painful procedure; usually 5 minutes prior to procedure; administration with a mucosal atomizer device (MAD) is preferred but use may be limited by the size of the patient and/or dose, in such cases administration without a MAD is appropriate (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-32214447','lexi-content-ref-30562908','lexi-content-ref-Lemus.1','lexi-content-ref-30842699','lexi-content-ref-32054982','lexi-content-ref-35231912']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-32214447','lexi-content-ref-30562908','lexi-content-ref-Lemus.1','lexi-content-ref-30842699','lexi-content-ref-32054982','lexi-content-ref-35231912'])">Ref</a></span>); one study which used an initial dose of 1.5 mcg/kg allowed for a repeat dose after 5 minutes based on nursing's clinical assessment with a maximum of 2 doses/procedure (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-35295509']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-35295509'])">Ref</a></span>).</p></div>
</div>
</div>
<div class="block dop drugH1Div" id="F170639"><span class="drugH1">Dosing: Pediatric</span>
<p style="text-indent:-2em;margin-left:2em;">
<b>Dosage guidance:</b></p>
<p style="text-indent:-2em;margin-left:4em;">
<b>Dosing:</b> Titrate dose to appropriate effects; wide range of doses exist, dependent upon desired degree of analgesia/anesthesia, clinical environment, patient's status, and presence of opioid tolerance. Route of administration is variable (eg, IV, intranasal, epidural); use caution.</p>
<div class="collapsible-indication">
<span class="collapsible-indication-title" data-indication-id="31f5065d-6663-4719-87ae-fd978af8ee69">Acute pain, severe</span>
<div class="collapsible-indication-wrap">
<p style="text-indent:-2em;margin-left:2em;">
<b>Acute pain, severe (opioid-naive):</b></p>
<p style="text-indent:-2em;margin-left:4em;">
<i>Intermittent IV doses: </i></p>
<p style="text-indent:-2em;margin-left:6em;">Infants, Children, and Adolescents: Limited data available in &lt;2 years of age:</p>
<p style="text-indent:-2em;margin-left:8em;">Patient weight &lt;50 kg: IV: Initial: 0.5 to 1 mcg/kg/dose; may repeat every 1 to 2 hours; more frequent dosing may be allowed (eg, every 30 minutes) if necessary; usual maximum dose: 50 mcg/dose; a higher maximum dose of 100 mcg/dose may be considered in critically ill patients in the ICU (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-31871244','lexi-content-ref-APA.1','lexi-content-ref-12362012','lexi-content-ref-32236681','lexi-content-ref-35119438','lexi-content-ref-Walker.1']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-31871244','lexi-content-ref-APA.1','lexi-content-ref-12362012','lexi-content-ref-32236681','lexi-content-ref-35119438','lexi-content-ref-Walker.1'])">Ref</a></span>).</p>
<p style="text-indent:-2em;margin-left:8em;">Patient weight ≥50 kg: Initial: IV: 25 to 50 mcg; repeat every 1 to 2 hours (more frequent dosing may be needed [eg, every 30 minutes]) (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-12362012','lexi-content-ref-32236681','lexi-content-ref-Walker.1']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-12362012','lexi-content-ref-32236681','lexi-content-ref-Walker.1'])">Ref</a></span>).</p>
<p style="text-indent:-2em;margin-left:4em;">
<i>Continuous IV infusion:</i></p>
<p style="text-indent:-2em;margin-left:6em;">Infants, Children, and Adolescents:</p>
<p style="text-indent:-2em;margin-left:8em;">Patient weight &lt;50 kg: Limited data available: Continuous IV infusion: Usual range: 0.5 to 2.5 mcg/kg/<b>hour</b>; initiate at the lower end and titrate to effect; an initial rate of 1 mcg/kg/<b>hour</b> has been suggested for critically ill patients in the ICU (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-APA.1','lexi-content-ref-12362012','lexi-content-ref-32236681','lexi-content-ref-35119438','lexi-content-ref-Walker.1','lexi-content-ref-Zeltzer.2020']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-APA.1','lexi-content-ref-12362012','lexi-content-ref-32236681','lexi-content-ref-35119438','lexi-content-ref-Walker.1','lexi-content-ref-Zeltzer.2020'])">Ref</a></span>).</p>
<p style="text-indent:-2em;margin-left:8em;">Patient weight ≥50 kg: Limited data available: Continuous IV infusion: Usual range: 25 to 100 mcg/<b>hour</b>; initiate at the lower end of dosage range and titrate to effect; an initial dose of 50 mcg/<b>hour </b>has been suggested for critically ill patients in the ICU (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-12362012','lexi-content-ref-35119438']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-12362012','lexi-content-ref-35119438'])">Ref</a></span>).</p>
<p style="text-indent:-2em;margin-left:4em;">
<i>Intranasal (using parenteral preparation):</i> Limited data available: Children ≥10 kg and Adolescents: Intranasal: Usual dose: 1.5 to 2 mcg/kg once; maximum dose: 100 mcg/dose (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-31871244','lexi-content-ref-17067720','lexi-content-ref-12487045','lexi-content-ref-19840089','lexi-content-ref-20152004','lexi-content-ref-30592476','lexi-content-ref-19682022','lexi-content-ref-30045355','lexi-content-ref-28926159','lexi-content-ref-21175512']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-31871244','lexi-content-ref-17067720','lexi-content-ref-12487045','lexi-content-ref-19840089','lexi-content-ref-20152004','lexi-content-ref-30592476','lexi-content-ref-19682022','lexi-content-ref-30045355','lexi-content-ref-28926159','lexi-content-ref-21175512'])">Ref</a></span>); some studies that used an initial dose of 1.5 mcg/kg allowed for second dose of 0.5 mcg/kg or 0.75 mcg/kg, at the discretion of the physician, 10 or 20 minutes, respectively, after the first dose (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-19840089','lexi-content-ref-28926159']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-19840089','lexi-content-ref-28926159'])">Ref</a></span>).</p></div>
</div>
<div class="collapsible-indication">
<span class="collapsible-indication-title" data-indication-id="2900c22d-22cd-49af-a22e-81fd159940bd">Analgesia, patient-controlled analgesia</span>
<div class="collapsible-indication-wrap">
<p style="text-indent:-2em;margin-left:2em;">
<b>Analgesia, patient-controlled analgesia (PCA):</b> Limited data available:</p>
<p style="text-indent:-2em;margin-left:4em;">
<b>Note:</b> PCA has been used in children as young as 5 years; however, clinicians need to assess children &lt;7 years of age to determine if they are able to use the PCA device correctly. All patients should receive an initial loading dose of an analgesic (to attain adequate control of pain) before starting PCA for maintenance. Adjust doses, lockouts, and limits based on required loading dose, age, state of health, and presence of opioid tolerance. Use lower end of dosing range for opioid-naive. Assess patient and pain control at regular intervals and adjust settings if needed (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-APS.2','lexi-content-ref-32236681']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-APS.2','lexi-content-ref-32236681'])">Ref</a></span>). Concentrations of PCA should be standardized, refer to institutional policy. The following are general dosing suggestions; refer to institutional policy.</p>
<p style="text-indent:-2em;margin-left:4em;">Children ≥5 years and Adolescents:</p>
<p style="text-indent:-2em;margin-left:6em;">Patient weight ≤50 kg:</p>
<p style="text-indent:-2em;margin-left:8em;">Demand dose: Usual initial range: IV: 0.2 to 0.5 mcg/kg/dose; an initial dose of 0.3 mcg/kg/dose has also been suggested (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-32236681','lexi-content-ref-Walker.1']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-32236681','lexi-content-ref-Walker.1'])">Ref</a></span>).</p>
<p style="text-indent:-2em;margin-left:8em;">Lockout interval: Range: 5 to 15 minutes (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-APS.1','lexi-content-ref-Walker.1']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-APS.1','lexi-content-ref-Walker.1'])">Ref</a></span>).</p>
<p style="text-indent:-2em;margin-left:8em;">Usual basal rate (optional): IV: 0 to 0.5 mcg/kg/<b>hour</b> (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-APS.1','lexi-content-ref-Walker.1']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-APS.1','lexi-content-ref-Walker.1'])">Ref</a></span>); an alternative range of 0.15 to 1 mcg/kg/<b>hour</b> (with an initial of 0.2 mcg/kg/<b>hour</b>) has also been suggested (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-32236681']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-32236681'])">Ref</a></span>).</p>
<p style="text-indent:-2em;margin-left:8em;">Maximum dose: Format of maximum total amount of fentanyl per unit of time varies with pump settings, ordering standards, and institutional policy. The following are different options that have been reported; refer to institutional policy.</p>
<p style="text-indent:-2em;margin-left:10em;">1-hour dose limit: Initial: 5 demand doses/<b>hour</b> (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-APS.1']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-APS.1'])">Ref</a></span>).</p>
<p style="text-indent:-2em;margin-left:10em;">2-hour dose limit: 80% of maximum quantity based on the sum of the basal rate and demand doses allowed in a 2-hour period of time (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-32236681']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-32236681'])">Ref</a></span>).</p>
<p style="text-indent:-2em;margin-left:10em;">4-hour dose limit: 7 to 10 mcg/kg (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-Walker.1']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-Walker.1'])">Ref</a></span>).</p>
<p style="text-indent:-2em;margin-left:6em;">Patient weight &gt;50 kg (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-APS.2']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-APS.2'])">Ref</a></span>):</p>
<p style="text-indent:-2em;margin-left:8em;">Loading dose: 25 mcg.</p>
<p style="text-indent:-2em;margin-left:8em;">Demand dose: Usual initial: 5 to 25 mcg.</p>
<p style="text-indent:-2em;margin-left:8em;">Lockout interval: Usual: 8 to 10 minutes.</p></div>
</div>
<div class="collapsible-indication">
<span class="collapsible-indication-title" data-indication-id="8fabc082-bd80-45c8-8172-1246c1df2bae">Anesthesia</span>
<div class="collapsible-indication-wrap">
<p style="text-indent:-2em;margin-left:2em;">
<b>Anesthesia: Note:</b> Dosing presented reflects general ranges; specific dose dependent on patient characteristics, procedure, and/or other anesthetic agents employed.</p>
<p style="text-indent:-2em;margin-left:4em;">
<i>Induction and maintenance:</i> Children 2 to 12 years: IV: 2 to 10 mcg/kg/dose; followed by a continuous infusion in some cases at 2 to 5 mcg/kg/<b>hour</b> (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-McClain.1','lexi-content-ref-manu.1']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-McClain.1','lexi-content-ref-manu.1'])">Ref</a></span>).</p>
<p style="text-indent:-2em;margin-left:4em;">
<i>Anesthesia, general; adjunct: </i>
<b>Note:</b> Specific dose dependent on type of procedure/surgery and other anesthetics in use. Dosing provided is a general range and dose should be individualized. Specific maintenance and total dosages should be based on intraoperative clinical response managed by clinicians trained in anesthesia: Adolescents: IV: 0.5 to 50 mcg/kg/dose.</p></div>
</div>
<div class="collapsible-indication">
<span class="collapsible-indication-title" data-indication-id="c1f7dc4d-f621-4b16-8ab2-080064fb71ac">Anesthesia; regional</span>
<div class="collapsible-indication-wrap">
<p style="text-indent:-2em;margin-left:2em;">
<b>Anesthesia, regional:</b> Limited data available: <b>Note: Use only preservative-free preparations</b>. Dosing presented reflects general ranges; specific dose dependent on patient characteristics, procedure, and/or other anesthetic agents employed.</p>
<p style="text-indent:-2em;margin-left:4em;">Infants, Children, and Adolescents: Epidural catheter: Continuous epidural infusion: 0.3 to 1 mcg/kg/<b>hour</b>; admixed in combination with bupivacaine or ropivacaine (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-32236681','lexi-content-ref-Walker.1']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-32236681','lexi-content-ref-Walker.1'])">Ref</a></span>).</p></div>
</div>
<div class="collapsible-indication">
<span class="collapsible-indication-title" data-indication-id="a6e031cc-dc06-4a60-a1d1-79b95159eb4a">Chronic cancer pain; breakthrough</span>
<div class="collapsible-indication-wrap">
<p style="text-indent:-2em;margin-left:2em;">
<b>Chronic cancer pain; breakthrough:</b>
<b>Note:</b> For use in patients who are tolerant to and currently receiving opioid therapy for persistent cancer pain; dosing should be individually titrated to provide adequate analgesia with minimal side effects. <b>Patients must remain on around-the-clock opioids during use.</b></p>
<p style="text-indent:-2em;margin-left:4em;">Transmucosal lozenge (eg, Actiq):<b> Note:</b> Do <b>not</b> convert patients from any other fentanyl product to Actiq on a mcg-per-mcg basis. Patients previously using another fentanyl product should be initiated in usual manner; individually titrate to provide adequate analgesia while minimizing adverse effects.</p>
<p style="text-indent:-2em;margin-left:6em;">Adolescents ≥16 years:</p>
<p style="text-indent:-2em;margin-left:8em;">
<i>Initial:</i> 200 mcg (consumed over 15 minutes) for all patients; if after 30 minutes from the start of the lozenge (ie, 15 minutes following the completion of the lozenge), the pain is unrelieved, a second 200 mcg dose may be given over 15 minutes. A maximum of 1 additional dose can be given per pain episode; <b>must wait at least 4 hours before treating another episode.</b> To limit the number of units in the home during titration, only prescribe an initial titration supply of six 200 mcg lozenges.</p>
<p style="text-indent:-2em;margin-left:8em;">
<i>Dose titration:</i> Dose titration should be done if patient requires more than 1 dose/breakthrough pain episode for several consecutive episodes. From the initial dose, closely follow patients and modify the dose until patient reaches a dose providing adequate analgesia using a single dosage unit per breakthrough cancer pain episode. If signs/symptoms of excessive opioid effects (eg, respiratory depression) occur, immediately remove the dosage unit from the patient's mouth, dispose of properly, and reduce subsequent doses. If adequate relief is not achieved 15 minutes after completion of the first dose (ie, 30 minutes after the start of the lozenge), only 1 additional lozenge of the same strength may be given for that episode; <b>must wait at least 4 hours before treating another episode.</b></p>
<p style="text-indent:-2em;margin-left:8em;">
<i>Maintenance dose:</i> Once titrated to an effective dose, patients should generally use a single dosage unit per breakthrough pain episode. During any pain episode, if adequate relief is not achieved 15 minutes after completion of the first dose (ie, 30 minutes after the start of the lozenge), only 1 additional lozenge of the same strength may be given over 15 minutes for that episode; <b>must wait at least 4 hours before treating another episode</b>. Consumption should be limited to ≤4 units per day (once an effective breakthrough dose is found). If adequate analgesia is <b>not </b>provided after treating several episodes of breakthrough pain using the same dose, increase dose to next highest lozenge strength (initially dispense no more than 6 units of the new strength). Consider increasing the around-the-clock opioid therapy in patients experiencing &gt;4 breakthrough pain episodes per day and have their long-term opioid re-evaluated. If signs/symptoms of excessive opioid effects (eg, respiratory depression) occur, immediately remove the dosage unit from the patient's mouth, dispose of properly, and reduce subsequent doses.</p></div>
</div>
<div class="collapsible-indication">
<span class="collapsible-indication-title" data-indication-id="75abac5b-7e75-44fa-b0f3-72ec21a9d158">Chronic pain, moderate to severe</span>
<div class="collapsible-indication-wrap">
<p style="text-indent:-2em;margin-left:2em;">
<b>Chronic pain, moderate to severe (opioid-tolerant):</b></p>
<p style="text-indent:-2em;margin-left:4em;">Transdermal patch (eg, Duragesic): <b>Note:</b> For use in patients who are opioid-tolerant receiving at least 60 mg oral morphine equivalents per day. Discontinue or taper all other around-the-clock or extended-release opioids when initiating therapy with fentanyl transdermal patch:</p>
<p style="text-indent:-2em;margin-left:6em;">Children ≥2 years and Adolescents:</p>
<p style="text-indent:-2em;margin-left:8em;">
<i>Initial:</i> 25 mcg<b>/hour</b> system or higher based on previous opioid dosing. To convert patients from oral or parenteral opioids to transdermal patch, a 24-hour analgesic requirement should be calculated (based on prior opioid use). Using the following tables, the appropriate initial dose can be determined. The initial fentanyl dosage may be approximated from the 24-hour morphine dosage equivalent and titrated to minimize adverse effects and provide analgesia. Substantial interpatient variability exists in relative potency. Therefore, it is safer to underestimate a patient's daily fentanyl requirement and provide breakthrough pain relief with rescue medication (eg, immediate release opioid) than to overestimate requirements. With the initial application, the absorption of transdermal fentanyl requires several hours to reach plateau; therefore, transdermal fentanyl is inappropriate for management of acute pain. Change patch every 72 hours.</p>
<p style="text-indent:-2em;margin-left:8em;">
<i>Conversion from continuous infusion of fentanyl:</i> In patients who have adequate pain relief with a fentanyl infusion, fentanyl may be converted to transdermal dosing at a rate equivalent to the intravenous rate. Based on experience in adults, a two-step taper of the infusion to be completed over 12 hours may be considered (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-11753984']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-11753984'])">Ref</a></span>) after the patch is applied. The infusion is decreased to 50% of the original rate 6 hours after the application of the first patch, and subsequently discontinued twelve hours after application.</p>
<p style="text-indent:-2em;margin-left:8em;">
<i>Titration:</i> Short-acting agents may be required until analgesic efficacy is established and/or as supplements for “breakthrough” pain. The amount of supplemental doses should be closely monitored. Appropriate dosage increases may be based on daily supplemental dosage using the ratio of 45 mg/24 hours of oral morphine to a 12.5 mcg/hour increase in fentanyl dosage.</p>
<p style="text-indent:-2em;margin-left:8em;">
<i>Frequency of adjustment: </i>The dosage should not be titrated more frequently than every 3 days after the initial dose or every 6 days thereafter. Titrate dose based on the daily dose of supplemental opioids required by the patient on the second or third day of the initial application. <b>Note:</b> Upon discontinuation, ~17 hours are required for a 50% decrease in fentanyl levels.</p>
<p style="text-indent:-2em;margin-left:8em;">
<i>Frequency of application:</i> The majority of patients may be controlled on every 72-hour administration; however, a small number of adult patients have required every 48-hour administration.</p>
<p style="text-indent:-2em;margin-left:8em;">
<i>Discontinuation:</i> When discontinuing transdermal fentanyl and not converting to another opioid, use a gradual downward titration, such as decreasing the dose by 50% every 6 days, to reduce the possibility of withdrawal symptoms.</p>
<p style="text-indent:-2em;margin-left:8em;">
<i>Dose conversion guidelines for transdermal fentanyl from other opioids (see tables).</i></p>
<p style="text-indent:-2em;margin-left:10em;">
<b>Note:</b> The conversion factors in these tables are only to be used for the conversion from current opioid therapy to Duragesic patch. Conversion factors in this table cannot be used to convert from Duragesic to another opioid (doing so may lead to fatal overdose due to overestimation of the new opioid). US and Canadian dose conversion guidelines differ; consult table for US recommendations. The Canadian product is not approved in pediatric patients. <b>These are not tables of equianalgesic doses</b>.</p>
<table border="1" data-table-id="fen4a" frame="border" rules="all" style="margin-left:8em;">
<caption>
<b>US Labeling: Dose Conversion Guidelines: Recommended Initial Duragesic Dose Based Upon Daily Oral Morphine Dose<sup>a</sup></b></caption>
<colgroup><col align="center"/>
<col align="center"/>
</colgroup><thead valign="middle">
<tr>
<th align="center">
<p style="text-indent:0em;">Oral 24-Hour Morphine</p>
<p style="text-indent:0em;">(mg/day)</p></th>
<th align="center">
<p style="text-indent:0em;">Duragesic Dose<sup>b,c</sup></p>
<p style="text-indent:0em;">(mcg/hour)</p></th></tr></thead>
<tfoot valign="middle">
<tr>
<td align="left" colspan="2">
<p style="text-indent:0em;text-align:left;">
<sup>a</sup>
<b>The table should NOT be used to convert from transdermal fentanyl (Duragesic) to other opioid analgesics.</b> Rather, following removal of the patch, titrate the dose of the new opioid until adequate analgesia is achieved.</p></td></tr>
<tr>
<td align="left" colspan="2">
<p style="text-indent:0em;text-align:left;">
<sup>b</sup>Pediatric patients initiating therapy on a 25 mcg/hour Duragesic system should be opioid-tolerant and receiving at least 60 mg oral morphine equivalents per day.</p></td></tr>
<tr>
<td align="center" colspan="2">
<p style="text-indent:0em;text-align:left;">
<sup>c</sup>A fentanyl 37.5 mcg/hour transdermal system is also available and may be considered during conversion from prior opioids or dose titration.</p></td></tr></tfoot>
<tbody valign="middle">
<tr>
<td align="center">
<p style="text-indent:0em;">60 to 134 mg/day</p></td>
<td align="center">
<p style="text-indent:0em;">25 mcg/hour</p></td></tr>
<tr>
<td align="center">
<p style="text-indent:0em;">135 to 224 mg/day</p></td>
<td align="center">
<p style="text-indent:0em;">50 mcg/hour</p></td></tr>
<tr>
<td align="center">
<p style="text-indent:0em;">225 to 314 mg/day</p></td>
<td align="center">
<p style="text-indent:0em;">75 mcg/hour</p></td></tr>
<tr>
<td align="center">
<p style="text-indent:0em;">315 to 404 mg/day</p></td>
<td align="center">
<p style="text-indent:0em;">100 mcg/hour</p></td></tr>
<tr>
<td align="center">
<p style="text-indent:0em;">405 to 494 mg/day</p></td>
<td align="center">
<p style="text-indent:0em;">125 mcg/hour</p></td></tr>
<tr>
<td align="center">
<p style="text-indent:0em;">495 to 584 mg/day</p></td>
<td align="center">
<p style="text-indent:0em;">150 mcg/hour</p></td></tr>
<tr>
<td align="center">
<p style="text-indent:0em;">585 to 674 mg/day</p></td>
<td align="center">
<p style="text-indent:0em;">175 mcg/hour</p></td></tr>
<tr>
<td align="center">
<p style="text-indent:0em;">675 to 764 mg/day</p></td>
<td align="center">
<p style="text-indent:0em;">200 mcg/hour</p></td></tr>
<tr>
<td align="center">
<p style="text-indent:0em;">765 to 854 mg/day</p></td>
<td align="center">
<p style="text-indent:0em;">225 mcg/hour</p></td></tr>
<tr>
<td align="center">
<p style="text-indent:0em;">855 to 944 mg/day</p></td>
<td align="center">
<p style="text-indent:0em;">250 mcg/hour</p></td></tr>
<tr>
<td align="center">
<p style="text-indent:0em;">945 to 1,034 mg/day</p></td>
<td align="center">
<p style="text-indent:0em;">275 mcg/hour</p></td></tr>
<tr>
<td align="center">
<p style="text-indent:0em;">1,035 to 1,124 mg/day</p></td>
<td align="center">
<p style="text-indent:0em;">300 mcg/hour</p></td></tr></tbody></table>
<table border="1" data-table-id="fentan4" frame="border" rules="all" style="margin-left:8em;">
<caption style="text-align:center;">
<b>US Labeling: Dose Conversion Guidelines<sup>a</sup></b></caption>
<colgroup><col/>
<col align="center"/>
<col align="center"/>
<col align="center"/>
<col align="center"/>
</colgroup><thead valign="middle">
<tr>
<th align="center">
<p style="text-indent:0em;">Current Analgesic</p></th>
<th align="center" colspan="4">
<p style="text-indent:0em;">Total Daily Dosage</p>
<p style="text-indent:0em;">(mg/day)</p></th></tr></thead>
<tfoot valign="middle">
<tr>
<td align="left" colspan="5">
<p style="text-indent:0em;">
<sup>a</sup>
<b>The table should NOT be used to convert from transdermal fentanyl (Duragesic) to other opioid analgesics.</b> Rather, following removal of the patch, titrate the dose of the new opioid until adequate analgesia is achieved.</p></td></tr></tfoot>
<tbody valign="middle">
<tr>
<td>
<p style="text-indent:0em;">Morphine (IM/IV)</p></td>
<td align="center">
<p style="text-indent:0em;">10 to 22 mg/day</p></td>
<td align="center">
<p style="text-indent:0em;">23 to 37 mg/day</p></td>
<td align="center">
<p style="text-indent:0em;">38 to 52 mg/day</p></td>
<td align="center">
<p style="text-indent:0em;">53 to 67 mg/day</p></td></tr>
<tr>
<td>
<p style="text-indent:0em;">Oxycodone (oral)</p></td>
<td align="center">
<p style="text-indent:0em;">30 to 67 mg/day</p></td>
<td align="center">
<p style="text-indent:0em;">67.5 to 112 mg/day</p></td>
<td align="center">
<p style="text-indent:0em;">112.5 to 157 mg/day</p></td>
<td align="center">
<p style="text-indent:0em;">157.5 to 202 mg/day</p></td></tr>
<tr>
<td>
<p style="text-indent:0em;">Codeine (oral)</p></td>
<td align="center">
<p style="text-indent:0em;">150 to 447 mg/day</p></td>
<td align="center">
<p style="text-indent:0em;">-</p></td>
<td align="center">
<p style="text-indent:0em;">-</p></td>
<td align="center">
<p style="text-indent:0em;">-</p></td></tr>
<tr>
<td>
<p style="text-indent:0em;">Hydromorphone (oral)</p></td>
<td align="center">
<p style="text-indent:0em;">8 to 17 mg/day</p></td>
<td align="center">
<p style="text-indent:0em;">17.1 to 28 mg/day</p></td>
<td align="center">
<p style="text-indent:0em;">28.1 to 39 mg/day</p></td>
<td align="center">
<p style="text-indent:0em;">39.1 to 51 mg/day</p></td></tr>
<tr>
<td>
<p style="text-indent:0em;">Hydromorphone (IV)</p></td>
<td align="center">
<p style="text-indent:0em;">1.5 to 3.4 mg/day</p></td>
<td align="center">
<p style="text-indent:0em;">3.5 to 5.6 mg/day</p></td>
<td align="center">
<p style="text-indent:0em;">5.7 to 7.9 mg/day</p></td>
<td align="center">
<p style="text-indent:0em;">8 to 10 mg/day</p></td></tr>
<tr>
<td>
<p style="text-indent:0em;">Meperidine (IM)</p></td>
<td align="center">
<p style="text-indent:0em;">75 to 165 mg/day</p></td>
<td align="center">
<p style="text-indent:0em;">166 to 278 mg/day</p></td>
<td align="center">
<p style="text-indent:0em;">279 to 390 mg/day</p></td>
<td align="center">
<p style="text-indent:0em;">391 to 503 mg/day</p></td></tr>
<tr>
<td>
<p style="text-indent:0em;">Methadone (oral)</p></td>
<td align="center">
<p style="text-indent:0em;">20 to 44 mg/day</p></td>
<td align="center">
<p style="text-indent:0em;">45 to 74 mg/day</p></td>
<td align="center">
<p style="text-indent:0em;">75 to 104 mg/day</p></td>
<td align="center">
<p style="text-indent:0em;">105 to 134 mg/day</p></td></tr>
<tr>
<td></td>
<td align="center"></td>
<td align="center"></td>
<td align="center"></td>
<td align="center"></td></tr>
<tr>
<td>
<p style="text-indent:0em;">
<b>Duragesic (fentanyl transdermal) recommended dose (mcg/hour) </b></p></td>
<td align="center">
<p style="text-indent:0em;">
<b>25 mcg/hour</b></p></td>
<td align="center">
<p style="text-indent:0em;">
<b>50 mcg/hour</b></p></td>
<td align="center">
<p style="text-indent:0em;">
<b>75 mcg/hour</b></p></td>
<td align="center">
<p style="text-indent:0em;">
<b>100 mcg/hour</b></p></td></tr></tbody></table></div>
</div>
<div class="collapsible-indication">
<span class="collapsible-indication-title" data-indication-id="c9ebc6cf-44bd-46be-bcc4-24fd0bda643f">Pain and sedation, patients who are critically ill</span>
<div class="collapsible-indication-wrap">
<p style="text-indent:-2em;margin-left:2em;">
<b>Pain and sedation, patients who are critically ill (ICU):</b></p>
<p style="text-indent:-2em;margin-left:4em;">Infants and Children: Limited data available in &lt;2 years of age: Initial IV bolus: 1 to 2 mcg/kg followed by continuous IV infusion at initial rate: 1 mcg/kg/<b>hour</b>; titrate to effect; usual range: 1 to 3 mcg/kg/<b>hour</b>; some patients may require higher rates (5 mcg/kg/<b>hour)</b> (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-23720867']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-23720867'])">Ref</a></span>).</p>
<p style="text-indent:-2em;margin-left:4em;">Adolescents:</p>
<p style="text-indent:-2em;margin-left:6em;">Patient weight ≤50 kg: Initial IV bolus: 0.5 to 2 mcg/kg followed by continuous IV infusion at initial rate: 0.5 to 2 mcg/kg/<b>hour</b> based on expert recommendations for children and pediatric patients ≤50 kg (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-APS.1','lexi-content-ref-12362012','lexi-content-ref-23720867']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-APS.1','lexi-content-ref-12362012','lexi-content-ref-23720867'])">Ref</a></span>).</p>
<p style="text-indent:-2em;margin-left:6em;">Patient weight &gt;50 kg: Initial IV bolus: 25 to 100 mcg/dose followed by continuous IV infusion at initial rate: 25 to 200 mcg/<b>hour</b> based on expert recommendations for pediatric patients and experience in adult patients (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-APS.1','lexi-content-ref-12362012','lexi-content-ref-12662124','lexi-content-ref-9952166']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-APS.1','lexi-content-ref-12362012','lexi-content-ref-12662124','lexi-content-ref-9952166'])">Ref</a></span>).</p></div>
</div>
<div class="collapsible-indication">
<span class="collapsible-indication-title" data-indication-id="e7c6b4ca-1d21-470a-8206-202d28244777">Procedural pain and sedation</span>
<div class="collapsible-indication-wrap">
<p style="text-indent:-2em;margin-left:2em;">
<b>Procedural pain and sedation</b>
<b>:</b> Limited data available: <b>Note</b>
<b>:</b> Dose and route of administration may vary with procedure; refer to institutional policy.</p>
<p style="text-indent:-2em;margin-left:4em;">
<i>Injection:</i></p>
<p style="text-indent:-2em;margin-left:6em;">Infants and Children: IV: 1 to 2 mcg/kg/dose; administer 3 minutes before the procedure; maximum dose: 50 mcg/dose; may repeat <sup>1</sup>/<sub>2</sub> original dose every 3 to 5 minutes if necessary; titrate to effect (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-22732639','lexi-content-ref-Cravero.1','lexi-content-ref-16517277','lexi-content-ref-2216645']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-22732639','lexi-content-ref-Cravero.1','lexi-content-ref-16517277','lexi-content-ref-2216645'])">Ref</a></span>).</p>
<p style="text-indent:-2em;margin-left:6em;">Adolescents: IV: 0.5 to 1 mcg/kg/dose; may repeat after 1 to 2 minutes (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-15829394']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-15829394'])">Ref</a></span>); or 25 to 50 mcg, repeat full dose in 5 minutes if needed, may repeat 4 to 5 times with 25 mcg at 5-minute intervals if needed (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-16517277','lexi-content-ref-2216645']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-16517277','lexi-content-ref-2216645'])">Ref</a></span>).</p>
<p style="text-indent:-2em;margin-left:4em;">
<i>Intranasal (using parenteral preparation)</i>: Infants and Children weighing ≥10 kg and Adolescents: Intranasal: 1.5 to 2 mcg/kg administered 15 minutes prior to procedure; maximum dose: 100 mcg/dose (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-31871244','lexi-content-ref-16005154','lexi-content-ref-20180109','lexi-content-ref-30275061']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-31871244','lexi-content-ref-16005154','lexi-content-ref-20180109','lexi-content-ref-30275061'])">Ref</a></span>).</p></div>
</div>
<div class="collapsible-indication">
<span class="collapsible-indication-title" data-indication-id="270a5158-d537-4787-a196-13424f633399">Rapid sequence intubation, pretreatment</span>
<div class="collapsible-indication-wrap">
<p style="text-indent:-2em;margin-left:2em;">
<b>Rapid sequence intubation, pretreatment: </b>Limited data available: Infants and Children: IV: 1 mcg/kg/dose; may repeat every 3 minutes; maximum dose: 50 mcg/dose (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-31871244']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-31871244'])">Ref</a></span>).</p></div>
</div>
<p style="text-indent:-2em;margin-left:2em;">
<b>Dosage adjustment for concomitant therapy:</b> Significant drug interactions exist, requiring dose/frequency adjustment or avoidance. Consult drug interactions database for more information.</p></div>
<div class="block dorp drugH1Div" id="F51110015"><span class="drugH1">Dosing: Kidney Impairment: Pediatric</span>
<p style="text-indent:-2em;margin-left:2em;">Injection: There are no dosage adjustments provided in the manufacturer's labeling; however, the following guidelines have been used by some clinicians (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-Aronoff.1']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-Aronoff.1'])">Ref</a></span>):</p>
<p style="text-indent:-2em;margin-left:4em;">Infants, Children, and Adolescents: The following assumes dosages of 0.5 to 2 mcg/kg/dose or 1 to 5 mcg/kg/<b>hour</b> in normal renal function: IV:</p>
<p style="text-indent:-2em;margin-left:6em;">GFR &gt;50 mL/minute/1.73 m<sup>2</sup>: No adjustment required.</p>
<p style="text-indent:-2em;margin-left:6em;">GFR 10 to 50 mL/minute/1.73 m<sup>2</sup>: Administer 75% of usual dose.</p>
<p style="text-indent:-2em;margin-left:6em;">GFR &lt;10 mL/minute/1.73 m<sup>2</sup>: Administer 50% of usual dose.</p>
<p style="text-indent:-2em;margin-left:6em;">Intermittent hemodialysis: Administer 50% of usual dose.</p>
<p style="text-indent:-2em;margin-left:6em;">Peritoneal dialysis (PD): Administer 50% of usual dose.</p>
<p style="text-indent:-2em;margin-left:6em;">Continuous renal replacement therapy (CRRT): Administer 75% of usual dose.</p>
<p style="text-indent:-2em;margin-left:2em;">Transdermal (patch): Pediatric patients ≥2 years: Degree of impairment (ie, CrCl) not defined in manufacturer's labeling.</p>
<p style="text-indent:-2em;margin-left:4em;">Mild to moderate impairment: Initial: Reduce dose by 50%.</p>
<p style="text-indent:-2em;margin-left:4em;">Severe impairment: Use not recommended.</p>
<p style="text-indent:-2em;margin-left:2em;">Transmucosal (lozenge [eg, Actiq]) and nasal spray: Adolescents ≥16 years: Although fentanyl pharmacokinetics may be altered in renal disease, fentanyl can be used successfully in the management of breakthrough cancer pain. Use with caution; reduce initial dose and titrate to reach clinical effect with careful monitoring of patients, especially those with severe renal disease.</p></div>
<div class="block dohp drugH1Div" id="F51110016"><span class="drugH1">Dosing: Hepatic Impairment: Pediatric</span>
<p style="text-indent:-2em;margin-left:2em;">Injection: There are no dosage adjustments provided in the manufacturer's labeling.</p>
<p style="text-indent:-2em;margin-left:2em;">Transdermal (patch): Pediatric patients ≥2 years:</p>
<p style="text-indent:-2em;margin-left:4em;">Mild to moderate impairment: Initial: Reduce dose by 50%.</p>
<p style="text-indent:-2em;margin-left:4em;">Severe impairment: Use not recommended.</p>
<p style="text-indent:-2em;margin-left:2em;">Transmucosal (lozenge [eg, Actiq]): Adolescents ≥16 years: Although fentanyl pharmacokinetics may be altered in hepatic disease, fentanyl can be used successfully in the management of breakthrough cancer pain. Use with caution; reduce initial dose and titrate to reach clinical effect with careful monitoring of patients, especially those with severe hepatic disease.</p></div>
<div class="block doa drugH1Div" id="F53914898"><span class="drugH1">Dosing: Adult</span><p>(For additional information <a class="drug drug_general" data-topicid="8441" href="/d/html/8441.html" rel="external">see "Fentanyl: Drug information"</a>)</p>
<p style="text-indent:-2em;margin-left:2em;">
<b>Dosage guidance:</b></p>
<p style="text-indent:-2em;margin-left:4em;">
<b>Safety: </b>Consider prescribing naloxone for patients with factors associated with an increased risk for overdose, such as history of overdose or substance use disorder, patients with sleep-disordered breathing, higher opioid dosages (≥50 morphine milligram equivalents [MME]/day orally), and/or concomitant benzodiazepine use (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-26827847','lexi-content-ref-36327391']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-26827847','lexi-content-ref-36327391'])">Ref</a></span>).</p>
<p style="text-indent:-2em;margin-left:4em;">
<b>Dosing: </b>Dosing provided is based on typical doses; some patients may require higher or lower doses. Individualize dosing based on patient-specific factors (eg, severity of pain, comorbidities, degree of opioid experience/tolerance) and titrate to patient-specific treatment goals (eg, improvement in function and quality of life, decrease in pain using validated pain rating scale). Use the lowest effective dose for the shortest period of time.</p>
<p style="text-indent:-2em;margin-left:4em;">
<b>Clinical considerations:</b> Opioids may be part of a comprehensive, multimodal, patient-specific treatment plan for managing severe pain. Maximize nonopioid analgesia (when appropriate) prior to initiation of opioid analgesia (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-36327391','lexi-content-ref-28267689']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-36327391','lexi-content-ref-28267689'])">Ref</a></span>).</p>
<div class="collapsible-indication">
<span class="collapsible-indication-title" data-indication-id="99b54d0a-b598-4d08-9cb5-4363e99a9c36">Acute pain, patient-controlled analgesia</span>
<div class="collapsible-indication-wrap">
<p style="text-indent:-2em;margin-left:2em;">
<b>Acute pain, patient-controlled analgesia (alternative agent):</b>
<b>Note: </b>Generally, fentanyl is the preferred opioid for patients with severe kidney or hepatic dysfunction and/or for patients who are unable to tolerate morphine or hydromorphone (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-Buys.1']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-Buys.1'])">Ref</a></span>). <b>For use in ICU, postoperative, or other closely monitored settings. </b>Do not prescribe fentanyl for use on an outpatient basis for acute noncancer-related pain; consider the use of other oral opioids (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-36327391']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-36327391'])">Ref</a></span>).</p>
<p style="text-indent:-2em;margin-left:4em;">
<b>IV:</b></p>
<table border="1" frame="border" rules="all" style="margin-left:2em;">
<caption>
<b>Example IV Patient-Controlled Analgesia Initial Dose Ranges for Opioid-Naive Patients<sup>a</sup></b></caption>
<colgroup><col align="center"/>
<col align="center"/>
</colgroup><tfoot>
<tr>
<td align="center" colspan="2">
<p style="text-indent:0em;text-align:left;">
<sup>a</sup> For use to maintain pain control after initial pain control achieved. May adjust dosing and provide rescue bolus doses (eg, 5 to 20 mcg) if analgesia is inadequate (Buys 2023).</p></td></tr>
<tr>
<td align="center" colspan="2">
<p style="text-indent:0em;text-align:left;">
<sup>b</sup> The use of a continuous background infusion for patient-controlled analgesia is generally <b>not</b> recommended for most patients because of the risk of respiratory depression, and use should be limited to carefully selected patients who are opioid tolerant and/or receiving care in a critical care unit, or if required to maintain baseline opioid dosing during intervals when oral or transdermal opioid administration is not possible (Arnold 2019; Buys 2023).</p></td></tr></tfoot>
<tbody>
<tr>
<td align="center">
<p style="text-indent:0em;">Usual concentration</p></td>
<td align="center">
<p style="text-indent:0em;">10 mcg/mL</p></td></tr>
<tr>
<td align="center">
<p style="text-indent:0em;">Demand dose</p></td>
<td align="center">
<p style="text-indent:0em;">Usual range: 5 to 20 mcg</p></td></tr>
<tr>
<td align="center">
<p style="text-indent:0em;">Basal dose</p></td>
<td align="center">
<p style="text-indent:0em;">In general, a continuous (basal) infusion is <b>not</b> recommended in an opioid-naive patient (ISMP 2009)<sup class="footnote-number">b</sup></p></td></tr>
<tr>
<td align="center">
<p style="text-indent:0em;">Lockout interval</p></td>
<td align="center">
<p style="text-indent:0em;">5 to 10 minutes</p></td></tr>
<tr>
<td align="center">
<p style="text-indent:0em;">Maximum cumulative dose</p></td>
<td align="center">
<p style="text-indent:0em;">300 mcg within a 4-hour period</p></td></tr></tbody></table></div>
</div>
<div class="collapsible-indication">
<span class="collapsible-indication-title" data-indication-id="673a3bf6-adb5-4933-ae09-13a5847a69e0">Acute postoperative pain</span>
<div class="collapsible-indication-wrap">
<p style="text-indent:-2em;margin-left:2em;">
<b>Acute postoperative pain: </b></p>
<p style="text-indent:-2em;margin-left:4em;">
<b>Postoperative recovery/Postanesthesia care unit (ie, immediate postoperative period): </b></p>
<p style="text-indent:-2em;margin-left:6em;">
<b>IV:</b> 25 to 50 mcg every 5 minutes (moderate pain) or 50 to 100 mcg every 2 to 5 minutes (severe pain) until pain is relieved or unwanted side effects appear; after initial pain control, readdress postoperative analgesic regimen to optimize comfort (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-Alexander.1']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-Alexander.1'])">Ref</a></span>).</p>
<p style="text-indent:-2em;margin-left:6em;">
<b>IM:</b> 50 to 100 mcg every 1 to 2 hours as needed. <b>Note:</b> IM route should only be used if IV administration is not available (eg, loss of IV access).</p>
<p style="text-indent:-2em;margin-left:6em;">
<b>Transdermal device (Ionsys):</b>
<b>Note:</b> Ionsys has been discontinued in the United States for &gt;1 year. For hospital use only by patients under medical supervision for whom alternative treatments are inadequate and only after patients have been titrated to an acceptable level of analgesia using another opioid analgesic.</p>
<p style="text-indent:-2em;margin-left:8em;">Apply 1 device to chest or upper outer arm only. Only the patient may activate the device (40 mcg dose of fentanyl per activation, delivered over 10 minutes; maximum: 6 doses per hour). Only 1 device may be applied at a time and operates for up to 24 hours or 80 doses, whichever comes first. Reapply every 24 hours, as necessary, with each subsequent device applied to a different skin site; maximum duration: 72 hours. If inadequate analgesia is achieved with 1 device, either provide additional supplemental analgesia or replace with an alternative analgesic. Refer to manufacturer's labeling for activation instructions and application sites.</p></div>
</div>
<div class="collapsible-indication">
<span class="collapsible-indication-title" data-indication-id="50bfcc5c-5659-404d-9085-b9933d060c66">Acute nonoperative severe pain</span>
<div class="collapsible-indication-wrap">
<p style="text-indent:-2em;margin-left:2em;">
<b>Acute nonoperative severe pain:</b></p>
<p style="text-indent:-2em;margin-left:4em;">
<b>Note:</b> For use in ICU or other closely monitored settings. Do not prescribe fentanyl for use on an outpatient basis for acute noncancer-related pain; consider the use of other oral opioids (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-36327391']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-36327391'])">Ref</a></span>).</p>
<p style="text-indent:-2em;margin-left:4em;">Intermittent dosing:</p>
<p style="text-indent:-2em;margin-left:6em;">
<b>IV, IM:</b> 25 to 50 mcg <b>or</b> 0.35 to 0.5 mcg/<b>kg</b> every 30 to 60 minutes as needed (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-Pandharipande.2019','lexi-content-ref-23269131']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-Pandharipande.2019','lexi-content-ref-23269131'])">Ref</a></span>). <b>Note:</b> More frequent administration may be necessary when used by the IV route due to short duration of activity. IM route should only be used if IV administration is not available (eg, loss of IV access).</p>
<p style="text-indent:-2em;margin-left:6em;">
<b>SUBQ (off-label route) (alternative agent):</b> 25 to 50 mcg every 1 to 2 hours as needed (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-Portenoy.1']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-Portenoy.1'])">Ref</a></span>). <b>Note: </b>Specific data on SUBQ intermittent dosing is not available; adjust dose according to patient response under close monitoring. If usual dose and frequency is insufficient, reassess patient and reconsider pain management strategies. Refer to institutional protocols.</p></div>
</div>
<div class="collapsible-indication">
<span class="collapsible-indication-title" data-indication-id="cde2d6a9-5930-4b05-818a-a638a59289ef">Chronic pain, including chronic cancer pain</span>
<div class="collapsible-indication-wrap">
<p style="text-indent:-2em;margin-left:2em;">
<b>Chronic pain, including chronic cancer pain: </b></p>
<p style="text-indent:-2em;margin-left:4em;">
<b>Note: </b>Opioids, including fentanyl, are <b>not</b> the preferred therapy for chronic noncancer pain due to insufficient evidence of benefit and risk of serious harm; nonpharmacologic treatment and nonopioid analgesics are preferred, with the exception of chronic pain from sickle cell disease and end-of-life care. Opioids, including fentanyl, should <b>only</b> be considered in patients with chronic, noncancer pain who are expected to experience clinically meaningful improvement in pain and function that outweighs patient safety risks (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-36327391']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-36327391'])">Ref</a></span>).</p>
<p style="text-indent:-2em;margin-left:4em;">
<b>SUBQ continuous infusion:</b>
<b>Note:</b> For progressive illnesses (eg, cancer), a continuous SUBQ infusion, with or without a patient-controlled analgesia option, can be used as pain requirements increase. In general, SUBQ continuous infusion dose is equivalent to IV continuous infusion dose (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-15122000']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-15122000'])">Ref</a></span>). Individualize dose based on previous opioid intake and appropriate opioid analgesic equivalents; titrate further, if needed, based on level of pain. Reported dosing varies greatly and is based on patient needs; refer to institutional protocols (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-8703661','lexi-content-ref-26762381','lexi-content-ref-8628593','lexi-content-ref-Portenoy.1']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-8703661','lexi-content-ref-26762381','lexi-content-ref-8628593','lexi-content-ref-Portenoy.1'])">Ref</a></span>).</p>
<p style="text-indent:-2em;margin-left:4em;">
<b>Transdermal patch:</b> Discontinue or taper all other around-the-clock or extended-release opioids when initiating therapy with fentanyl transdermal patch.</p>
<p style="text-indent:-2em;margin-left:6em;">
<i>
<b>Initial:</b></i> To convert patients from oral or parenteral opioids to fentanyl transdermal patch, a 24-hour analgesic requirement should be calculated (based on prior opioid use). Using the table below, the appropriate initial dose can be determined. The initial fentanyl dosage may be approximated from the 24-hour morphine dosage equivalent and titrated to minimize adverse effects and provide analgesia. While there are useful tables of opioid equivalents available, substantial interpatient variability exists in relative potency of different opioids and products. Therefore, it is safer to underestimate the daily fentanyl requirement and provide breakthrough pain relief with rescue medication (eg, immediate-release opioid) than to overestimate requirements, which could result in adverse reactions. With the initial application, the absorption of transdermal fentanyl requires several hours to reach plateau; therefore, transdermal fentanyl is inappropriate for management of acute pain. Change patch every 72 hours. The majority of patients may be controlled on every-72-hour administration; however, some patients may require every-48-hour administration because of more breakthrough pain in the last 24 hours of each cycle.</p>
<p style="text-indent:-2em;margin-left:8em;">
<i>Conversion from continuous IV infusion of fentanyl:</i> In patients who have adequate pain relief with IV fentanyl infusion, may convert to transdermal dosing at a rate equivalent to the IV rate using a 2-step taper of the infusion to be completed over 12 hours after the patch is applied. Six hours after the application of the first patch, decrease the infusion to 50% of the original rate; discontinue infusion 12 hours after patch application (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-11753984']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-11753984'])">Ref</a></span>).</p>
<p style="text-indent:-2em;margin-left:6em;">
<i>
<b>Titration:</b></i> Do not titrate more frequently than every 3 days after the initial application or every 6 days thereafter. Short-acting opioids may be required until analgesic efficacy is established and/or as supplements for breakthrough pain. The number and quantity of supplemental doses should be closely monitored. When increasing the dose, base the new dose on the daily requirement of supplemental opioids required by the patient during the second or third day of initial application. For example, if 24-hour oral morphine requirement for breakthrough pain is 50 mg, then may increase transdermal fentanyl dose by 25 mcg/hour (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-McPherson.1']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-McPherson.1'])">Ref</a></span>).</p>
<p style="text-indent:-2em;margin-left:4em;">
<b>Dose conversion guidelines for transdermal fentanyl (see table below):</b></p>
<p style="text-indent:-2em;margin-left:4em;">
<b>Note:</b> Using the manufacturer's recommended dose conversion guidelines, based upon the daily oral morphine dose, may underestimate the transdermal fentanyl strength required and result in the need for supplemental immediate-release opioid therapy for breakthrough pain or in the patient experiencing withdrawal syndrome (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-15537367']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-15537367'])">Ref</a></span>). The manufacturers recommend a ratio of approximately 45 mg/24 hours of oral morphine to a 12 mcg/hour fentanyl dosage (US labeling) or the ratio of 45 to 59 mg/24 hours of oral morphine to a 12 mcg/hour fentanyl dosage (Canadian labeling). Below is a less conservative dosing conversion strategy based on a 2:1 ratio of oral morphine to transdermal fentanyl (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-McPherson.1','lexi-content-ref-Portenoy.2']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-McPherson.1','lexi-content-ref-Portenoy.2'])">Ref</a></span>). For the more conservative dose conversion strategy, see the manufacturer's labeling. The table is only to be used for the conversion from current opioid therapy to transdermal fentanyl. <b>Do not use this table to convert from transdermal fentanyl to another opioid (doing so may lead to fatal overdose due to overestimation of the new opioid).</b> This is <b>not</b> a table of equianalgesic doses.</p>
<p style="text-indent:-2em;margin-left:6em;">
<b>Step 1:</b> Determine the patient's 24-hour oral morphine requirement. If patient was not receiving oral morphine, must convert the 24-hour requirement to the oral morphine equivalent using a conversion chart or tool.</p>
<p style="text-indent:-2em;margin-left:6em;">
<b>Step 2:</b> Once the 24-hour oral morphine requirement is determined, use the Dose Conversion Guidelines to determine the appropriate fentanyl transdermal dose (mcg/hour).</p>
<table border="1" frame="border" rules="all" style="margin-left:4em;">
<caption>
<b>Dose Conversion Guidelines: Recommended Initial Fentanyl Transdermal Dose Based Upon Daily Oral Morphine Dose<sup>a,b,c</sup></b></caption>
<colgroup><col align="center"/>
<col align="center"/>
</colgroup><thead>
<tr>
<th align="center">
<p style="text-indent:0em;">Oral 24-Hour Morphine Dose (mg/day)</p></th>
<th align="center">
<p style="text-indent:0em;">Fentanyl Transdermal Dose (mcg/hour)</p></th></tr></thead>
<tfoot>
<tr>
<td align="center" colspan="2">
<p style="text-indent:0em;text-align:left;">
<sup>a </sup>Portenoy 2019a.</p></td></tr>
<tr>
<td align="center" colspan="2">
<p style="text-indent:0em;text-align:left;">
<sup>b </sup>The table should <b>not </b>be used to convert from transdermal fentanyl to other opioid analgesics. Rather, following removal of the patch, titrate the dose of the new opioid until adequate analgesia is achieved.</p></td></tr>
<tr>
<td align="center" colspan="2">
<p style="text-indent:0em;text-align:left;">
<sup>c</sup> Suggested doses for conversion to transdermal fentanyl from other opioids are less conservative than recommendations in the US product labeling. The recommendations in this table are based on guidance available at experienced centers.</p></td></tr></tfoot>
<tbody>
<tr>
<td align="center">
<p style="text-indent:0em;">25</p></td>
<td align="center">
<p style="text-indent:0em;">12</p></td></tr>
<tr>
<td align="center">
<p style="text-indent:0em;">50</p></td>
<td align="center">
<p style="text-indent:0em;">25</p></td></tr>
<tr>
<td align="center">
<p style="text-indent:0em;">100</p></td>
<td align="center">
<p style="text-indent:0em;">50</p></td></tr>
<tr>
<td align="center">
<p style="text-indent:0em;">150</p></td>
<td align="center">
<p style="text-indent:0em;">75</p></td></tr>
<tr>
<td align="center">
<p style="text-indent:0em;">200</p></td>
<td align="center">
<p style="text-indent:0em;">100</p></td></tr>
<tr>
<td align="center">
<p style="text-indent:0em;">250</p></td>
<td align="center">
<p style="text-indent:0em;">125</p></td></tr>
<tr>
<td align="center">
<p style="text-indent:0em;">300</p></td>
<td align="center">
<p style="text-indent:0em;">150</p></td></tr>
<tr>
<td align="center">
<p style="text-indent:0em;">350</p></td>
<td align="center">
<p style="text-indent:0em;">175</p></td></tr>
<tr>
<td align="center">
<p style="text-indent:0em;">400</p></td>
<td align="center">
<p style="text-indent:0em;">200</p></td></tr>
<tr>
<td align="center">
<p style="text-indent:0em;">450</p></td>
<td align="center">
<p style="text-indent:0em;">225</p></td></tr>
<tr>
<td align="center">
<p style="text-indent:0em;">500</p></td>
<td align="center">
<p style="text-indent:0em;">250</p></td></tr>
<tr>
<td align="center">
<p style="text-indent:0em;">550</p></td>
<td align="center">
<p style="text-indent:0em;">275</p></td></tr>
<tr>
<td align="center">
<p style="text-indent:0em;">600</p></td>
<td align="center">
<p style="text-indent:0em;">300</p></td></tr></tbody></table>
<p style="text-indent:-2em;margin-left:4em;">
<b>Discontinuation or tapering of therapy</b>
<b>: </b></p>
<p style="text-indent:-2em;margin-left:6em;">When reducing the dose, discontinuing, or tapering long-term opioid therapy, the dose should be gradually tapered. An optimal tapering schedule has not been established. Individualize tapering based on discussions with patient to minimize withdrawal, while considering patient-specific goals and concerns and the opioid’s pharmacokinetics. Proposed initial schedules range from slow (eg, 10% reduction per week or 10% reduction per month depending on duration of long-term therapy) to rapid (eg, 25% to 50% reduction every few days) (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-CDC.1','lexi-content-ref-36327391']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-CDC.1','lexi-content-ref-36327391'])">Ref</a></span>). When discontinuing transdermal fentanyl and not converting to another opioid, particularly in patients who are physically opioid dependent, use a gradual downward titration (eg, decrease the dose by 25% every 2 to 4 weeks) (manufacturer's labeling). Upon system removal of transdermal fentanyl, ≥17 hours are required for a 50% decrease in fentanyl levels. Slower tapers may be appropriate after long-term use (eg, &gt;1 year), whereas more rapid tapers may be appropriate in patients experiencing severe adverse effects. During tapering, patients may be at an increased risk of overdose if they return to their original (or higher) opioid dose or use illicit opioids, due to rapid loss of tolerance; consider prescribing naloxone. Monitor carefully for signs/symptoms of withdrawal. If the patient displays withdrawal symptoms, consider slowing the taper schedule; alterations may include increasing the interval between dose reductions, decreasing amount of daily dose reduction, pausing the taper and restarting when the patient is ready, and/or coadministration of an alpha-2 agonist (eg, clonidine) to blunt autonomic withdrawal symptoms and other adjunctive agents to treat GI symptoms and muscle spasms, as needed. Continue to offer nonopioid analgesics as needed for pain management during the taper (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-36327391']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-36327391'])">Ref</a></span>). In patients who continue to take long-term opioid therapy but no longer require fentanyl for breakthrough pain, fentanyl can usually be discontinued without a taper.</p></div>
</div>
<div class="collapsible-indication">
<span class="collapsible-indication-title" data-indication-id="2d7575b8-8076-4b3f-b657-f1e23e8c157b">Chronic cancer pain, management of breakthrough pain episodes</span>
<div class="collapsible-indication-wrap">
<p style="text-indent:-2em;margin-left:2em;">
<b>Chronic cancer pain, management of breakthrough pain episodes: </b></p>
<p style="text-indent:-2em;margin-left:6em;">
<b>Transmucosal:</b></p>
<p style="text-indent:-2em;margin-left:8em;">
<b>Note: </b>For patients who are tolerant to and currently receiving opioid therapy for persistent cancer pain; dosing should be individually titrated to provide adequate analgesia with minimal side effects. Dose titration should be done if patient requires more than 1 dose per breakthrough pain episode for several consecutive episodes. Patients experiencing &gt;4 breakthrough pain episodes per day should have the dose of their long-term opioid reevaluated. <b>Patients must remain on around-the-clock opioids during use </b>(<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-Portenoy.1']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-Portenoy.1'])">Ref</a></span>).</p>
<p style="text-indent:-2em;margin-left:8em;">
<b>Lozenge (Actiq):</b>
<b>Note:</b> Do <b>not</b> convert patients from any other fentanyl product to Actiq on a mcg-per-mcg basis. Patients previously using another fentanyl product should be initiated at a dose of 200 mcg; individually titrate to provide adequate analgesia while minimizing adverse effects.</p>
<p style="text-indent:-2em;margin-left:10em;">
<i>Initial dose: </i>200 mcg (consumed over 15 minutes) for all patients; if after 30 minutes from the start of the lozenge (ie, 15 minutes following the completion of the lozenge) pain is unrelieved, a second 200 mcg dose may be given over 15 minutes. A maximum of 1 additional dose can be given per pain episode; <b>must wait at least 4 hours before treating another episode</b>. To limit the number of units in the home during titration, only prescribe an initial titration supply of six 200 mcg lozenges.</p>
<p style="text-indent:-2em;margin-left:10em;">
<i>Dose titration:</i> From the initial dose, closely monitor patients and modify the dose until patient reaches a dose providing adequate analgesia using a single dosage unit per breakthrough cancer pain episode. If signs/symptoms of excessive opioid effects (eg, respiratory depression) occur, immediately remove the dosage unit from the patient's mouth, dispose of properly, and reduce subsequent doses. If adequate relief is not achieved 15 minutes after completion of the first dose (ie, 30 minutes after the start of the lozenge), only 1 additional lozenge of the same strength may be given for that episode; <b>must wait at least 4 hours before treating another episode.</b></p>
<p style="text-indent:-2em;margin-left:10em;">
<i>Maintenance dose:</i> Once titrated to an effective dose, patients should generally use a single dosage unit per breakthrough pain episode. During any pain episode, if adequate relief is not achieved 15 minutes after completion of the first dose (ie, 30 minutes after the start of the lozenge), only 1 additional lozenge of the same strength may be given over 15 minutes for that episode; <b>must wait at least 4 hours before treating another episode</b>. Consumption should be limited to ≤4 units per day (once an effective breakthrough dose is found). If adequate analgesia is <b>not </b>provided after treating several episodes of breakthrough pain using the same dose, increase dose to next highest lozenge strength (initially dispense no more than 6 units of the new strength). Reevaluate the around-the-clock opioid therapy in patients experiencing &gt;4 breakthrough pain episodes per day. If signs/symptoms of excessive opioid effects (eg, respiratory depression) occur, immediately remove the dosage unit from the patient's mouth, dispose of properly, and reduce subsequent doses.</p>
<p style="text-indent:-2em;margin-left:8em;">
<b>Buccal tablet (Fentora):</b>
<b>Note:</b> Do <b>not</b> convert patients from any other fentanyl product to Fentora on a mcg-per-mcg basis. Patients previously using another fentanyl product should be initiated at a dose of 100 mcg (except Actiq); individually titrate to provide adequate analgesia while minimizing adverse effects. For patients previously using the transmucosal lozenge (Actiq), the initial dose should be selected using the conversions listed; see "Conversion From Lozenge (Actiq) to Buccal Tablet (Fentora)".</p>
<p style="text-indent:-2em;margin-left:10em;">
<i>Initial dose:</i> 100 mcg for all patients unless patient is already using Actiq; see "Conversion From Lozenge (Actiq) to Buccal Tablet (Fentora)"<i>.</i> If after 30 minutes pain is unrelieved, a second 100 mcg dose may be administered (US labeling) or an alternative analgesic rescue medication (other than Fentora) may be given (Canadian labeling). A maximum of 2 doses (or 1 dose [Canadian labeling]) can be given per breakthrough pain episode. <b>Must wait at least 4 hours before treating another episode with buccal tablet.</b></p>
<p style="text-indent:-2em;margin-left:10em;">
<i>Dose titration: </i>If titration required, the 100 mcg dose may be increased to 200 mcg using two 100 mcg tablets (one on each side of mouth) with the next breakthrough pain episode. If 200 mcg dose is not successful, patient can use four 100 mcg tablets (two on each side of mouth) with the next breakthrough pain episode. If titration requires &gt;400 mcg per dose, titrate using 200 mcg tablets; do not use more than 4 tablets simultaneously (maximum single dose: 800 mcg). During any breakthrough pain episode, if adequate relief is not achieved 30 minutes after buccal tablet application, a second dose of same strength for that breakthrough pain episode may be used (US labeling) or an alternative analgesic rescue medication (other than Fentora) may be given (Canadian labeling). <b>Must wait at least 4 hours before treating another episode with buccal tablet. </b></p>
<p style="text-indent:-2em;margin-left:10em;">
<i>Maintenance dose: </i>Following titration, the effective maintenance dose using 1 tablet of the appropriate strength should be administered once per episode; if after 30 minutes pain is unrelieved, may administer a second dose of the same strength (US labeling) or an alternative analgesic rescue medication (other than Fentora) may be given (Canadian labeling). <b>Must wait at least 4 hours before treating another episode with buccal tablet.</b> Limit to 4 applications per day. Reevaluate the around-the-clock opioid therapy in patients experiencing &gt;4 breakthrough pain episodes per day. Once an effective maintenance dose has been established, the buccal tablet may be administered sublingually (alternative route). To prevent confusion, patient should only have one strength available at a time. Once maintenance dose is determined, all other unused tablets should be disposed of and that strength (using a single tablet) should be used. Using more than 4 buccal tablets at a time has not been studied.</p>
<p style="text-indent:-2em;margin-left:10em;">
<i>Conversion from lozenge (Actiq) to buccal tablet (Fentora):</i></p>
<p style="text-indent:-2em;margin-left:12em;">Lozenge dose 200 or 400 mcg: Initial buccal tablet dose is 100 mcg; may titrate using multiples of 100 mcg.</p>
<p style="text-indent:-2em;margin-left:12em;">Lozenge dose 600 or 800 mcg: Initial buccal tablet dose is 200 mcg; may titrate using multiples of 200 mcg.</p>
<p style="text-indent:-2em;margin-left:12em;">Lozenge dose 1,200 or 1,600 mcg: Initial buccal tablet dose is 400 mcg (using two 200 mcg tablets); may titrate using multiples of 200 mcg.</p>
<p style="text-indent:-2em;margin-left:6em;">
<b>Intranasal (Lazanda): Note:</b> Do <b>not</b> convert patients from any other fentanyl product to Lazanda on a mcg-per-mcg basis. Patients previously using another fentanyl product should be initiated at a dose of 100 mcg (except Actiq); individually titrate to provide adequate analgesia while minimizing adverse effects.</p>
<p style="text-indent:-2em;margin-left:8em;">
<i>Initial dose:</i> 100 mcg (one 100 mcg spray in one nostril) for all patients; if after 30 minutes pain is unrelieved, an alternative rescue medication may be used. <b>Must wait at least 2 hours before treating another episode with fentanyl intranasal.</b> However, for the next pain episode, increase to a higher dose using the recommended dose titration steps.</p>
<p style="text-indent:-2em;margin-left:8em;">
<i>Dose titration:</i> If titration required, increase to a higher dose for the next pain episode using the following titration steps <b>(Note: Must wait at least 2 hours before treating another episode with fentanyl intranasal)</b>: If no relief with 100 mcg dose, increase to 200 mcg dose per episode (one 100 mcg spray in each nostril); if no relief with 200 mcg dose, increase to 300 mcg dose per episode (alternating one 100 mcg spray in right nostril, one 100 mcg spray in left nostril, and one 100 mcg spray in the right nostril); if no relief with 300 mcg dose, increase to 400 mcg dose per episode (one 400 mcg spray in one nostril or alternating two 100 mcg sprays in each nostril); if no relief with 400 mcg dose, increase to 600 mcg dose per episode (one 300 mcg spray in each nostril); if no relief with 600 mcg dose, increase to 800 mcg dose per episode (one 400 mcg spray in each nostril). <b>Note:</b> Single doses &gt;800 mcg have not been evaluated. Avoid use of a combination of dose strengths to treat an episode, as this may cause confusion and dosing errors.</p>
<p style="text-indent:-2em;margin-left:8em;">
<i>Maintenance dose:</i> Once maintenance dose for breakthrough pain episode has been determined, use that dose for subsequent episodes. For pain that is not relieved 30 minutes after Lazanda administration or if a separate breakthrough pain episode occurs within the 2-hour window before the next Lazanda dose is permitted, a rescue medication may be used. Limit Lazanda use to ≤4 doses per day. If patient is experiencing &gt;4 breakthrough pain episodes per day, consider increasing the around-the-clock, long-acting opioid therapy; if long-acting opioid therapy dose is altered, reevaluate and retitrate Lazanda dose as needed. If response to maintenance dose changes (increase in adverse reactions or alterations in pain relief), dose readjustment may be necessary.</p>
<p style="text-indent:-2em;margin-left:6em;">
<b>Sublingual:</b></p>
<p style="text-indent:-2em;margin-left:8em;">
<b>Sublingual spray (Subsys):</b>
<b>Note:</b> Do <b>not</b> convert patients from any other fentanyl product to Subsys on a mcg-per-mcg basis. Patients previously using another fentanyl product should be initiated at a dose of 100 mcg (except Actiq); individually titrate to provide adequate analgesia while minimizing adverse effects. For patients previously using the transmucosal lozenge (Actiq), the initial dose should be selected using the conversions listed; see "Conversion From Lozenge (Actiq) to Sublingual Spray (Subsys)".</p>
<p style="text-indent:-2em;margin-left:10em;">
<i>Initial dose:</i> 100 mcg for all patients unless patient is already using Actiq; see "Conversion From Lozenge (Actiq) to Sublingual Spray (Subsys)". If after 30 minutes pain is unrelieved, 1 additional 100 mcg dose may be given. A maximum of 2 doses can be given per breakthrough pain episode. <b>Must wait at least 4 hours before treating another episode with sublingual spray.</b></p>
<p style="text-indent:-2em;margin-left:10em;">
<i>Dose titration: </i>If titration required, titrate to a dose that provides adequate analgesia (with tolerable side effects) using the following titration steps: If no relief with 100 mcg dose, increase to 200 mcg dose (using one 200 mcg unit); if no relief with 200 mcg dose, increase to 400 mcg dose (using one 400 mcg unit); if no relief with 400 mcg dose, increase to 600 mcg dose (using one 600 mcg unit); if no relief with 600 mcg dose, increase to 800 mcg dose (using one 800 mcg unit); if no relief with 800 mcg dose, increase to 1,200 mcg dose (using two 600 mcg units); if no relief with 1,200 mcg dose, increase to 1,600 mcg dose (using two 800 mcg units). During dose titration, if breakthrough pain is unrelieved 30 minutes after Subsys administration, 1 additional dose using the same strength may be administered (maximum: 2 doses per breakthrough pain episode); <b>patient must wait 4 hours before treating another breakthrough pain episode with sublingual spray.</b></p>
<p style="text-indent:-2em;margin-left:10em;">
<i>Maintenance dose: </i>Once maintenance dose for breakthrough pain episode has been determined, use that dose for subsequent episodes. If occasional episodes of unrelieved breakthrough pain occur 30 minutes after Subsys administration, 1 additional dose using the same strength may be administered (maximum: 2 doses per breakthrough pain episode); <b>patient must wait 4 hours before treating another breakthrough pain episode with sublingual spray.</b> Once maintenance dose is determined, limit Subsys use to ≤4 doses per day. If response to maintenance dose changes (increase in adverse reactions or alterations in pain relief), dose readjustment may be necessary. If patient is experiencing &gt;4 breakthrough pain episodes per day, reevaluate the around-the-clock, long-acting opioid therapy.</p>
<p style="text-indent:-2em;margin-left:10em;">
<i>Conversion from lozenge (Actiq) to sublingual spray (Subsys):</i></p>
<p style="text-indent:-2em;margin-left:12em;">Lozenge dose 200 or 400 mcg: Initial sublingual spray dose is 100 mcg; may titrate using multiples of 100 mcg.</p>
<p style="text-indent:-2em;margin-left:12em;">Lozenge dose 600 or 800 mcg: Initial sublingual spray dose is 200 mcg; may titrate using multiples of 200 mcg.</p>
<p style="text-indent:-2em;margin-left:12em;">Lozenge dose 1,200 or 1,600 mcg: Initial sublingual spray dose is 400 mcg; may titrate using multiples of 400 mcg.</p>
<p style="text-indent:-2em;margin-left:8em;">
<b>Sublingual tablet (Abstral):</b>
<b>Note:</b> Abstral has been discontinued in the United States for &gt;1 year. Do <b>not</b> convert patients from any other fentanyl product to Abstral on a mcg-per-mcg basis. Patients previously using another fentanyl product should be initiated at a dose of 100 mcg (except Actiq); individually titrate to provide adequate analgesia while minimizing adverse effects. For patients previously using the transmucosal lozenge (Actiq), the initial dose should be selected using the conversions listed; see "Conversion From Lozenge (Actiq) to Sublingual Tablet (Abstral)".</p>
<p style="text-indent:-2em;margin-left:10em;">
<i>Initial dose:</i> 100 mcg for all patients unless patient is already using Actiq; see "Conversion From Lozenge (Actiq) to Sublingual Tablet (Abstral)". If after 30 minutes pain is unrelieved, a second 100 mcg dose may be given (US labeling) or an alternative rescue medication (other than Abstral) may be given (Canadian labeling). A maximum of 2 doses (or 1 dose [Canadian labeling]) can be given per breakthrough pain episode. <b>Must wait at least 2 hours before treating another episode with sublingual tablet.</b></p>
<p style="text-indent:-2em;margin-left:10em;">
<i>Dose titration:</i> If titration required, increase in 100 mcg increments (up to 400 mcg) over consecutive breakthrough episodes. If titration requires &gt;400 mcg per dose, increase in increments of 200 mcg, starting with a 600 mcg dose and titrating up to 800 mcg. During titration, patients may use multiples of 100 mcg and/or 200 mcg tablets for any single dose; do not exceed 4 tablets at one time; safety and efficacy of doses &gt;800 mcg have not been evaluated. During dose titration, if breakthrough pain is unrelieved 30 minutes after sublingual tablet administration, 1 additional dose using the same strength may be administered (US labeling) or an alternative rescue medication (other than Abstral) may be given (Canadian labeling). A maximum of 2 doses (or 1 dose [Canadian labeling]) can be given per breakthrough pain episode. <b>Must wait 2 hours before treating another breakthrough pain episode with sublingual tablet.</b></p>
<p style="text-indent:-2em;margin-left:10em;">
<i>Maintenance dose: </i>Once maintenance dose for breakthrough pain episode has been determined, use only 1 tablet of the appropriate strength per episode; if pain is unrelieved with maintenance dose, a second dose may be given after 30 minutes (US labeling) or an alternative rescue medication (other than Abstral) may be given (Canadian labeling). A maximum of 2 doses (or 1 dose [Canadian labeling]) can be given per breakthrough pain episode. Separate treatment of subsequent episodes by ≥2 hours; limit Abstral use to ≤4 doses per day. Consider reevaluating the around-the-clock, long-acting opioid therapy in patients experiencing &gt;4 breakthrough pain episodes per day; if long-acting opioid therapy dose altered, reevaluate and retitrate Abstral dose as needed.</p>
<p style="text-indent:-2em;margin-left:10em;">
<i>Conversion from lozenge (Actiq) to sublingual tablet (Abstral):</i></p>
<p style="text-indent:-2em;margin-left:12em;">Lozenge dose of 200 mcg: Initial sublingual tablet dose is 100 mcg; may titrate using multiples of 100 mcg.</p>
<p style="text-indent:-2em;margin-left:12em;">Lozenge dose of 400, 600, 800, or 1,200 mcg: Initial sublingual tablet dose is 200 mcg; may titrate using multiples of 200 mcg.</p>
<p style="text-indent:-2em;margin-left:12em;">Lozenge dose of 1,600 mcg: Initial sublingual tablet dose is 400 mcg; may titrate using multiples of 400 mcg.</p></div>
</div>
<div class="collapsible-indication">
<span class="collapsible-indication-title" data-indication-id="8a80762b-1a8b-4dc9-a302-107feae4f165">Critically ill patients in the ICU, analgesia and sedation</span>
<div class="collapsible-indication-wrap">
<p style="text-indent:-2em;margin-left:2em;">
<b>Critically ill patients in the ICU, analgesia and sedation (off-label use):</b></p>
<p style="text-indent:-2em;margin-left:4em;">
<b>Note: </b>Multimodal approaches (eg, a combination of analgesics and techniques) should typically be employed for pain control in this setting. Pain should be monitored using validated scales (eg, behavioral pain scale, critical-care pain observation tool) in ICU patients who are unable to self-report (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-30113379']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-30113379'])">Ref</a></span>).</p>
<p style="text-indent:-2em;margin-left:4em;">
<b>Intermittent dosing: </b></p>
<p style="text-indent:-2em;margin-left:6em;">
<i>Loading dose:</i>
<b>IV:</b> 25 to 100 mcg <b>or</b> 1 to 2 mcg/<b>kg</b>; may repeat dose if severe pain persists and adverse effects are minimal at the time of expected peak effect (eg, ~5 minutes after administration) (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-Pandharipande.2019']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-Pandharipande.2019'])">Ref</a></span>). Follow with intermittent maintenance dose or a continuous infusion.</p>
<p style="text-indent:-2em;margin-left:6em;">
<i>Maintenance dose:</i>
<b>IV:</b> 25 to 50 mcg <b>or</b> 0.35 to 0.5 mcg/<b>kg</b> every 30 to 60 minutes as needed (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-Pandharipande.2019','lexi-content-ref-23269131']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-Pandharipande.2019','lexi-content-ref-23269131'])">Ref</a></span>).</p>
<p style="text-indent:-2em;margin-left:4em;">
<b>Continuous infusion: </b></p>
<p style="text-indent:-2em;margin-left:6em;">
<b>IV:</b> After initial loading dose, begin continuous infusion at an initial rate of 25 to 50 mcg/hour; titrate every 30 to 60 minutes to clinical effect (ie, pain control and/or sedation). May administer an additional small bolus dose (eg, 25 mcg) prior to increasing the infusion rate (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-9952166','lexi-content-ref-1952204']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-9952166','lexi-content-ref-1952204'])">Ref</a></span>). Usual dosing range: 50 to 300 mcg/hour; weight-based dosing range: 0.7 to 10 mcg/<b>kg</b>/hour (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-Pandharipande.2019','lexi-content-ref-23269131']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-Pandharipande.2019','lexi-content-ref-23269131'])">Ref</a></span>).<b> Note: </b>Fentanyl can accumulate in lipid stores when used for extended periods of time and may result in prolonged sedation and reduced ability to liberate from mechanical ventilator (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-Pandharipande.2019']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-Pandharipande.2019'])">Ref</a></span>).</p></div>
</div>
<div class="collapsible-indication">
<span class="collapsible-indication-title" data-indication-id="69afa7b6-eefe-45f6-975d-002eb321a427">Procedural sedation and analgesia</span>
<div class="collapsible-indication-wrap">
<p style="text-indent:-2em;margin-left:2em;">
<b>Procedural sedation and analgesia: </b></p>
<p style="text-indent:-2em;margin-left:4em;">
<b>
<i>Outside the operating room (alternative agent) </i></b>
<b>
<i>(off-label use)</i></b>
<b>
<i>:</i></b></p>
<p style="text-indent:-2em;margin-left:6em;">
<b>IV:</b> 0.5 to 1 mcg/<b>kg</b> every 2 minutes until desired level of sedation and analgesia achieved (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-15829394','lexi-content-ref-Frank.2019']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-15829394','lexi-content-ref-Frank.2019'])">Ref</a></span>); generally, the maximum total dose is 250 mcg. If administered with other sedatives (eg, etomidate, propofol, midazolam), do not exceed single doses of 0.5 mcg/<b>kg</b> (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-Frank.2019']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-Frank.2019'])">Ref</a></span>).</p>
<p style="text-indent:-2em;margin-left:6em;">
<b>Intranasal (using parenteral solution [50 mcg/mL])</b> (off-label route): 1 to 2 mcg/<b>kg</b> as a single dose; administer half the dose in each nostril; maximum total dose: 100 mcg (50 mcg per nostril; based on volume) (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-28259526','lexi-content-ref-31740092','lexi-content-ref-30275061']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-28259526','lexi-content-ref-31740092','lexi-content-ref-30275061'])">Ref</a></span>). <b>Note:</b> Recommend using a nasal atomizer for delivery (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-28259526','lexi-content-ref-30275061']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-28259526','lexi-content-ref-30275061'])">Ref</a></span>).</p>
<p style="text-indent:-2em;margin-left:4em;">
<b>
<i>Analgesia during monitored anesthesia care or regional anesthesia: </i>IV:</b> Usual initial dose range: 0.5 to 2 mcg/<b>kg</b>, administered in incremental boluses of 25 to 50 mcg, titrated to effect. When used in combination with a sedative (eg, midazolam), consider dosage reduction (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-Rosero.2019']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-Rosero.2019'])">Ref</a></span>). <b>Note:</b> Since an IV should be in place with anesthesia, the IM route is rarely used but still maintained as an option in the manufacturer's labeling. If IM route is used, the dose is equivalent to the recommended IV dose.</p></div>
</div>
<div class="collapsible-indication">
<span class="collapsible-indication-title" data-indication-id="270a5158-d537-4787-a196-13424f633399">Rapid sequence intubation, pretreatment</span>
<div class="collapsible-indication-wrap">
<p style="text-indent:-2em;margin-left:2em;">
<b>Rapid sequence intubation, pretreatment (off-label use): IV:</b> Usual dose: 50 to 200 mcg (or 1 to 3 mcg/<b>kg</b>) over 30 to 60 seconds administered ~3 minutes prior to induction. In patients with tenuous hemodynamic status, avoid use or use lower doses (eg, 1 mcg/<b>kg</b> [or 50 mcg]); in patients with elevated intracranial pressure, use higher doses (eg, 3 mcg/<b>kg</b> [or 200 mcg]). Avoid use in patients with shock or significant hemodynamic instability (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-Caro.2019','lexi-content-ref-29413725','lexi-content-ref-Roberts.2019','lexi-content-ref-24259635']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-Caro.2019','lexi-content-ref-29413725','lexi-content-ref-Roberts.2019','lexi-content-ref-24259635'])">Ref</a></span>).</p></div>
</div>
<div class="collapsible-indication">
<span class="collapsible-indication-title" data-indication-id="d181a5f4-ff4e-4c53-9710-1ef232f62b7c">General anesthesia</span>
<div class="collapsible-indication-wrap">
<p style="text-indent:-2em;margin-left:2em;">
<b>General anesthesia: </b></p>
<p style="text-indent:-2em;margin-left:4em;">
<i>Preinduction: </i>
<b>IV:</b> 25 mcg; may repeat in increments of 25 mcg (typical total dose is ≤100 mcg) to provide pain relief or if patient requires a regional anesthesia procedure prior to surgery (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-Alexander.1','lexi-content-ref-Roberts.2019']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-Alexander.1','lexi-content-ref-Roberts.2019'])">Ref</a></span>).</p>
<p style="text-indent:-2em;margin-left:4em;">
<i>Induction: </i>
<b>IV:</b> 25 to 100 mcg (or 0.5 to 1 mcg/<b>kg</b>) (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-Alexander.1','lexi-content-ref-Bravenec.1']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-Alexander.1','lexi-content-ref-Bravenec.1'])">Ref</a></span>). Some use a high-dose opioid induction technique (eg, 10 to 25 mcg/<b>kg</b>) for select patients (eg, those with poor myocardial function) who will remain intubated for several hours postoperatively (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-Alexander.1']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-Alexander.1'])">Ref</a></span>).</p>
<p style="text-indent:-2em;margin-left:4em;">
<i>Maintenance: </i></p>
<p style="text-indent:-2em;margin-left:6em;">Intermittent:<b> IV:</b> 25 to 50 mcg bolus as needed; may be used to provide supplemental analgesia during maintenance of general anesthesia with inhaled agents (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-Alexander.1']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-Alexander.1'])">Ref</a></span>).</p>
<p style="text-indent:-2em;margin-left:6em;">Continuous infusion: <b>IV:</b> 1 to 2 mcg/<b>kg</b>/hour as supplement to total IV anesthesia (TIVA) when controlled postoperative ventilation is planned (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-Alexander.1']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-Alexander.1'])">Ref</a></span>).</p></div>
</div>
<div class="collapsible-indication">
<span class="collapsible-indication-title" data-indication-id="8cbb558f-8158-4d1b-9441-af184bc939e3">Neuraxial analgesia</span>
<div class="collapsible-indication-wrap">
<p style="text-indent:-2em;margin-left:2em;">
<b>Neuraxial analgesia:</b></p>
<p style="text-indent:-2em;margin-left:4em;">
<b>Epidural: </b>
<b>Note: </b>Reserve use for patients with severe acute pain (eg, after major abdominal surgery, cancer pain, during labor and delivery). Must be administered by health care providers skilled in the care of patients receiving intraspinal opioids (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-26827847']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-26827847'])">Ref</a></span>). Use a <b>preservative-free</b> formulation intended for neuraxial use. Example regimens and usual doses are provided; specific regimens and doses vary based on type of surgery, comorbidities, and institutional policies and practices.</p>
<p style="text-indent:-2em;margin-left:6em;">
<b>
<i>Single dose</i>:</b> 25 to 100 mcg; may provide adequate relief for up to 8 hours. May repeat with additional 100 mcg boluses on demand (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-manu.1']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-manu.1'])">Ref</a></span>) or alternatively may administer by a continuous infusion (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-APS.1','lexi-content-ref-manu.2']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-APS.1','lexi-content-ref-manu.2'])">Ref</a></span>).</p>
<p style="text-indent:-2em;margin-left:6em;">
<b>
<i>Continuous infusion</i>:</b> 25 to 100 mcg/hour (fentanyl alone). When combined with a local anesthetic (eg, bupivacaine), fentanyl requirement is less (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-APS.1','lexi-content-ref-21606825']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-APS.1','lexi-content-ref-21606825'])">Ref</a></span>).</p>
<p style="text-indent:-2em;margin-left:4em;">
<b>Intrathecal:</b>
<b>Note: </b>Reserve use for patients with severe acute pain (eg, after major abdominal surgery, cancer pain, during labor and delivery). Must be administered by health care providers skilled in the care of patients receiving intraspinal opioids (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-26827847']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-26827847'])">Ref</a></span>). Use a <b>preservative-free </b>formulation intended for neuraxial use.</p>
<p style="text-indent:-2em;margin-left:6em;">
<b>
<i>Single dose:</i></b> 15 to 25 mcg; may provide adequate relief for up to 6 hours. When combined with a local anesthetic (eg, bupivacaine), fentanyl dose requirement is less (eg, 10 to 15 mcg instead of 15 to 25 mcg) (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-APS.1','lexi-content-ref-Darby.2019']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-APS.1','lexi-content-ref-Darby.2019'])">Ref</a></span>).</p></div>
</div>
<p style="text-indent:-2em;margin-left:2em;">
<b>Dosage adjustment for concomitant therapy:</b> Significant drug interactions exist, requiring dose/frequency adjustment or avoidance. Consult drug interactions database for more information.</p></div>
<div class="block dora drugH1Div" id="F50991138"><span class="drugH1">Dosing: Kidney Impairment: Adult</span>
<p style="text-indent:0em;display:inline">The renal dosing recommendations are based upon the best available evidence and clinical expertise. Senior Editorial Team: Bruce Mueller, PharmD, FCCP, FASN, FNKF; Jason Roberts, PhD, BPharm (Hons), B App Sc, FSHP, FISAC; Michael Heung, MD, MS.</p>
<p style="text-indent:-2em;margin-left:2em;">
<b>Note: </b>Although limited pharmacokinetic data exist in patients with renal insufficiency, &lt;7% to 10% of fentanyl is excreted as unchanged drug and its metabolites are inactive. Fentanyl may be used and is generally considered safe for use in patients with kidney impairment with low initial doses and careful monitoring for accumulation and adverse effects (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-30833302','lexi-content-ref-24517512','lexi-content-ref-27881247']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-30833302','lexi-content-ref-24517512','lexi-content-ref-27881247'])">Ref</a></span>).</p>
<p style="text-indent:-2em;margin-left:2em;">
<b>Altered kidney function:</b></p>
<p style="text-indent:-2em;margin-left:4em;">
<b>Injection:</b> CrCl &lt;50 mL/minute:</p>
<p style="text-indent:-2em;margin-left:6em;">No dosage adjustment necessary when single or infrequent bolus doses are used for short interventional procedures (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-21338400']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-21338400'])">Ref</a></span>). For more frequent dosing, use small, incremental doses to titrate based on analgesic response and adverse effects (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-22300860','lexi-content-ref-Nemecek.1']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-22300860','lexi-content-ref-Nemecek.1'])">Ref</a></span>). May need to decrease dose to avoid accumulation (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-15504625','lexi-content-ref-16898102']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-15504625','lexi-content-ref-16898102'])">Ref</a></span>), especially with continuous infusions (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-11902253']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-11902253'])">Ref</a></span>).</p>
<p style="text-indent:-2em;margin-left:4em;">
<b>Transdermal (patch):</b></p>
<p style="text-indent:-2em;margin-left:6em;">
<b>Note</b>: Although the manufacturer recommends to avoid use of transdermal fentanyl in severe impairment, fentanyl can be used safely in these patients with caution and close monitoring with initial and long-term use (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-20041843']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-20041843'])">Ref</a></span>). The following dose adjustments have been proposed when initiating transdermal fentanyl:</p>
<p style="text-indent:-2em;margin-left:8em;">CrCl &gt;50 mL/minute: No dosage adjustment necessary.</p>
<p style="text-indent:-2em;margin-left:8em;">CrCl 10 to 50 mL/minute: Initial: 75% of normal dose (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-27881247']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-27881247'])">Ref</a></span>).</p>
<p style="text-indent:-2em;margin-left:8em;">CrCl &lt;10 mL/minute: Initial: 50% of normal dose (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-27881247']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-27881247'])">Ref</a></span>).</p>
<p style="text-indent:-2em;margin-left:4em;">
<b>Transdermal (device):</b> There are no dosage adjustments provided in the manufacturer's labeling (has not been studied); fentanyl pharmacokinetics may be altered in kidney disease.</p>
<p style="text-indent:-2em;margin-left:4em;">
<b>Transmucosal (buccal tablet, sublingual spray/tablet, lozenge) and intranasal:</b> There are no dosage adjustments provided in the manufacturer's labeling; use with caution. Although fentanyl pharmacokinetics may be altered in kidney disease, transmucosal fentanyl can be used successfully in the management of breakthrough cancer pain. Doses should be titrated to reach clinical effect with careful monitoring of patients with severe kidney disease.</p>
<p style="text-indent:-2em;margin-left:2em;">
<b>Dialysis, intermittent (thrice weekly):</b> Not dialyzable (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-9430910','lexi-content-ref-15504625','lexi-content-ref-9459269']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-9430910','lexi-content-ref-15504625','lexi-content-ref-9459269'])">Ref</a></span>):</p>
<p style="text-indent:-2em;margin-left:4em;">
<b>Transdermal patch:</b> Initial: 50% of normal dose (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-27881247']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-27881247'])">Ref</a></span>).</p>
<p style="text-indent:-2em;margin-left:4em;">
<b>All other formulations/routes:</b> Use lowest effective dose with gradual titration and close monitoring of response and adverse effects (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-Expert.DOR']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-Expert.DOR'])">Ref</a></span>).</p>
<p style="text-indent:-2em;margin-left:2em;">
<b>Peritoneal dialysis:</b></p>
<p style="text-indent:-2em;margin-left:4em;">
<b>Transdermal patch:</b> Initial: 50% of normal dose (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-27881247']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-27881247'])">Ref</a></span>).</p>
<p style="text-indent:-2em;margin-left:4em;">
<b>All other formulations/routes:</b> Use lowest effective dose with gradual titration and close monitoring of response and adverse effects (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-Expert.DOR']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-Expert.DOR'])">Ref</a></span>).</p>
<p style="text-indent:-2em;margin-left:2em;">
<b>CRRT: </b></p>
<p style="text-indent:-2em;margin-left:4em;">
<b>All formulations/routes:</b> Use lowest effective dose with gradual titration and close monitoring of response and adverse effects (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-Expert.DOR']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-Expert.DOR'])">Ref</a></span>).</p></div>
<div class="block doha drugH1Div" id="F50988471"><span class="drugH1">Dosing: Hepatic Impairment: Adult</span>
<p style="text-indent:-2em;margin-left:2em;">Injection: There are no dosage adjustments provided in the manufacturer’s labeling; use with caution.</p>
<p style="text-indent:-2em;margin-left:2em;">Transdermal (device): There are no dosage adjustments provided in the manufacturer’s labeling (has not been studied); fentanyl pharmacokinetics may be altered in hepatic disease.</p>
<p style="text-indent:-2em;margin-left:2em;">Transdermal (patch):</p>
<p style="text-indent:-2em;margin-left:4em;">Mild to moderate impairment: Initial: Reduce dose by 50%.</p>
<p style="text-indent:-2em;margin-left:4em;">Severe impairment: Use not recommended.</p>
<p style="text-indent:-2em;margin-left:2em;">Transmucosal (buccal tablet, sublingual spray/tablet, lozenge) and intranasal: There are no dosage adjustments provided in the manufacturer’s labeling; use with caution. Although fentanyl pharmacokinetics may be altered in hepatic disease, fentanyl can be used successfully in the management of breakthrough cancer pain. Doses should be titrated to reach clinical effect with careful monitoring of patients with severe hepatic disease.</p></div>
<div class="block arsc drugH1Div" id="F56437628"><span class="drugH1">Adverse Reactions (Significant): Considerations</span>
<div class="collapsible">
<span class="collapsible-title">Opioid-induced constipation</span>
<div class="collapsible-wrap">
<p style="text-indent:-2em;margin-left:2em;">Opioid-induced <b>constipation</b> (OIC) is the most common subtype of opioid-induced bowel dysfunction (OIBD), which is a broader term that encompasses additional GI opioid-induced adverse reactions including nausea, vomiting, and gastroesophageal reflux. Tolerance does not develop to OIC (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-30788113','lexi-content-ref-28034973','lexi-content-ref-17087429']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-30788113','lexi-content-ref-28034973','lexi-content-ref-17087429'])">Ref</a></span>). Constipation due to fentanyl may decrease quality of life, contribute to nonadherence, and result in treatment failure (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-30855724']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-30855724'])">Ref</a></span>). Transdermal fentanyl may cause less constipation than oral opioids (eg, oxycodone, morphine) (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-17087429']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-17087429'])">Ref</a></span>). Fentanyl may cause less constipation than morphine in critically ill children (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-26254837']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-26254837'])">Ref</a></span>).</p>
<p style="text-indent:-2em;margin-left:4em;">
<i>Mechanism</i>: Time-related; activity in both the central and enteric nervous systems, predominantly via the mu-opioid receptor, delays gastric emptying, inhibits peristalsis, impairs enzyme release, and produces antisecretory effects (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-29273520']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-29273520'])">Ref</a></span>).</p>
<p style="text-indent:-2em;margin-left:4em;">
<i>Onset:</i> Varied; changes in peristalsis may occur 5 to 25 minutes after administration of opioids (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-15153834']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-15153834'])">Ref</a></span>). However, OIC is defined based on a 7-day period of change (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-30778756']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-30778756'])">Ref</a></span>).</p>
<p style="text-indent:-2em;margin-left:4em;">
<i>Risk factors:</i></p>
<p style="text-indent:-2em;margin-left:6em;">• Chronic opioid administration (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-26136838']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-26136838'])">Ref</a></span>)</p></div>
</div>
<div class="collapsible">
<span class="collapsible-title">Opioid-induced respiratory depression</span>
<div class="collapsible-wrap">
<p style="text-indent:-2em;margin-left:2em;">Serious, life-threatening, or fatal opioid-induced <b>respiratory depression</b> (OIRD) may occur with use of fentanyl (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-20010421','lexi-content-ref-20547520']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-20010421','lexi-content-ref-20547520'])">Ref</a></span>). Fentanyl may be particularly hazardous secondary to potency, faster onset of action, and lower cross tolerance (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-31499594']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-31499594'])">Ref</a></span>).</p>
<p style="text-indent:-2em;margin-left:4em;">
<i>Mechanism:</i> Dose-related; mediated predominately via the mu-opioid receptor. Activates specific CNS sites (ie, pre-Bötzinger complex and Kölliker-Fuse nucleus) that control respiratory rhythms (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-22747535','lexi-content-ref-31589332']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-22747535','lexi-content-ref-31589332'])">Ref</a></span>).</p>
<p style="text-indent:-2em;margin-left:4em;">
<i>Onset:</i> Rapid; OIRD reported from 5 minutes to 1.2 hours (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-30915997']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-30915997'])">Ref</a></span>).</p>
<p style="text-indent:-2em;margin-left:4em;">
<i>Risk factors:</i></p>
<p style="text-indent:-2em;margin-left:6em;">• Overdose (but may also occur at therapeutic doses)</p>
<p style="text-indent:-2em;margin-left:6em;">• Initiation or dose escalation</p>
<p style="text-indent:-2em;margin-left:6em;">• Opioid naive (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-32925318']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-32925318'])">Ref</a></span>)</p>
<p style="text-indent:-2em;margin-left:6em;">• Opioid misuse/abuse (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-28646524']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-28646524'])">Ref</a></span>)</p>
<p style="text-indent:-2em;margin-left:6em;">• Respiratory disease (eg, obstructive sleep apnea) (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-29120929','lexi-content-ref-32925317']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-29120929','lexi-content-ref-32925317'])">Ref</a></span>)</p>
<p style="text-indent:-2em;margin-left:6em;">• Cardiac disease (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-29120929']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-29120929'])">Ref</a></span>)</p>
<p style="text-indent:-2em;margin-left:6em;">• Morbid obesity (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-20010421']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-20010421'])">Ref</a></span>)</p>
<p style="text-indent:-2em;margin-left:6em;">• Older adults</p>
<p style="text-indent:-2em;margin-left:6em;">• Kidney and/or liver impairment</p>
<p style="text-indent:-2em;margin-left:6em;">• Cachectic or debilitated</p>
<p style="text-indent:-2em;margin-left:6em;">• Concurrent benzodiazepines or other CNS depressants</p>
<p style="text-indent:-2em;margin-left:6em;">• Concurrent use with cytochrome P450 3A4 inhibitors</p></div>
</div>
<div class="collapsible">
<span class="collapsible-title">Opioid-induced withdrawal</span>
<div class="collapsible-wrap">
<p style="text-indent:-2em;margin-left:2em;">Abrupt discontinuation or dose reduction in patients who are physically dependent (ie, have <b>opioid dependence</b>) to opioids has been associated with a serious opioid-induced <b>withdrawal syndrome </b>(OIW), uncontrolled pain, attempts to find other opioids (including illicit), and suicide in all ages. Concurrent use of mixed agonist/antagonist analgesics (eg, pentazocine, nalbuphine, butorphanol) or partial agonist (eg, buprenorphine) analgesics may also precipitate withdrawal symptoms and/or reduced analgesic efficacy in patients following prolonged therapy with mu opioid agonists. Reversal of analgesia, irritability, nausea, and vomiting, abdominal cramping, tachycardia, restlessness, and sweating are common symptoms. Symptoms typically dissipate over 4 to 7 days and fully resolve within 14 days; may cause significant distress but are rarely life-threatening (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-30701615']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-30701615'])">Ref</a></span>).</p>
<p style="text-indent:-2em;margin-left:4em;">
<i>Mechanism:</i> Withdrawal; abrupt discontinuation in patients who are physically dependent on opioids results in noradrenergic hyperactivity. This hyperactivity occurs due to abrupt reversal of adaptive mechanisms related to cAMP, locus coeruleus firing rate, and norepinephrine levels that occur with prolonged exposure to opioids (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-30701615']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-30701615'])">Ref</a></span>).</p>
<p style="text-indent:-2em;margin-left:4em;">
<i>Onset:</i> Rapid; symptoms typically occur within 12 hours after discontinuation and peak at 36 to 72 hours; varies based on half-life of opioid (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-30701615']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-30701615'])">Ref</a></span>).</p>
<p style="text-indent:-2em;margin-left:4em;">
<i>Risk factors:</i></p>
<p style="text-indent:-2em;margin-left:6em;">• Prolonged exposure to opioids (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-9559604','lexi-content-ref-8181283','lexi-content-ref-35119438','lexi-content-ref-28866754']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-9559604','lexi-content-ref-8181283','lexi-content-ref-35119438','lexi-content-ref-28866754'])">Ref</a></span>)</p>
<p style="text-indent:-2em;margin-left:8em;">- Pediatrics: Neonates &gt;1 week, infants, and children &lt;22 months: Duration of ≥9 days or a total dose ≥2.5 mg/kg has been associated with a 100% chance of developing opioid withdrawal; similarly, a duration of 5 days or a total dose of 1.5 mg/kg has a reported 50% chance of developing opioid withdrawal (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-8181283']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-8181283'])">Ref</a></span>)</p>
<p style="text-indent:-2em;margin-left:6em;">• Opioid use disorder (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-32199668','lexi-content-ref-30701615']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-32199668','lexi-content-ref-30701615'])">Ref</a></span>)</p>
<p style="text-indent:-2em;margin-left:6em;">• Abrupt discontinuation or dose reduction (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-32199668']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-32199668'])">Ref</a></span>)</p>
<p style="text-indent:-2em;margin-left:6em;">• Concurrent use of mixed agonist/antagonist analgesics (eg, pentazocine, nalbuphine, butorphanol) or partial agonist (eg, buprenorphine) analgesics</p>
<p style="text-indent:0em;margin-left:4em;">• Discontinuation of concurrent cytochrome P450 3A4 inhibitors</p></div>
</div>
</div>
<div class="block adr drugH1Div" id="F170574"><span class="drugH1">Adverse Reactions</span>
<p style="text-indent:0em;display:inline">The following adverse drug reactions and incidences are derived from product labeling unless otherwise specified.</p>
<p style="text-indent:-2em;margin-left:2em;">&gt;10%:</p>
<p style="text-indent:-2em;margin-left:4em;">Cardiovascular: Peripheral edema (5% to 32%)</p>
<p style="text-indent:-2em;margin-left:4em;">Dermatologic: Hyperhidrosis (1% to 14%)</p>
<p style="text-indent:-2em;margin-left:4em;">Endocrine &amp; metabolic: Dehydration (9% to 21%), hypokalemia (2% to 15%), weight loss (3% to 11%)</p>
<p style="text-indent:-2em;margin-left:4em;">Gastrointestinal: Abdominal pain (3% to 15%), anorexia (5% to 11%), constipation (1% to 26%), diarrhea (6% to 16%), dysgeusia (1% to 14%), nausea (2% to 42%), vomiting (1% to 37%)</p>
<p style="text-indent:-2em;margin-left:4em;">Hematologic &amp; oncologic: Anemia (3% to 32%), cancer pain (2% to 16%)</p>
<p style="text-indent:-2em;margin-left:4em;">Local: Application site erythema (transdermal device: 14%)</p>
<p style="text-indent:-2em;margin-left:4em;">Nervous system: Confusion (1% to 16%), depression (1% to 11%), dizziness (1% to 32%), drowsiness (3% to 20%), fatigue (2% to 20%), headache (1% to 17%), insomnia (1% to 11%)</p>
<p style="text-indent:-2em;margin-left:4em;">Neuromuscular &amp; skeletal: Asthenia (2% to 30%), back pain (4% to 11%)</p>
<p style="text-indent:-2em;margin-left:4em;">Respiratory: Dyspnea (2% to 19%), pneumonia (2% to 16%)</p>
<p style="text-indent:-2em;margin-left:2em;">1% to 10%:</p>
<p style="text-indent:-2em;margin-left:4em;">Cardiovascular: Bradycardia (≥1%), chest pain (≥1%), chest wall pain (≥1%), deep vein thrombosis (≥1%), edema (≥1%), hypertension (≥1%), hypotension (2%), palpitations (4%), pulmonary embolism (nasal spray: ≥1%), sinus tachycardia (≥1%), tachycardia (≥1%), vascular injury (≥1%), vasodilation (1% to 4%)</p>
<p style="text-indent:-2em;margin-left:4em;">Dermatologic: Alopecia (≥1%), cellulitis (≥1%), dermal ulcer (≥1%), diaphoresis (1% to 3%), ecchymoses (≥1%), erythema of skin (1%), night sweats (≥1%), pallor (≥1%), pressure ulcer (≥1%), pruritus (1% to 6%), skin lesion (≥1%), skin rash (1% to 8%)</p>
<p style="text-indent:-2em;margin-left:4em;">Endocrine &amp; metabolic: Cachexia (≥1%), hypercalcemia (≥1%), hyperglycemia (≥1%), hypoalbuminemia (≥1%), hypocalcemia (≥1%), hypomagnesemia (≥1%), hyponatremia (≥1%), lactic acidosis (≥1%)</p>
<p style="text-indent:-2em;margin-left:4em;">Gastrointestinal: Abdominal distention (≥1%), aphthous stomatitis (sublingual tablet: ≥1%), decreased appetite (≥1%), delayed gastric emptying (≥1%), dyspepsia (≥1%), dysphagia (lozenge, buccal tablet, sublingual spray: ≥1%), eructation (≥1%), flatulence (≥1%), gastritis (≥1%), gastroenteritis (≥1%), gastroesophageal reflux disease (≥1%), gastrointestinal hemorrhage (≥1%), gingival pain (buccal tablet: ≥1%), gingival ulceration (sublingual tablet: ≥1%), gingivitis (lozenge: ≥1%), glossalgia (≥1%), glossitis (lozenge: ≥1%), hematemesis (≥1%), intestinal obstruction (2% to 4%; subileus: &lt;1%), mucosal swelling (buccal tablet: ≥1%), oral candidiasis (lozenge, buccal tablet, sublingual spray: ≥1%), oral herpes simplex infection (≥1%), oral mucosa ulcer (lozenge, buccal and sublingual tablets, nasal spray: ≥1%; including lip ulceration), periodontal abscess (lozenge: (≥1%), rectal disease (≥1%), rectal pain (≥1%), stomach discomfort (≥1%), stomatitis (lozenge, buccal and sublingual tablets, sublingual spray: 1% to 8%), tongue disease (sublingual tablet: ≥1%), upper abdominal pain (3%), xerostomia (1% to 6%)</p>
<p style="text-indent:-2em;margin-left:4em;">Genitourinary: Difficulty in micturition (≥1%), dysuria (≥1%), erectile dysfunction (≥1%), hematuria (≥1%), mastalgia (≥1%), pelvic pain (≥1%), scrotal edema (≥1%), urinary incontinence (≥1%), urinary retention (1% to 3%), urinary tract infection (≥1%), urinary urgency (≥1%), vaginal hemorrhage (≥1%), vaginitis (≥1%)</p>
<p style="text-indent:-2em;margin-left:4em;">Hematologic &amp; oncologic: Breast neoplasm (≥1%), bruise (≥1%), leukopenia (≥1%), lymphadenopathy (≥1%), lymphedema (≥1%), neutropenia (2% to 8%), pancytopenia (≥1%), rectal hemorrhage (≥1%), thrombocytopenia (≥1%)</p>
<p style="text-indent:-2em;margin-left:4em;">Hepatic: Ascites (≥1%), increased serum alkaline phosphatase (≥1%), increased serum aspartate aminotransferase (≥1%), jaundice (≥1%)</p>
<p style="text-indent:-2em;margin-left:4em;">Hypersensitivity: Hypersensitivity reaction (≥1%)</p>
<p style="text-indent:-2em;margin-left:4em;">Infection: Fungal infection (≥1%), infection (≥1%), influenza (≥1%), sepsis (≥1%), tooth abscess (≥1%), viral infection (≥1%)</p>
<p style="text-indent:-2em;margin-left:4em;">Local: Application site irritation (buccal tablet, sublingual spray: ≤3%), application site pain (buccal tablet, transdermal device: ≤4%), application site reaction (buccal tablet, transdermal patch: ≤10%), application site vesicles (buccal tablet, nasal spray, transdermal patch and device: ≤3%)</p>
<p style="text-indent:-2em;margin-left:4em;">Nervous system: Abnormal dreams (1%), abnormal gait (1% to 5%), abnormality in thinking (1% to 2%), agitation (≥1%), altered sense of smell (≥1%), amnesia (≥1%), anxiety (2% to 9%), balance impairment (≥1%), chills (≥1%), disorientation (≥1%), disturbance in attention (≥1%), dysphoria (≥1%), emotional lability (≥1%), euphoria (≥1%), falling (≥1%), hallucination (1% to 2%), hypertonia (2%), hypoesthesia (≥1%), irritability (≥1%), lethargy (≥1%), malaise (4%), mental status changes (≥1%), migraine (≥1%), myasthenia (≥1%), myoclonus (4%), nervousness (1% to 4%), neuropathy (≥1%), pain (≥1%), paranoid ideation (≥1%), paresthesia (2%), peripheral neuropathy (≥1%), restlessness (≥1%), sedated state (≥1%), seizure (1% to 2%), sensation of cold (6%), sleep disturbance (≥1%), speech disturbance (≥1%), stupor (1% to 4%), tightness in chest or throat (≥1%), vertigo (1% to 4%), withdrawal syndrome (≥1%)</p>
<p style="text-indent:-2em;margin-left:4em;">Neuromuscular &amp; skeletal: Arthralgia (3% to 8%), arthropathy (≥1%), bone disease (≥1%), hypokinesia (≥1%), limb pain (≥1%), lower limb cramp (≥1%), muscle spasm (4%), myalgia (≥1%), neck pain (≥1%), ostealgia (≥1%), pathological fracture (≥1%), shoulder pain (≥1%), tremor (1% to 3%)</p>
<p style="text-indent:-2em;margin-left:4em;">Ophthalmic: Blepharoptosis (nasal spray: ≥1%), blurred vision (≥1%), conjunctivitis (≥1%), dry eye syndrome (nasal spray: ≥1%), strabismus (nasal spray: ≥1%), swelling of eye (nasal spray: ≥1%), visual disturbance (1% to 2%)</p>
<p style="text-indent:-2em;margin-left:4em;">Otic: Ear disease (≥1%, including pain), tinnitus (≥1%)</p>
<p style="text-indent:-2em;margin-left:4em;">Renal: Hydronephrosis (≥1%), renal failure syndrome (≥1%)</p>
<p style="text-indent:-2em;margin-left:4em;">Respiratory: Asthma (≥1%), bradypnea (≥1%), bronchitis (≥1%), cough (3% to 9%; increased cough: ≥1%), dyspnea on exertion (≥1%), epistaxis (≥1%), flu-like symptoms (≥1%), hemoptysis (≥1%), hypoxia (≥1%), increased bronchial secretions (≥1%), laryngitis (sublingual spray: ≥1%), nasal congestion (nasal spray: ≥1%), nasal discomfort (nasal spray: ≥1%), nasopharyngitis (≥1%), oropharyngeal pain (≥1%), pharyngitis (≥1%), pharyngolaryngeal pain (≥1%), pleural effusion (≥1%), post nasal drip (nasal spray: ≥1%), rhinitis (≥1%), rhinorrhea (nasal spray: ≥1%), sinusitis (≥1%), upper respiratory tract infection (≥1%), wheezing (≥1%)</p>
<p style="text-indent:-2em;margin-left:4em;">Miscellaneous: Fever (5% to 7%), reduced intake of food/fluids (buccal tablet: ≥1%)</p>
<p style="text-indent:-2em;margin-left:2em;">&lt;1%:</p>
<p style="text-indent:-2em;margin-left:4em;">Cardiovascular: Angina pectoris, cerebral ischemia, facial edema, orthostatic hypotension, peripheral vascular disease, subdural hematoma</p>
<p style="text-indent:-2em;margin-left:4em;">Dermatologic: Allergic dermatitis, cheilitis, contact dermatitis, contact hypersensitivity (transdermal patch, application site), eczema, exfoliative dermatitis, maculopapular rash, skin discoloration, urticaria, vesiculobullous rash (application site: transdermal device, lozenge)</p>
<p style="text-indent:-2em;margin-left:4em;">Endocrine &amp; metabolic: Decreased libido, hypoglycemia, increased thirst</p>
<p style="text-indent:-2em;margin-left:4em;">Gastrointestinal: Dental caries, esophagitis, fecal impaction, fecal incontinence, gastrointestinal disease, gingival hemorrhage (lozenge), hiccups, mucous membrane disease</p>
<p style="text-indent:-2em;margin-left:4em;">Genitourinary: Nocturia, oliguria, sexual disorder</p>
<p style="text-indent:-2em;margin-left:4em;">Hematologic &amp; oncologic: Granuloma, hemorrhage, prolonged bleeding time</p>
<p style="text-indent:-2em;margin-left:4em;">Hepatic: Hepatorenal syndrome, liver tenderness</p>
<p style="text-indent:-2em;margin-left:4em;">Infection: Bacterial infection, herpes zoster infection</p>
<p style="text-indent:-2em;margin-left:4em;">Local: Application-site dermatitis (transdermal patch), local skin hyperpigmentation (transdermal device, lasting 2 to 3 weeks)</p>
<p style="text-indent:-2em;margin-left:4em;">Nervous system: Ataxia, delirium, facial nerve paralysis, flank pain, hemiplegia, voice disorder</p>
<p style="text-indent:-2em;margin-left:4em;">Neuromuscular &amp; skeletal: Amyotrophy, arthritis, foot-drop, muscle twitching, myopathy, neck stiffness, synovitis, tendinopathy</p>
<p style="text-indent:-2em;margin-left:4em;">Ophthalmic: Disease of the lacrimal apparatus, injury to eye region (hemorrhage), miosis</p>
<p style="text-indent:-2em;margin-left:4em;">Otic: Deafness, reversible hearing loss</p>
<p style="text-indent:-2em;margin-left:4em;">Renal: Polyuria, pyelonephritis, renal pain</p>
<p style="text-indent:-2em;margin-left:4em;">Respiratory: Cyanosis, hyperventilation, pneumothorax, pulmonary disease, respiratory depression, respiratory failure, respiratory insufficiency</p>
<p style="text-indent:-2em;margin-left:4em;">Miscellaneous: Cyst</p>
<p style="text-indent:-2em;margin-left:2em;">Frequency not defined:</p>
<p style="text-indent:-2em;margin-left:4em;">Cardiovascular: Acute myocardial infarction, atrial fibrillation, bigeminy, cardiac arrhythmia, flushing, syncope</p>
<p style="text-indent:-2em;margin-left:4em;">Dermatologic: Exfoliation of skin (application site, transdermal device), papule of skin (application site, transdermal device), pustules (application site, transdermal device), xeroderma (application site, transdermal device)</p>
<p style="text-indent:-2em;margin-left:4em;">Infection: Abscess</p>
<p style="text-indent:-2em;margin-left:4em;">Local: Application site burning (transdermal device), application site discharge (transdermal device), application site edema (transdermal device), application site itching (transdermal device), application site rash (transdermal device)</p>
<p style="text-indent:-2em;margin-left:4em;">Nervous system: Drug abuse, hypothermia, neonatal withdrawal, opioid dependence</p>
<p style="text-indent:-2em;margin-left:4em;">Respiratory: Atelectasis</p>
<p style="text-indent:-2em;margin-left:4em;">Miscellaneous: Abnormal healing</p>
<p style="text-indent:-2em;margin-left:2em;">Postmarketing:</p>
<p style="text-indent:-2em;margin-left:4em;">Dermatologic: Crusted skin (application site scab, transdermal device), skin erosion (application site, transdermal patch)</p>
<p style="text-indent:-2em;margin-left:4em;">Gastrointestinal: Gingival recession (lozenge), tooth loss (lozenge)</p>
<p style="text-indent:-2em;margin-left:4em;">Genitourinary: Hypogonadism (Brennan 2013; Debono 2011)</p>
<p style="text-indent:-2em;margin-left:4em;">Hematologic &amp; oncologic: Local hemorrhage (application site, transdermal device)</p>
<p style="text-indent:-2em;margin-left:4em;">Infection: Localized infection (application site, transdermal device)</p>
<p style="text-indent:-2em;margin-left:4em;">Local<b>: </b>Local tissue necrosis (application site, transdermal device)</p>
<p style="text-indent:-2em;margin-left:4em;">Nervous system: Allodynia (opioid-induced hyperalgesia) (FDA Safety Communication 2023), hyperesthesia, impaired consciousness, loss of consciousness</p>
<p style="text-indent:-2em;margin-left:4em;">Neuromuscular &amp; skeletal: Laryngospasm, muscle rigidity (can be dose related)</p>
<p style="text-indent:-2em;margin-left:4em;">Respiratory: Apnea, hypoventilation, respiratory distress</p></div>
<div class="block coi drugH1Div" id="F170590"><span class="drugH1">Contraindications</span>
<p style="text-indent:-2em;margin-left:2em;">Hypersensitivity (eg, anaphylaxis, hypersensitivity) to fentanyl or any component of the formulation.</p>
<p style="text-indent:-2em;margin-left:2em;">Additional contraindications for transdermal device (Ionsys): Significant respiratory depression; acute or severe bronchial asthma in an unmonitored setting or in the absence of resuscitative equipment; gastrointestinal obstruction, including paralytic ileus (known or suspected); hypersensitivity to cetylpyridinium chloride (eg, Cepacol).</p>
<p style="text-indent:-2em;margin-left:2em;">Additional contraindications for transdermal patch (Duragesic): Significant respiratory depression; acute or severe bronchial asthma in an unmonitored setting or in the absence of resuscitative equipment; gastrointestinal obstruction, including paralytic ileus (known or suspected); patients requiring short-term therapy, management of acute or intermittent pain, postoperative or mild pain; patients who are <b>not</b> opioid tolerant.</p>
<p style="text-indent:-2em;margin-left:2em;">Additional contraindications for transmucosal buccal tablets (Fentora), lozenges (Actiq), sublingual tablets (Abstral), sublingual spray (Subsys), intranasal (Lazanda): Significant respiratory depression (Actiq, Fentora only); acute or severe bronchial asthma in an unmonitored setting or in the absence of resuscitative equipment; gastrointestinal obstruction, including paralytic ileus (known or suspected); acute or postoperative pain (including headache, migraine, or dental pain); patients who are <b>not</b> opioid tolerant; acute pain management in the emergency room.</p>
<p style="text-indent:0em;margin-top:2em;">
<i>Canadian labeling:</i> Additional contraindication (not in US labeling):</p>
<p style="text-indent:-2em;margin-left:4em;">Injection: Hypersensitivity to other opioids; known or suspected mechanical GI obstruction (eg, bowel obstruction, strictures) or any diseases/conditions that affect bowel transit (eg, ileus of any type); suspected surgical abdomen (eg, acute appendicitis, pancreatitis); mild pain that can be managed with other pain medications; acute or severe bronchial asthma, chronic obstructive airway, or status asthmaticus; acute respiratory depression; hypercapnia; cor pulmonale; acute alcoholism, delirium tremens, and convulsive disorders; severe CNS depression, increased cerebrospinal or intracranial pressure and head injury; concurrent use or use within 14 days of a monoamine oxidase inhibitor (MAOI); septicemia; severe hemorrhage or shock; local infection at proposed injection site; disturbances in blood morphology and/or anticoagulant therapy or other concomitant drug therapy or medical conditions which could contraindicate the technique of epidural administration</p>
<p style="text-indent:-2em;margin-left:4em;">Sublingual tablets (Abstral): Severe bronchial asthma, chronic obstructive airway, or status asthmaticus; acute respiratory depression; hypercapnia; cor pulmonale; known or suspected mechanical GI obstruction (eg, bowel obstruction or strictures) or any diseases/conditions that affect bowel transit (eg, ileus of any type); suspected surgical abdomen (eg, acute appendicitis or pancreatitis); mild pain that can be managed with other pain medications; acute pain management other than breakthrough or postoperative pain (including headache or migraine, dental pain or emergency room use); acute alcoholism, delirium tremens, and convulsive disorders; severe CNS depression, increased cerebrospinal or intracranial pressure and head injury; concurrent use or use within 14 days of an MAOI; breastfeeding women; during labor and delivery; opioid-nontolerant patients (including patients on intermittent or as needed opioid dosing).</p>
<p style="text-indent:-2em;margin-left:4em;">Transdermal patch: Hypersensitivity to other opioids; suspected surgical abdomen (eg, acute appendicitis, pancreatitis); known or suspected mechanical GI obstruction (eg, bowel obstruction, strictures) or any diseases/conditions that affect bowel transit (eg, ileus of any type); acute alcoholism, delirium tremens, and convulsive disorders; severe CNS depression, increased cerebrospinal or intracranial pressure and head injury; concurrent use of MAOIs or within 14 days of therapy; perioperative pain; women who are nursing, pregnant, or during labor and delivery</p>
<p style="text-indent:-2em;margin-left:4em;">Transmucosal buccal tablets (Fentora): Hypersensitivity to other opioids; acute pain management in the emergency room; known or suspected mechanical GI obstruction (eg, bowel obstruction or strictures) or any diseases/conditions that affect bowel transit (eg, ileus of any type); suspected surgical abdomen (eg, acute appendicitis or pancreatitis); acute or severe bronchial asthma, chronic obstructive airway, status asthmaticus; acute respiratory depression; hypercapnia; cor pulmonale; acute alcoholism, delirium tremens, and convulsive disorders; severe CNS depression, increased cerebrospinal or intracranial pressure and head injury; concurrent use or use within 14 days of an MAOI</p>
<p style="text-indent:-2em;margin-left:2em;margin-top:2em;">Significant drug interactions exist, requiring dose/frequency adjustment or avoidance. Consult drug interactions database for more information.</p></div>
<div class="block war drugH1Div" id="F170571"><span class="drugH1">Warnings/Precautions</span>
<p style="text-indent:-2em;margin-left:2em;">
<b>
<i>Concerns related to adverse effects:</i></b></p>
<p style="text-indent:-2em;margin-left:4em;">• Hyperalgesia: Opioid-induced hyperalgesia (OIH) has occurred with short-term and prolonged use of opioid analgesics. Symptoms may include increased levels of pain upon opioid dosage increase, decreased levels of pain upon opioid dosage decrease, or pain from ordinarily nonpainful stimuli; symptoms may be suggestive of OIH if there is no evidence of underlying disease progression, opioid tolerance, opioid withdrawal, or addictive behavior. Consider decreasing the current opioid dose or opioid rotation in patients who experience OIH.</p>
<p style="text-indent:-2em;margin-left:4em;">• Hypotension: May cause severe hypotension (including orthostatic hypotension and syncope); use with caution in patients with hypovolemia, cardiovascular disease (including acute MI), or drugs which may exaggerate hypotensive effects (including phenothiazines or general anesthetics). Monitor for symptoms of hypotension following initiation or dose titration. Avoid use in patients with circulatory shock.</p>
<p style="text-indent:-2em;margin-left:4em;">• Serotonin syndrome: Potentially life-threatening serotonin syndrome (SS) has occurred with concomitant use of fentanyl and serotonergic agents (eg, selective serotonin reuptake inhibitors, serotonin and norepinephrine reuptake inhibitors, triptans, tricyclic antidepressants, 5-HT<sub>3</sub> receptor antagonists, mirtazapine, trazodone, tramadol) and agents that impair metabolism of serotonin (eg, monoamine oxidase inhibitors). Monitor patients closely for signs of SS such as mental status changes (eg, agitation, hallucinations, delirium, coma); autonomic instability (eg, tachycardia, labile BP, diaphoresis); neuromuscular changes (eg, tremor, rigidity, myoclonus); and GI symptoms (eg, nausea, vomiting, diarrhea). Discontinue fentanyl if SS is suspected.</p>
<p style="text-indent:-2em;margin-left:2em;">
<b>
<i>Disease-related concerns:</i></b></p>
<p style="text-indent:-2em;margin-left:4em;">• Abdominal conditions: May obscure diagnosis or clinical course of patients with acute abdominal conditions.</p>
<p style="text-indent:-2em;margin-left:4em;">• Adrenocortical insufficiency: Use with caution in patients with adrenal insufficiency, including Addison's disease. Long-term opioid use may cause secondary hypogonadism, which may lead to mood disorders and osteoporosis (Brennan 2013).</p>
<p style="text-indent:-2em;margin-left:4em;">• Allergic rhinitis: Intranasal: Allergic rhinitis is not expected to alter fentanyl absorption following nasal administration; however, use of nasal decongestants (eg, oxymetazoline) during episodes of rhinitis may result in lower peak concentrations and delayed T<sub>max</sub>, therefore, titration of intranasal fentanyl is not recommended during use of nasal decongestants.</p>
<p style="text-indent:-2em;margin-left:4em;">• Biliary tract impairment: Use with caution in patients with biliary tract dysfunction, including acute pancreatitis; may cause constriction of sphincter of Oddi.</p>
<p style="text-indent:-2em;margin-left:4em;">• Bradycardia: Use with caution in patients with bradycardia or bradyarrhythmias (may produce further bradycardia).</p>
<p style="text-indent:-2em;margin-left:4em;">• CNS depression/coma: Avoid use in patients with impaired consciousness or coma as these patients are susceptible to intracranial effects of CO<sub>2</sub> retention.</p>
<p style="text-indent:-2em;margin-left:4em;">• Delirium tremens: Use with caution in patients with delirium tremens.</p>
<p style="text-indent:-2em;margin-left:4em;">• Head trauma: Use with extreme caution in patients with head injury, intracranial lesions, or elevated intracranial pressure (ICP); exaggerated elevation of ICP may occur.</p>
<p style="text-indent:-2em;margin-left:4em;">• Hepatic impairment: Use with caution in patients with hepatic impairment. Avoid transdermal (patch) in patients with severe hepatic impairment.</p>
<p style="text-indent:-2em;margin-left:4em;">• Mental health conditions: Use opioids with caution for chronic pain in patients with mental health conditions (eg, depression, anxiety disorders, post-traumatic stress disorder) due to potential increased risk for opioid use disorder and overdose; more frequent monitoring is recommended (CDC [Dowell 2022]).</p>
<p style="text-indent:-2em;margin-left:4em;">• Obesity: Use with caution in patients who are morbidly obese.</p>
<p style="text-indent:-2em;margin-left:4em;">• Oral mucositis: Sublingual spray (Subsys): Cancer patients with oral mucositis experienced increased fentanyl exposure following sublingual spray administration; avoid use in patients with ≥ grade 2 mucositis; use with caution in patients with grade 1 mucositis, and closely monitor for respiratory and CNS depression.</p>
<p style="text-indent:-2em;margin-left:4em;">• Prostatic hyperplasia/urinary stricture: Use with caution in patients with prostatic hyperplasia and/or urinary stricture.</p>
<p style="text-indent:-2em;margin-left:4em;">• Psychosis: Use with caution in patients with toxic psychosis.</p>
<p style="text-indent:-2em;margin-left:4em;">• Renal impairment: Use with caution in patients with renal impairment.</p>
<p style="text-indent:-2em;margin-left:4em;">• Respiratory disease: Use with caution and monitor for respiratory depression in patients with significant chronic obstructive pulmonary disease or cor pulmonale, and those with a substantially decreased respiratory reserve, hypoxia, hypercapnia, or preexisting respiratory depression, particularly when initiating and titrating therapy; critical respiratory depression may occur, even at therapeutic dosages. Consider the use of alternative nonopioid analgesics in these patients.</p>
<p style="text-indent:-2em;margin-left:4em;">• Seizures: Use with caution in patients with a history of seizure disorders; may cause or exacerbate seizures.</p>
<p style="text-indent:-2em;margin-left:4em;">• Sleep-related disorders: Use with caution in patients with sleep-related disorders, including sleep apnea, due to increased risk for respiratory and central nervous system depression. Monitor carefully and titrate dosage cautiously in patients with mild sleep-disordered breathing. Avoid opioids in patients with moderate to severe sleep-disordered breathing (CDC [Dowell 2022]).</p>
<p style="text-indent:-2em;margin-left:4em;">• Thyroid dysfunction: Use with caution in patients with thyroid dysfunction.</p>
<p style="text-indent:-2em;margin-left:2em;">
<b>
<i>Special populations:</i></b></p>
<p style="text-indent:-2em;margin-left:4em;">• Older adult: Use opioids with caution in older adults; may be more sensitive to adverse effects. Clearance may also be reduced in older adults (with or without renal impairment) resulting in a narrow therapeutic window and increased adverse effects. Monitor closely for adverse effects associated with opioid therapy (eg, respiratory and central nervous system depression, falls, cognitive impairment, constipation) (CDC [Dowell 2022]). Consider the use of alternative nonopioid analgesics in these patients when possible.</p>
<p style="text-indent:-2em;margin-left:2em;">
<b>
<i>Dosage form specific issues: </i></b></p>
<p style="text-indent:-2em;margin-left:4em;">• Transdermal iontophoretic system (Ionsys):</p>
<p style="text-indent:-2em;margin-left:6em;">
<b>- Accidental exposure to an intact Ionsys device or to the hydrogel component, especially by children, can result in a fatal overdose of fentanyl.</b> Following accidental contact with the device or its components, immediately rinse the affected area thoroughly with water. Do not use soap, alcohol, or other solvent because they may enhance the drug's ability to penetrate the skin; monitor for signs of respiratory or CNS depression. If the device is not handled correctly using gloves, healthcare professionals are at risk of accidental exposure to a fatal overdose of fentanyl.</p>
<p style="text-indent:-2em;margin-left:6em;">- Ionsys device is considered magnetic resonance unsafe. The device contains metal parts and must be removed and properly disposed of before an MRI procedure to avoid injury to the patient and damage to device. It is unknown if exposure to an MRI procedure increases release of fentanyl from the device. Monitor any patients wearing the device with inadvertent exposure to an MRI for signs of CNS and respiratory depression.</p>
<p style="text-indent:-2em;margin-left:6em;">- Use of Ionsys device during cardioversion, defibrillation, X-ray, CT, or diathermy can damage the device from the strong electromagnetic fields set up by these procedures. The device contains radio-opaque components and may interfere with an X-ray image or CT scan. Remove and properly dispose of the device prior to cardioversion, defibrillation, X-ray, CT, or diathermy. Avoid contact with synthetic materials (such as carpeted flooring) to reduce the possibility of electrostatic discharge and damage to the device. Avoid exposing the device to electronic security systems to reduce the possibility of damage. Use near communications equipment (eg, base stations for radio telephones and land mobile radios, amateur radio, AM and FM radio broadcast and TV broadcast Radio) and Radio Frequency Identification (RFID) transmitters can damage the device. Depending on the rated maximum output power and frequency of the transmitter, the recommended separation distance between the device and communications equipment or the RFID transmitter ranges between 0.12 and 23 meters. The low-level electrical current provided by the device does not result in electromagnetic interference with other electromechanical devices like pacemakers or electrical monitoring equipment. If exposure to the procedures listed above, electronic security systems, electrostatic discharge, communications equipment, or RFID transmitters occurs, and if the device does not appear to function normally, remove and replace with a new device.</p>
<p style="text-indent:-2em;margin-left:6em;">- Topical skin reactions (erythema, sweating, vesicles, papules/pustules) may occur with use and are typically limited to the application site area. If a severe skin reaction is observed, remove device and discontinue further use.</p>
<p style="text-indent:-2em;margin-left:4em;">• Transdermal patch:</p>
<p style="text-indent:-2em;margin-left:6em;">- Serum fentanyl concentrations may increase by approximately one-third for patients with a body temperature of 40°C (104°F) secondary to a temperature-dependent increase in fentanyl release from the patch and increased skin permeability.</p>
<p style="text-indent:-2em;margin-left:6em;">- Avoid unclothed/unwashed application site exposure, inadvertent person-to-person patch transfer (eg, while hugging), incidental exposure (eg, sharing same bed, sitting on patch), intentional exposure (eg, chewing), or accidental exposure by caregivers when applying/removing patch.</p>
<p style="text-indent:-2em;margin-left:6em;">- May contain conducting metal (eg, aluminum); remove patch prior to MRI.</p>
<p style="text-indent:-2em;margin-left:2em;">
<b>
<i>Other warnings/precautions:</i></b></p>
<p style="text-indent:-2em;margin-left:4em;">• Abuse/misuse/diversion: Use with caution in patients with a history of substance abuse disorder; potential for drug dependency exists. Other factors associated with increased risk for misuse include concomitant depression or other mental health conditions, higher opioid dosages, or taking other central nervous system depressants. Consider offering naloxone prescriptions in patients with an increased risk for overdose, such as history of overdose or substance use disorder, higher opioid dosages (≥50 morphine milligram equivalents [MME]/day orally), concomitant benzodiazepine use, and patients at risk for returning to a high dose after losing tolerance (CDC [Dowell 2022]).</p>
<p style="text-indent:-2em;margin-left:4em;">• Appropriate use: Outpatient setting: Opioids should <b>not</b> be used as first-line therapy for acute (&lt;1-month duration), subacute (1- to 3-month duration), or chronic pain (&gt;3-month duration [outside of end-of-life or palliative care, active cancer treatment, sickle cell disease, or medication-based opioid use disorder treatment]). Preferred management includes nonpharmacologic therapy and nonopioid therapy (eg, nonsteroidal anti-inflammatory drugs, acetaminophen, certain antiseizure medications and antidepressants) as appropriate for the specific condition. If opioid therapy is initiated, it should be combined with nonpharmacologic and non-opioid therapy, as appropriate. Prior to initiation, known risks and realistic benefits of opioid therapy should be discussed with the patient. Therapy should be initiated at the lowest effective dosage using IR opioids (instead of ER/long-acting opioids). For the treatment of acute pain, therapy should only be given for the expected duration of pain severe enough to require opioids and prescribed as needed (not scheduled). For the treatment of subacute and chronic pain, realistic treatment goals for pain/function should be established, including consideration for discontinuation if benefits do not outweigh risks. Therapy should be continued only if clinically meaningful improvement in pain/function outweighs risks. Risk to patients increases with higher opioid dosages. Dosages ≥50 MME/day are likely to not have increased benefit to pain relief or function relative to overall risk to patients; before increasing dosage to ≥50 MME/day, readdress pain and reassess evidence of individual benefits and risks (CDC [Dowell 2022]).</p>
<p style="text-indent:-2em;margin-left:4em;">• Naloxone access: Discuss the availability of naloxone with all patients who are prescribed opioid analgesics, as well as their caregivers, and consider prescribing it to patients who are at increased risk of opioid overdose. These include patients who are also taking benzodiazepines or other CNS depressants, have an opioid use disorder (OUD) (current or history of) or substance use disorder, have higher opioid dosages (≥50 MME/day orally), patients at risk for returning to a high dose after losing tolerance (CDC [Dowell 2022]), or have experienced opioid-induced respiratory depression/opioid overdose. Additionally, health care providers should consider prescribing naloxone to patients prescribed medications to treat OUD; patients at risk of opioid overdose even if they are not taking an opioid analgesic or medication to treat OUD; and patients taking opioids, including methadone or buprenorphine for OUD, if they have household members, including children, or other close contacts at risk for accidental ingestion or opioid overdose. Inform patients and caregivers on options for obtaining naloxone (eg, by prescription, directly from a pharmacist, a community-based program) as permitted by state dispensing and prescribing guidelines. Educate patients and caregivers on how to recognize respiratory depression, proper administration of naloxone, and getting emergency help.</p>
<p style="text-indent:-2em;margin-left:4em;">• Optimal regimen: An opioid-containing analgesic regimen should be tailored to each patient's needs and based upon the type of pain being treated (acute versus chronic), the route of administration, degree of tolerance for opioids (naive versus chronic user), age, weight, and medical condition. The optimal analgesic dose varies widely among patients; doses should be titrated to pain relief/prevention.</p>
<p style="text-indent:-2em;margin-left:4em;">• Surgery: Opioids decrease bowel motility; monitor for decreased bowel motility in postoperative patients receiving opioids. Use with caution in the perioperative setting; individualize treatment when transitioning from parenteral to oral analgesics.</p></div>
<div class="block add-pediatric-warn-info drugH1Div" id="F52878453"><span class="drugH1">Warnings: Additional Pediatric Considerations</span>
<p style="text-indent:-2em;margin-left:2em;">Dosage form specific:</p>
<p style="text-indent:-2em;margin-left:4em;">Use transdermal patch in pediatric patients only if they are opioid-tolerant, receiving at least 60 mg oral morphine equivalents per day, and ≥2 years of age.</p>
<p style="text-indent:-2em;margin-left:4em;">Use of Actiq was evaluated in a clinical trial of 15 opioid-tolerant pediatric patients (age: 5 to 15 years) with breakthrough pain; 12 of the 15 patients received doses of 200 mcg to 600 mcg; no conclusions about safety and efficacy could be drawn due to the small sample size.</p>
<p style="text-indent:0em;margin-top:2em;">Some dosage forms may contain propylene glycol; in neonates large amounts of propylene glycol delivered orally, intravenously (eg, &gt;3,000 mg/day), or topically have been associated with potentially fatal toxicities which can include metabolic acidosis, seizures, renal failure, and CNS depression; toxicities have also been reported in children and adults including hyperosmolality, lactic acidosis, seizures, and respiratory depression; use caution (AAP 1997; Shehab 2009).</p></div>
<div class="block prod-avail drugH1Div" id="F55778054"><span class="drugH1">Product Availability</span>
<p style="text-indent:0em;display:inline">Ionsys (transdermal device) and Abstral (sublingual tablets) have been discontinued in the United States for &gt;1 year.</p></div>
<div class="block foc drugH1Div" id="F170583"><span class="drugH1">Dosage Forms: US</span>
<p style="text-indent:0em;text-align:justify;display:inline">Excipient information presented when available (limited, particularly for generics); consult specific product labeling.  [DSC] = Discontinued product</p>
<p style="text-indent:-2em;margin-left:2em;text-align:justify;">Liquid, Sublingual, as base: </p>
<p style="text-indent:-2em;margin-left:4em;text-align:justify;">Subsys: 100 mcg (1 ea [DSC], 10 ea [DSC]); 200 mcg (1 ea [DSC], 30 ea [DSC]); 400 mcg (1 ea [DSC], 30 ea [DSC]); 600 mcg (1 ea [DSC], 30 ea [DSC]); 800 mcg (1 ea [DSC], 30 ea [DSC]); 1200 mcg (2 ea [DSC]); 1600 mcg (2 ea [DSC]) [contains alcohol, usp, levomenthol, propylene glycol]</p>
<p style="text-indent:-2em;margin-left:2em;text-align:justify;">Lozenge on a Handle, Buccal, as citrate [strength expressed as base]: </p>
<p style="text-indent:-2em;margin-left:4em;text-align:justify;">Actiq: 200 mcg (1 ea [DSC], 30 ea [DSC]); 400 mcg (1 ea [DSC], 30 ea [DSC]); 600 mcg (1 ea [DSC], 30 ea [DSC]); 800 mcg (1 ea [DSC], 30 ea [DSC]); 1200 mcg (1 ea [DSC], 30 ea [DSC]); 1600 mcg (1 ea [DSC], 30 ea [DSC]) [berry flavor]</p>
<p style="text-indent:-2em;margin-left:4em;text-align:justify;">Generic: 200 mcg (1 ea, 30 ea); 400 mcg (1 ea, 30 ea); 600 mcg (1 ea, 30 ea); 800 mcg (1 ea, 30 ea); 1200 mcg (1 ea, 30 ea); 1600 mcg (1 ea, 30 ea)</p>
<p style="text-indent:-2em;margin-left:2em;text-align:justify;">Patch, Transdermal, as hydrochloride [strength expressed as base]: </p>
<p style="text-indent:-2em;margin-left:4em;text-align:justify;">Ionsys: 40 mcg/actuation (1 ea [DSC], 6 ea [DSC])</p>
<p style="text-indent:-2em;margin-left:2em;text-align:justify;">Patch 72 Hour, Transdermal, as base: </p>
<p style="text-indent:-2em;margin-left:4em;text-align:justify;">Duragesic-12: 12 [delivers 12.5 mcg/hr] (5 ea [DSC])</p>
<p style="text-indent:-2em;margin-left:4em;text-align:justify;">Duragesic-25: 25 [delivers 25 mcg/hr] (5 ea [DSC])</p>
<p style="text-indent:-2em;margin-left:4em;text-align:justify;">Duragesic-50: 50 [delivers 50 mcg/hr] (5 ea [DSC])</p>
<p style="text-indent:-2em;margin-left:4em;text-align:justify;">Duragesic-75: 75 [delivers 75 mcg/hr] (5 ea [DSC])</p>
<p style="text-indent:-2em;margin-left:4em;text-align:justify;">Duragesic-100: 100 [delivers 100 mcg/hr] (5 ea [DSC])</p>
<p style="text-indent:-2em;margin-left:4em;text-align:justify;">Generic: 100 [delivers 100 mcg/hr] (1 ea, 5 ea); 12 [delivers 12.5 mcg/hr] (1 ea, 5 ea); 25 [delivers 25 mcg/hr] (1 ea, 5 ea); 37.5 [delivers 37.5 mcg/hr] (1 ea, 5 ea); 50 [delivers 50 mcg/hr] (1 ea, 5 ea); 62.5 [delivers 62.5 mcg/hr] (1 ea, 5 ea); 75 [delivers 75 mcg/hr] (1 ea, 5 ea); 87.5 [delivers 87.5 mcg/hr] (1 ea, 5 ea)</p>
<p style="text-indent:-2em;margin-left:2em;text-align:justify;">Solution, Injection [preservative free]: </p>
<p style="text-indent:-2em;margin-left:4em;text-align:justify;">Generic: 2500 mcg/50 mL (50 mL)</p>
<p style="text-indent:-2em;margin-left:2em;text-align:justify;">Solution, Injection, as citrate [preservative free]: </p>
<p style="text-indent:-2em;margin-left:4em;text-align:justify;">Generic: 50 mcg/mL (1 mL); 2500 mcg/50 mL (50 mL)</p>
<p style="text-indent:-2em;margin-left:2em;text-align:justify;">Solution, Injection, as citrate [strength expressed as base, preservative free]: </p>
<p style="text-indent:-2em;margin-left:4em;text-align:justify;">Generic: 100 mcg/2 mL (2 mL); 1000 mcg/20 mL (20 mL); 250 mcg/5 mL (5 mL); 500 mcg/10 mL (10 mL)</p>
<p style="text-indent:-2em;margin-left:2em;text-align:justify;">Solution, Intravenous, as citrate [strength expressed as base]: </p>
<p style="text-indent:-2em;margin-left:4em;text-align:justify;">Generic: 2500 mcg/50 mL (50 mL)</p>
<p style="text-indent:-2em;margin-left:2em;text-align:justify;">Solution, Nasal, as citrate [strength expressed as base]: </p>
<p style="text-indent:-2em;margin-left:4em;text-align:justify;">Lazanda: 100 mcg/actuation (1 ea [DSC]); 400 mcg/actuation (1 ea [DSC]); 300 mcg/spray (1 ea [DSC]) [contains propylparaben]</p>
<p style="text-indent:-2em;margin-left:2em;text-align:justify;">Solution Cartridge, Injection, as citrate [strength expressed as base, preservative free]: </p>
<p style="text-indent:-2em;margin-left:4em;text-align:justify;">Generic: 100 mcg/2 mL (2 mL [DSC])</p>
<p style="text-indent:-2em;margin-left:2em;text-align:justify;">Solution Prefilled Syringe, Injection, as citrate: </p>
<p style="text-indent:-2em;margin-left:4em;text-align:justify;">Generic: 100 mcg/2 mL (2 mL [DSC])</p>
<p style="text-indent:-2em;margin-left:2em;text-align:justify;">Solution Prefilled Syringe, Injection, as citrate [preservative free]: </p>
<p style="text-indent:-2em;margin-left:4em;text-align:justify;">Generic: 50 mcg/mL (1 mL); 100 mcg/2 mL (2 mL)</p>
<p style="text-indent:-2em;margin-left:2em;text-align:justify;">Tablet, Buccal, as citrate [strength expressed as base]: </p>
<p style="text-indent:-2em;margin-left:4em;text-align:justify;">Fentora: 100 mcg, 200 mcg, 400 mcg, 600 mcg, 800 mcg</p>
<p style="text-indent:-2em;margin-left:4em;text-align:justify;">Generic: 100 mcg, 200 mcg, 400 mcg, 600 mcg, 800 mcg</p>
<p style="text-indent:-2em;margin-left:2em;text-align:justify;">Tablet Sublingual, Sublingual, as citrate [strength expressed as base]: </p>
<p style="text-indent:-2em;margin-left:4em;text-align:justify;">Abstral: 400 mcg [DSC], 600 mcg [DSC], 800 mcg [DSC]</p></div>
<div class="block geq drugH1Div" id="F170567"><span class="drugH1">Generic Equivalent Available: US</span>
<p style="text-indent:0em;display:inline">May be product dependent</p></div>
<div class="block fee drugH1Div" id="F5989383"><span class="drugH1">Pricing: US</span>
<p style="text-indent:-2em;margin-left:2em;text-align:justify;">
<b>Lozenge</b> (fentaNYL Citrate Buccal)</p>
<p style="text-indent:-2em;margin-left:4em;text-align:justify;">200 mcg (per each): $18.80 - $18.83</p>
<p style="text-indent:-2em;margin-left:4em;text-align:justify;">400 mcg (per each): $23.82 - $23.85</p>
<p style="text-indent:-2em;margin-left:4em;text-align:justify;">600 mcg (per each): $29.18 - $29.21</p>
<p style="text-indent:-2em;margin-left:4em;text-align:justify;">800 mcg (per each): $34.57 - $34.61</p>
<p style="text-indent:-2em;margin-left:4em;text-align:justify;">1200 mcg (per each): $44.95 - $45.00</p>
<p style="text-indent:-2em;margin-left:4em;text-align:justify;">1600 mcg (per each): $55.44 - $55.50</p>
<p style="text-indent:-2em;margin-left:2em;text-align:justify;">
<b>Patch, 72-hour</b> (fentaNYL Transdermal)</p>
<p style="text-indent:-2em;margin-left:4em;text-align:justify;">12 mcg/hr (per each): $20.30</p>
<p style="text-indent:-2em;margin-left:4em;text-align:justify;">25 mcg/hr (per each): $14.42 - $21.27</p>
<p style="text-indent:-2em;margin-left:4em;text-align:justify;">37.5 mcg/hr (per each): $65.31</p>
<p style="text-indent:-2em;margin-left:4em;text-align:justify;">50 mcg/hr (per each): $26.36 - $38.88</p>
<p style="text-indent:-2em;margin-left:4em;text-align:justify;">62.5 mcg/hr (per each): $94.91</p>
<p style="text-indent:-2em;margin-left:4em;text-align:justify;">75 mcg/hr (per each): $40.21 - $59.31</p>
<p style="text-indent:-2em;margin-left:4em;text-align:justify;">87.5 mcg/hr (per each): $129.22</p>
<p style="text-indent:-2em;margin-left:4em;text-align:justify;">100 mcg/hr (per each): $53.36 - $78.71</p>
<p style="text-indent:-2em;margin-left:2em;text-align:justify;">
<b>Solution</b> (fentaNYL Citrate (PF) Injection)</p>
<p style="text-indent:-2em;margin-left:4em;text-align:justify;">50 mcg/mL (per mL): $2.34 - $2.65</p>
<p style="text-indent:-2em;margin-left:4em;text-align:justify;">100 mcg/2 mL (per mL): $0.92 - $1.28</p>
<p style="text-indent:-2em;margin-left:4em;text-align:justify;">250 mcg/5 mL (per mL): $0.55 - $0.66</p>
<p style="text-indent:-2em;margin-left:4em;text-align:justify;">500MCG/10ML (per mL): $0.45</p>
<p style="text-indent:-2em;margin-left:4em;text-align:justify;">1000 mcg/20 mL (per mL): $0.47 - $0.66</p>
<p style="text-indent:-2em;margin-left:4em;text-align:justify;">2500 mcg/50 mL (per mL): $0.52 - $0.60</p>
<p style="text-indent:-2em;margin-left:2em;text-align:justify;">
<b>Solution</b> (fentaNYL Citrate Intravenous)</p>
<p style="text-indent:-2em;margin-left:4em;text-align:justify;">2500 mcg/50 mL (per mL): $0.53</p>
<p style="text-indent:-2em;margin-left:2em;text-align:justify;">
<b>Solution Prefilled Syringe</b> (fentaNYL Citrate Injection)</p>
<p style="text-indent:-2em;margin-left:4em;text-align:justify;">100 mcg/2 mL (per mL): $3.12</p>
<p style="text-indent:-2em;margin-left:2em;text-align:justify;">
<b>Solution Prefilled Syringe</b> (fentaNYL Citrate PF Injection)</p>
<p style="text-indent:-2em;margin-left:4em;text-align:justify;">50 mcg/mL (per mL): $2.65</p>
<p style="text-indent:-2em;margin-left:2em;text-align:justify;">
<b>Tablets</b> (fentaNYL Citrate Buccal)</p>
<p style="text-indent:-2em;margin-left:4em;text-align:justify;">100 mcg (per each): $58.06</p>
<p style="text-indent:-2em;margin-left:4em;text-align:justify;">200 mcg (per each): $73.35</p>
<p style="text-indent:-2em;margin-left:4em;text-align:justify;">400 mcg (per each): $106.43</p>
<p style="text-indent:-2em;margin-left:4em;text-align:justify;">600 mcg (per each): $138.18</p>
<p style="text-indent:-2em;margin-left:4em;text-align:justify;">800 mcg (per each): $170.23</p>
<p style="text-indent:-2em;margin-left:2em;text-align:justify;">
<b>Tablets</b> (Fentora Buccal)</p>
<p style="text-indent:-2em;margin-left:4em;text-align:justify;">100 mcg (per each): $94.38</p>
<p style="text-indent:-2em;margin-left:4em;text-align:justify;">200 mcg (per each): $119.24</p>
<p style="text-indent:-2em;margin-left:4em;text-align:justify;">400 mcg (per each): $173.02</p>
<p style="text-indent:-2em;margin-left:4em;text-align:justify;">600 mcg (per each): $224.62</p>
<p style="text-indent:-2em;margin-left:4em;text-align:justify;">800 mcg (per each): $276.72</p>
<p style="text-indent:0em;">
<b>Disclaimer: </b>A representative AWP (Average Wholesale Price) price or price range is provided as reference price only. A range is provided when more than one manufacturer's AWP price is available and uses the low and high price reported by the manufacturers to determine the range. The pricing data should be used for benchmarking purposes only, and as such should not be used alone to set or adjudicate any prices for reimbursement or purchasing functions or considered to be an exact price for a single product and/or manufacturer.  Medi-Span expressly disclaims all warranties of any kind or nature, whether express or implied, and assumes no liability with respect to accuracy of price or price range data published in its solutions.  In no event shall Medi-Span be liable for special, indirect, incidental, or consequential damages arising from use of price or price range data.  Pricing data is updated monthly.</p></div>
<div class="block dinfoc drugH1Div" id="F52912015"><span class="drugH1">Dosage Forms: Canada</span>
<p style="text-indent:0em;text-align:justify;display:inline">Excipient information presented when available (limited, particularly for generics); consult specific product labeling.</p>
<p style="text-indent:-2em;margin-left:2em;text-align:justify;">Patch 72 Hour, Transdermal: </p>
<p style="text-indent:-2em;margin-left:4em;text-align:justify;">Generic: 37 mcg/hr (5 ea)</p>
<p style="text-indent:-2em;margin-left:2em;text-align:justify;">Patch 72 Hour, Transdermal, as base: </p>
<p style="text-indent:-2em;margin-left:4em;text-align:justify;">Generic: 100 [delivers 100 mcg/hr] (5 ea); 12 [delivers 12.5 mcg/hr] (5 ea); 25 [delivers 25 mcg/hr] (5 ea); 50 [delivers 50 mcg/hr] (5 ea); 75 [delivers 75 mcg/hr] (5 ea)</p>
<p style="text-indent:-2em;margin-left:2em;text-align:justify;">Solution, Injection, as citrate: </p>
<p style="text-indent:-2em;margin-left:4em;text-align:justify;">Generic: 50 mcg/mL (1 mL, 2 mL, 5 mL, 10 mL, 20 mL, 50 mL)</p>
<p style="text-indent:-2em;margin-left:2em;text-align:justify;">Solution, Injection, as citrate [strength expressed as base]: </p>
<p style="text-indent:-2em;margin-left:4em;text-align:justify;">Generic: 100 mcg/2 mL (2 mL)</p>
<p style="text-indent:-2em;margin-left:2em;text-align:justify;">Tablet, Buccal, as citrate [strength expressed as base]: </p>
<p style="text-indent:-2em;margin-left:4em;text-align:justify;">Fentora: 100 mcg, 200 mcg, 400 mcg, 600 mcg, 800 mcg</p></div>
<div class="block csi drugH1Div" id="F170661"><span class="drugH1">Controlled Substance</span>
<p style="text-indent:0em;display:inline">C-II</p></div>
<div class="block accres drugH1Div" id="F50183666"><span class="drugH1">Prescribing and Access Restrictions</span>
<p style="text-indent:-2em;margin-left:2em;">As a requirement of the REMS program, access is restricted.</p>
<p style="text-indent:-2em;margin-left:2em;">Transmucosal immediate-release fentanyl products (eg, sublingual tablets and spray, oral lozenges, buccal tablets, intranasal) are only available through the Transmucosal Immediate-Release Fentanyl (TIRF) REMS ACCESS program. Enrollment in the program is required for outpatients, prescribers for outpatient use, pharmacies (inpatient and outpatient), and distributors. Enrollment is not required for inpatient administration (eg, hospitals, hospices, long-term care facilities), inpatients, and prescribers who prescribe to inpatients. Further information is available at 1-866-822-1483 or at www.TIRFREMSaccess.com</p>
<p style="text-indent:-2em;margin-left:2em;">
<b>Note:</b> Effective December, 2011, individual REMs programs for TIRF products were combined into a single access program (TIRF REMS Access). Prescribers and pharmacies that were enrolled in at least one individual REMS program for these products will automatically be transitioned to the single access program.</p></div>
<div class="block admp drugH1Div" id="F52612822"><span class="drugH1">Administration: Pediatric</span>
<p style="text-indent:-2em;margin-left:2em;">Parenteral: IV:</p>
<p style="text-indent:-2em;margin-left:4em;">Neonates: Administer as a continuous infusion via an infusion pump or by slow IV push over 3 to 5 minutes. Larger bolus doses (&gt;5 mcg/kg) should be administered over 5 to 10 minutes; may also administer intermittent doses via syringe pump over 15 to 30 minutes (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-Domonoske.1','lexi-content-ref-ISMP.2']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-Domonoske.1','lexi-content-ref-ISMP.2'])">Ref</a></span>). Risk of chest wall rigidity is minimized when doses are administered over at least 1 to 2 minutes (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-20176672']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-20176672'])">Ref</a></span>).</p>
<p style="text-indent:-2em;margin-left:4em;">Infants, Children, and Adolescents: Administer by slow IV push over 3 to 5 minutes or by continuous infusion via an infusion pump. Larger bolus doses (&gt;5 mcg/kg) should be given by slow IV push over 5 to 10 minutes.</p>
<p style="text-indent:-2em;margin-left:2em;">Transdermal patch: Children ≥2 years and Adolescents: Apply to nonhairy, clean, dry, nonirritated, intact skin of the flat area of front or back of upper torso, flank area, or upper arm; apply to upper back in young children or in people with cognitive impairment to decrease the potential of the patient removing the patch. Monitor the adhesion of the system closely in children. Clip hair prior to application, do <b>not</b> shave area; prior to application, skin may be cleaned with clear water (do not use soaps, lotions, alcohol, oils, or other substances which may irritate the skin); allow skin to dry thoroughly prior to application. Apply patch immediately after removing from package; firmly press in place and hold for at least 30 seconds; change patch every 72 hours; remove old patch before applying new patch; do not apply new patch to same place as old patch; wash hands after applying patch. If there is difficulty with patch adhesion, the edges of the system may be taped in place with first-aid tape; if difficulty with adhesion persists, an adhesive film dressing (eg, Bioclusive, Tegaderm) may be applied over the system. If patch falls off before 72 hours, a new patch may be applied to a different skin site. Dispose of any used or unused patches by removing patch from protective pouch and liner, fold adhesive ends together and flush patch down toilet immediately. Do not flush pouch or protective liner as such items can be discarded in the trash.</p>
<p style="text-indent:-2em;margin-left:4em;">
<b>Note:</b> Transdermal patch is a membrane-controlled system; do <b>not</b> cut the patch to deliver partial doses; do <b>not</b> use patches that are cut, damaged, or leaking; do <b>not</b> use if seal of package is broken; rate of drug delivery may be significantly increased if patch is cut, damaged, or leaking and result in absorption of a potentially fatal dose; reservoir contents and adhesion may be affected if cut; if partial dose is needed, surface area of patch can be blocked proportionally using adhesive bandage (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-9262751']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-9262751'])">Ref</a></span>). Do <b>not</b> use soap, alcohol, or other solvents to remove transdermal gel if it accidentally touches skin as they may increase transdermal absorption; use copious amounts of water. Avoid exposing application site to external heat sources (eg, electric blanket, heating pad, heat lamp, tanning lamp, sauna, heated water bed, hot tub, hot baths, sunbathing). Dispose of properly.</p>
<p style="text-indent:-2em;margin-left:2em;">Transmucosal products:</p>
<p style="text-indent:-2em;margin-left:4em;">Intranasal (using parenteral preparation):</p>
<p style="text-indent:-2em;margin-left:6em;">Solution (parenteral preparation): If congested, suction nostrils prior to administration. Using a 50 mcg/mL solution, administer half of the dose to each nostril using an atomizer such as the MAD Nasal Drug delivery device or drip into the nostril slowly with a syringe; higher concentrations (150 mcg/mL and 300 mcg/mL) have been studied to prevent excess volume administration, but comparative trials have not been performed (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-16005154','lexi-content-ref-19840089','lexi-content-ref-30592476','lexi-content-ref-19682022','lexi-content-ref-30045355','lexi-content-ref-30275061']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-16005154','lexi-content-ref-19840089','lexi-content-ref-30592476','lexi-content-ref-19682022','lexi-content-ref-30045355','lexi-content-ref-30275061'])">Ref</a></span>).</p>
<p style="text-indent:-2em;margin-left:4em;">Oral lozenge (eg, Actiq): Adolescents ≥16 years: Oral: Foil overwrap should be removed just prior to administration, patient should place the unit in mouth between cheek and lower gum; occasionally move lozenge from one side of the mouth to the other and allow it to dissolve. Do not bite or chew lozenge; consume lozenge over 15 minutes. Remove handle after lozenge is consumed. Early removal should be considered if the patient has achieved an adequate response and/or shows signs of respiratory depression. After consumption of a complete unit, the handle may be disposed of in a trash container that is out of the reach of children. For a partially consumed unit, or a unit that still has any drug matrix remaining on the handle, the handle should be placed under hot running tap water until the drug matrix has dissolved. Special child-resistant containers are available to temporarily store partially consumed units that cannot be disposed of immediately.</p></div>
<div class="block adm drugH1Div" id="F170587"><span class="drugH1">Administration: Adult</span>
<p style="text-indent:-2em;margin-left:2em;">Epidural (Canadian labeling; not in US labeling): For postoperative pain management may administer as bolus dose (diluted in preservative free NS to a final concentration of 10 mcg/mL) or by continuous infusion at a rate of 1 mcg/kg/hour. Use within 24 hours.</p>
<p style="text-indent:-2em;margin-left:2em;">Parenteral: Administer IM or IV slowly over 1 to 2 minutes; rapid IV infusion may result in skeletal muscle and chest wall rigidity, impaired ventilation, or respiratory distress/arrest. May administer as a continuous IV infusion or patient-controlled analgesia (off label). May also administer SUBQ (intermittent or continuous infusion [off label]).</p>
<p style="text-indent:-2em;margin-left:2em;">Transdermal device (eg, Ionsys): Always wear gloves when handling the device. Avoid contact with synthetic materials (such as carpeted flooring) while assembling and avoid exposing the device to electronic security systems. Prior to administration, clip excessive hair from application site if necessary (do not shave); clean the site with alcohol and let dry; do not use soaps, lotions, or other agents. Apply one device to healthy, unbroken/intact, non-irritated, and non-irradiated skin on the chest or upper outer arm only. Allow only the patient to self-administer doses; each on-demand dose is delivered over a 10-minute period. Each device operates up to 24 hours or 80 doses, whichever comes first. After 24 hours have elapsed, or 80 doses have been delivered, the device will not deliver any additional doses; if the patient tries to initiate a dose, the device will ignore the dose request. Ionsys may be used for a maximum of 72 hours, with each subsequent device applied to a different skin site. Refer to manufacturer's labeling for complete activation, administration, and removal instructions.</p>
<p style="text-indent:-2em;margin-left:2em;">Transdermal patch (eg, Duragesic): Apply to nonirritated and nonirradiated skin on a flat surface, such as chest, back, flank, or upper arm; apply to the upper back in patients with cognitive impairment. Hair at application site may be clipped (do not shave). If application site must be cleaned prior to application, clean site with clear water and allow to dry completely. Do not use damaged, cut or leaking patches; patch may be less effective. Do not use soaps, oils, lotions, alcohol, or any other agents to cleanse skin before application because they may irritate the skin or alter its characteristics. Immediately after removal from sealed package, firmly press patch in place and hold for 30 seconds. Wash hands immediately with soap and water after applying patch. Change patch every 72 hours; apply new patch to a different skin site. Contact with unwashed or unclothed application sites can result in secondary exposure to fentanyl and should be avoided. Avoid exposing application site to external heat sources (eg, heating pad, electric blanket, heat lamp, tanning lamps, hot tub, sunbathing, saunas, heated water beds). If there is difficulty with patch adhesion, the edges of the system may be taped in place with first-aid tape. If there is continued difficulty with adhesion, an adhesive film dressing (eg, Bioclusive, Tegaderm) may be applied over the system. Dispose of any used or unused patches by removing patch from protective pouch and liner, fold adhesive ends together and flush patch down toilet immediately. Do not flush pouch or protective liner as such items can be discarded in the trash. For used and unused patches, the Canadian labeling recommends folding adhesive ends together and returning to a pharmacy for proper disposal; temporary storage in a biohazard container may be used before returning to pharmacy.</p>
<p style="text-indent:-2em;margin-left:2em;">Lozenge: Foil overwrap should be removed just prior to administration. Place the unit in mouth between the cheek and gum and allow it to dissolve. Do not chew. Lozenge may be moved from one side of the mouth to the other using the handle. The unit should be consumed over a period of 15 minutes. After consumption of a complete unit, the handle may be disposed of in a trash container that is out of the reach of children. For a unit that still has any drug matrix remaining on the handle, the handle should be placed under hot running tap water until the entire drug matrix has dissolved. Special child-resistant containers are available to temporarily store partially consumed units that cannot be disposed of immediately. Refer to manufacturer's labeling for additional disposal instructions.</p>
<p style="text-indent:-2em;margin-left:2em;">Buccal tablet: Patient should not open blister until ready to administer. The blister backing should be peeled back to expose the tablet; tablet should not be pushed out through the blister. Immediately use tablet once removed from blister. Place entire tablet in the buccal cavity (above a rear molar, between the upper cheek and gum) or under the tongue (US labeling recommends for maintenance dosing only; Canadian labeling does not restrict sublingual use to maintenance dosing only); should dissolve in about 14 to 25 minutes. If remnants remain after 30 minutes, they may be swallowed with water. Tablet should not be split, crushed, sucked, chewed, or swallowed whole. When possible, alternate sides of mouth with each dose.</p>
<p style="text-indent:-2em;margin-left:2em;">Intranasal:</p>
<p style="text-indent:-2em;margin-left:4em;">Lazanda: Prior to initial use, prime device by spraying 4 sprays into the provided pouch (the counting window will show a green bar when the bottle is ready for use). Insert nozzle a short distance into the nose (~<sup>1</sup>/<sub>2</sub> inch or 1 cm) and point towards the bridge of the nose (while closing off the other nostril using 1 finger). Press on finger grips until a “click” sound is heard and the number in the counting window advances by one. The “click” sound and dose counter are the only reliable methods for ensuring a dose has been administered (spray is not always felt on the nasal mucosa). Patient should remain seated for at least 1 minute following administration. Do not blow nose for ≥30 minutes after administration. Wash hands before and after use. If not used within 5 days, re-prime by spraying once. There are 8 full therapeutic sprays in each bottle; do not continue to use bottle after “8” sprays have been used. Dispose of bottle and contents if it has been ≥60 days since first use. Before disposal, all unopened or partially used bottles must be completely emptied by spraying the contents into the provided pouch. After “8” therapeutic sprays has been reached on the counter, patients should continue to spray an additional four sprays into the pouch to ensure that any residual fentanyl has been expelled (an audible click will no longer be heard and the counter will not advance beyond “8”). The empty bottle and the sealed pouch must be put into the child-resistant container before placing in the trash. Wash hands with soap and water immediately after handling the pouch. If the pouch is lost, another one can be ordered by the patient or caregiver by calling 1-866-458-6389.</p>
<p style="text-indent:-2em;margin-left:4em;">Parenteral solution (off-label route): Using 50 mcg/mL parenteral solution, administer half the dose in each nostril using a mucosal atomizer device (preferred) or drip into nostril with a needleless syringe; maximum volume per nostril: 1 mL (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-28259526','lexi-content-ref-30275061']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-28259526','lexi-content-ref-30275061'])">Ref</a></span>).</p>
<p style="text-indent:-2em;margin-left:2em;">SUBQ continuous infusions: Change site every 3 to 7 days or when erythema occurs (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-15122000']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-15122000'])">Ref</a></span>). To maintain comfort, the SUBQ infusion rate should generally not exceed 5 <b>mL</b>/hour (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-Portenoy.1']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-Portenoy.1'])">Ref</a></span>).</p>
<p style="text-indent:-2em;margin-left:2em;">Sublingual spray: Open sealed blister unit with scissors immediately prior to administration. Contents of unit should be sprayed into mouth under the tongue. Dispose of each unit dose immediately after use; place used unit into one of the provided white disposal bags. After sealing appropriately, discard in the trash. Dispose of any unused units as soon as no longer needed. Prior to disposal, empty all the medicine into the provided charcoal-lined disposal pouch. The disposal pouch should then be placed into the white disposal bag, sealed appropriately, and discarded in the trash.</p>
<p style="text-indent:-2em;margin-left:2em;">Sublingual tablet: Remove from the blister unit immediately prior to administration. Place tablet directly under the tongue on the floor of the mouth and allow to completely dissolve; do not chew, suck, or swallow. Do not eat or drink anything until tablet is completely dissolved. In patients with a dry mouth, water may be used to moisten the buccal mucosa just before administration. To dispose of sublingual tablets; remove any unused tablets from the blister cards and dispose by flushing down the toilet. In Canada, it is recommended that unused tablets be disposed of via a pharmacy take back program.</p></div>
<div class="block uicn drugH1Div" id="F14472638"><span class="drugH1">Usual Infusion Concentrations: Neonatal</span>
<p style="text-indent:0em;display:inline">
<b>IV infusion:</b> 2 <b>mcg</b>/mL, 10 <b>mcg</b>/mL.</p></div>
<div class="block uicp drugH1Div" id="F14472637"><span class="drugH1">Usual Infusion Concentrations: Pediatric</span>
<p style="text-indent:0em;display:inline">
<b>IV infusion:</b> 10 <b>mcg</b>/mL, 50 <b>mcg</b>/mL.</p></div>
<div class="block sts drugH1Div" id="F170604"><span class="drugH1">Storage/Stability</span>
<p style="text-indent:-2em;margin-left:2em;">Injection: Store intact vials in original carton at 20°C to 25°C (68°F to 77°F); excursions permitted to 15°C to 30°C (59°F to 86°F). Protect from light.</p>
<p style="text-indent:-2em;margin-left:2em;">Intranasal: Do not store above 25°C (77°F); do not freeze. Protect from light. Bottle should be stored in the provided child-resistant container when not in use and kept out of the reach of children at all times.</p>
<p style="text-indent:-2em;margin-left:2em;">Transdermal device, transdermal patch, transmucosal (buccal tablet, lozenge, sublingual spray, sublingual tablet): Store at 20°C to 25°C (68°F to 77°F); excursions permitted to 15°C to 30°C (59°F to 86°F). Protect transmucosal products from freezing and moisture. Keep all products out of the reach of children.</p></div>
<div class="block meg drugH1Div" id="F7874432"><span class="drugH1">Medication Guide and/or Vaccine Information Statement (VIS)</span>
<p style="text-indent:0em;display:inline">An FDA-approved patient medication guide, which is available with the product information and as follows, must be dispensed with this medication:</p>
<p style="text-indent:-2em;margin-left:4em;">Abstral: <a href="/external-redirect?target_url=https%3A%2F%2Fwww.accessdata.fda.gov%2Fdrugsatfda_docs%2Flabel%2F2019%2F022510s018lbl.pdf%23page%3D29&amp;token=ztJXkj6KOFXccjLtS%2FWzHVQSIouramtpnW4vYdDsiscbznKt8slGyUZtuEi6g3xJO5EHwZX72p4w7K2Ma7HUGgFSwqxkPSxtsySY9HwM6wrh6XVmH%2FZPfBTPjV%2FLMKe0&amp;TOPIC_ID=13298" target="_blank">https://www.accessdata.fda.gov/drugsatfda_docs/label/2019/022510s018lbl.pdf#page=29</a></p>
<p style="text-indent:-2em;margin-left:4em;">Actiq: <a href="/external-redirect?target_url=https%3A%2F%2Fwww.accessdata.fda.gov%2Fdrugsatfda_docs%2Flabel%2F2023%2F020747s062lbl.pdf%23page%3D44&amp;token=GWTMfhhnnFLWDZ1IKwdvOexxpbO0vdzZ9BXAwXJCXPwbznKt8slGyUZtuEi6g3xJArFkRZhzWeuw1cER2nAqTkbcfnJX%2B7eA0mqjx%2BtPqh2lShV5MwCGhIMiKpodewpp&amp;TOPIC_ID=13298" target="_blank">https://www.accessdata.fda.gov/drugsatfda_docs/label/2023/020747s062lbl.pdf#page=44</a></p>
<p style="text-indent:-2em;margin-left:4em;">Duragesic: <a href="/external-redirect?target_url=https%3A%2F%2Fwww.accessdata.fda.gov%2Fdrugsatfda_docs%2Flabel%2F2021%2F019813s081lbl.pdf%23page%3D52&amp;token=0xArWZkun6glelWIj5kLrKY8zeWn0LV6BifEA%2BNtfJ7rm8%2F17fPXzper%2FSMtd%2FD8RkpAupqQgeHVu%2Fmj1HrQgmA281zQOkCEDHZFqHlomEPJT5%2FxbdFpcVTnDJB7uuMC&amp;TOPIC_ID=13298" target="_blank">https://www.accessdata.fda.gov/drugsatfda_docs/label/2021/019813s081lbl.pdf#page=52</a></p>
<p style="text-indent:-2em;margin-left:4em;">Fentora: <a href="/external-redirect?target_url=https%3A%2F%2Fwww.accessdata.fda.gov%2Fdrugsatfda_docs%2Flabel%2F2023%2F021947s043lbl.pdf%23page%3D43&amp;token=ezsa3dX9X4Bo1BLXwWaITs9TTP9YmB1B00PhvuksEF7rm8%2F17fPXzper%2FSMtd%2FD8cc4oJlUgO1MGGRDZc6uiqXDcoNJZVeIdfBkZec76lcryMo%2BmoAuajhdl21Dc1P1o&amp;TOPIC_ID=13298" target="_blank">https://www.accessdata.fda.gov/drugsatfda_docs/label/2023/021947s043lbl.pdf#page=43</a></p>
<p style="text-indent:-2em;margin-left:4em;">Lazanda: <a href="/external-redirect?target_url=https%3A%2F%2Fwww.accessdata.fda.gov%2Fdrugsatfda_docs%2Flabel%2F2021%2F022569s030lbl.pdf%23page%3D35&amp;token=%2BMSqJ44lwKvamOjsrDUnAZJv1TUIVdlt8pR%2F1M82RagUuQF9xQLUtk%2B3Ci6WbaTsAymgJ8WeyK1tcKIDAWfZMa9glbxJREIfLrgItkrDiyq%2BcO8r%2BTkt%2BCApIAR5CkLZ&amp;TOPIC_ID=13298" target="_blank">https://www.accessdata.fda.gov/drugsatfda_docs/label/2021/022569s030lbl.pdf#page=35</a></p>
<p style="text-indent:-2em;margin-left:4em;">Onsolis: <a href="/external-redirect?target_url=https%3A%2F%2Fwww.accessdata.fda.gov%2Fdrugsatfda_docs%2Flabel%2F2021%2F022266s025lbl.pdf%23page%3D32&amp;token=kvRpOzkmrUyp4ugBN3mBCLeNJQeyCfFb8x3Tp9j%2BELVwGj1p0mm5nLm08FaEfchnECumXinEyax6HKDfeH5dBo%2Fthvv8%2F4EfxlU%2BL%2FpIAyZ1YCvEsSLJr7Yqf1l8U%2FiM&amp;TOPIC_ID=13298" target="_blank">https://www.accessdata.fda.gov/drugsatfda_docs/label/2021/022266s025lbl.pdf#page=32</a></p>
<p style="text-indent:-2em;margin-left:4em;">Subsys: <a href="/external-redirect?target_url=https%3A%2F%2Fwww.accessdata.fda.gov%2Fdrugsatfda_docs%2Flabel%2F2021%2F202788s023lbl.pdf%23page%3D40&amp;token=he7i6TED%2F%2FH4UyKsQwzSbF1mKjRkBQBOyyoKOA3Le8kppBbQq3ggoTyOI4v4FBAlDyNPs5cNX8qARQLocWGPLd%2BaT1%2BHYOXUQTEPmGyFSKczuSx5beAEC%2FIiaz0HQdhG&amp;TOPIC_ID=13298" target="_blank">https://www.accessdata.fda.gov/drugsatfda_docs/label/2021/202788s023lbl.pdf#page=40</a></p></div>
<div class="block usep drugH1Div" id="F53566884"><span class="drugH1">Use</span>
<p style="text-indent:-2em;margin-left:2em;">Parenteral: Injection: Analgesic adjunct to general or regional anesthesia; preoperative medication; analgesic during anesthesia and in the immediate postoperative period (FDA approved in ages ≥2 years and adults); has also been used for sedation and intranasally for analgesia.</p>
<p style="text-indent:-2em;margin-left:2em;">Transdermal patch (eg, Duragesic): Management of pain in opioid-tolerant patients, severe enough to require daily, around-the-clock, long-term opioid treatment and for which alternative treatment options are inadequate (FDA approved in ages ≥2 years and adults); see <b>Note</b>.</p>
<p style="text-indent:-2em;margin-left:2em;">Transmucosal products:</p>
<p style="text-indent:-2em;margin-left:4em;">Buccal tablet (eg, Fentora): Breakthrough cancer pain in opioid-tolerant patients who are currently receiving around-the-clock opioids for persistent cancer pain (FDA approved in adults); see <b>Note</b>.</p>
<p style="text-indent:-2em;margin-left:4em;">Nasal spray (eg, Lazanda): Breakthrough cancer pain in opioid-tolerant patients who are currently receiving around-the-clock opioids for persistent cancer pain (FDA approved in adults); see <b>Note</b>.</p>
<p style="text-indent:-2em;margin-left:4em;">Oral lozenge (eg, Actiq): Breakthrough cancer pain in opioid-tolerant patients who are currently receiving around-the-clock opioids for persistent cancer pain (FDA approved in ages ≥16 years and adults); see <b>Note</b>.</p>
<p style="text-indent:-2em;margin-left:4em;">Sublingual spray (eg, Subsys): Breakthrough cancer pain in opioid-tolerant patients who are currently receiving around-the-clock opioids for persistent cancer pain (FDA approved in adults); see <b>Note</b>.</p>
<p style="text-indent:-2em;margin-left:2em;">
<b>Note:</b> Patients are considered opioid-tolerant if they are receiving around-the-clock opioids at a dose of at least 60 mg/day of oral morphine, 25 mcg/hour of transdermal fentanyl, 30 mg/day of oral oxycodone, 8 mg/day of oral hydromorphone, 25 mg/day of oral oxymorphone or an equivalent dose of another opioid for 1 week or longer.</p></div>
<div class="block mst drugH1Div" id="F170670"><span class="drugH1">Medication Safety Issues</span>
<div class="collapsible">
<span class="collapsible-title">Sound-alike/look-alike issues:</span>
<div class="collapsible-wrap">
<p style="text-indent:-2em;margin-left:4em;">FentaNYL may be confused with ALfentanil, SUFentanil</p></div>
</div>
<div class="collapsible">
<span class="collapsible-title">High alert medication:</span>
<div class="collapsible-wrap">
<p style="text-indent:-2em;margin-left:4em;">The Institute for Safe Medication Practices (ISMP) includes this medication among its list of drug classes which have a heightened risk of causing significant patient harm when used in error.</p></div>
</div>
<div class="collapsible">
<span class="collapsible-title">Administration issues:</span>
<div class="collapsible-wrap">
<p style="text-indent:-2em;margin-left:4em;">Fentanyl transdermal system patches: Leakage of fentanyl gel from the patch has been reported; patch may be less effective; do not use. Thoroughly wash any skin surfaces coming into direct contact with gel with water (do not use soap). May contain conducting metal (eg, aluminum); remove patch prior to MRI.</p></div>
</div>
<div class="collapsible">
<span class="collapsible-title">Other safety concerns:</span>
<div class="collapsible-wrap">
<p style="text-indent:-2em;margin-left:4em;">Fentanyl transdermal system patches:</p>
<p style="text-indent:-2em;margin-left:6em;">Avoid use of patches in opioid-naive patients and/or acute pain. Patches are only intended for use in opioid-tolerant patients; steps should be taken to verify opioid status and type of pain being treated prior to prescribing to prevent inappropriate use. Serious harm, including fatalities, are associated with use of patches in opioid-naive patients. Dosing of transdermal fentanyl patches may be confusing. Transdermal fentanyl patches should always be prescribed in mcg/hour, not size. Patch dosage form of Duragesic-12 actually delivers 12.5 mcg/hour of fentanyl. Use caution, as orders may be written as “Duragesic 12.5” which can be erroneously interpreted as a 125 mcg dose.</p>
<p style="text-indent:-2em;margin-left:6em;">Patches should be stored and disposed of with care to avoid accidental exposure to children. The FDA has issued numerous safety advisories to warn users of the possible consequences (including hospitalization and death) of inappropriate storage or disposal of patches. According to the 2020 to 2021 <i>ISMP Targeted Medication Safety Best Practices for Hospitals</i>, patches should <b>not</b> be stored in automated dispensing cabinets or as unit stock in clinical areas where acute pain is primarily treated (eg, emergency departments, operating rooms, postanesthesia care units, procedural areas).</p>
<p style="text-indent:-2em;margin-left:4em;">Abstral, Actiq, Fentora, and Subsys are not interchangeable; do not substitute doses on a mcg-per-mcg basis.</p></div>
</div>
</div>
<div class="block cyt drugH1Div" id="F170653"><span class="drugH1">Metabolism/Transport Effects</span>
<p style="text-indent:0em;display:inline">
<b>Substrate</b> of CYP3A4 (major); <b>Note:</b> Assignment of Major/Minor substrate status based on clinically relevant drug interaction potential</p></div>
<div class="block dri drugH1Div" id="F170576"><span class="drugH1">Drug Interactions</span><br/><br/><div class="clear"></div><p xmlns=""></p><div class="inner" xmlns=""><p style="text-indent:0em;display:inline"><b>Note</b>: Interacting drugs may <b>not be individually listed below</b> if they are part of a group interaction (eg, individual drugs within “CYP3A4 Inducers [Strong]” are NOT listed).  For a complete list of drug interactions by individual drug name and detailed management recommendations, use the Lexicomp drug interactions program by clicking on the “Launch drug interactions program” link above.</p><p xmlns=""></p></div>
<p style="text-indent:-2em;margin-left:2em;">Alizapride: May enhance the CNS depressant effect of CNS Depressants.<i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">Almotriptan: May enhance the serotonergic effect of Serotonergic Agents (High Risk). This could result in serotonin syndrome. Management: Monitor for signs and symptoms of serotonin syndrome/serotonin toxicity (eg, hyperreflexia, clonus, hyperthermia, diaphoresis, tremor, autonomic instability, mental status changes) when these agents are combined.<i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">Alosetron: May enhance the serotonergic effect of Serotonergic Agents (High Risk). This could result in serotonin syndrome. Management: Monitor for signs and symptoms of serotonin syndrome/serotonin toxicity (eg, hyperreflexia, clonus, hyperthermia, diaphoresis, tremor, autonomic instability, mental status changes) when these agents are combined.<i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">Alvimopan: Opioid Agonists may enhance the adverse/toxic effect of Alvimopan. This is most notable for patients receiving long-term (i.e., more than 7 days) opiates prior to alvimopan initiation.  Management: Alvimopan is contraindicated in patients receiving therapeutic doses of opioids for more than 7 consecutive days immediately prior to alvimopan initiation.<i> Risk D: Consider therapy modification</i></p>
<p style="text-indent:-2em;margin-left:2em;">Amphetamines: May enhance the analgesic effect of Opioid Agonists.<i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">Amphetamines: May enhance the serotonergic effect of Serotonergic Agents (High Risk). This could result in serotonin syndrome. Management: Monitor for signs and symptoms of serotonin syndrome/serotonin toxicity (eg, hyperreflexia, clonus, hyperthermia, diaphoresis, tremor, autonomic instability). Initiate amphetamines at lower doses, monitor frequently, and adjust doses as needed.<i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">Anticholinergic Agents: May enhance the adverse/toxic effect of Opioid Agonists. Specifically, the risk for constipation and urinary retention may be increased with this combination.<i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">Antiemetics (5HT3 Antagonists): May enhance the serotonergic effect of Serotonergic Agents (High Risk). This could result in serotonin syndrome. Management: Monitor for signs and symptoms of serotonin syndrome/serotonin toxicity (eg, hyperreflexia, clonus, hyperthermia, diaphoresis, tremor, autonomic instability, mental status changes) when these agents are combined.<i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">Antiplatelet Agents (P2Y12 Inhibitors): FentaNYL may diminish the antiplatelet effect of Antiplatelet Agents (P2Y12 Inhibitors). FentaNYL may decrease the serum concentration of Antiplatelet Agents (P2Y12 Inhibitors). <i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">Azelastine (Nasal): May enhance the CNS depressant effect of CNS Depressants.<i> Risk X: Avoid combination</i></p>
<p style="text-indent:-2em;margin-left:2em;">Blonanserin: CNS Depressants may enhance the CNS depressant effect of Blonanserin.  Management: Use caution if coadministering blonanserin and CNS depressants; dose reduction of the other CNS depressant may be required. Strong CNS depressants should not be coadministered with blonanserin.<i> Risk D: Consider therapy modification</i></p>
<p style="text-indent:-2em;margin-left:2em;">Bradycardia-Causing Agents: May enhance the bradycardic effect of other Bradycardia-Causing Agents.<i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">Brimonidine (Topical): May enhance the CNS depressant effect of CNS Depressants.<i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">Bromopride: May enhance the CNS depressant effect of CNS Depressants.<i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">Bromperidol: May enhance the CNS depressant effect of CNS Depressants.<i> Risk X: Avoid combination</i></p>
<p style="text-indent:-2em;margin-left:2em;">BusPIRone: May enhance the serotonergic effect of Serotonergic Agents (High Risk). This could result in serotonin syndrome. Management: Monitor for signs and symptoms of serotonin syndrome/serotonin toxicity (eg, hyperreflexia, clonus, hyperthermia, diaphoresis, tremor, autonomic instability, mental status changes) when these agents are combined.<i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">Cannabinoid-Containing Products: CNS Depressants may enhance the CNS depressant effect of Cannabinoid-Containing Products. <i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">Ceritinib: Bradycardia-Causing Agents may enhance the bradycardic effect of Ceritinib.  Management: If this combination cannot be avoided, monitor patients for evidence of symptomatic bradycardia, and closely monitor blood pressure and heart rate during therapy.<i> Risk D: Consider therapy modification</i></p>
<p style="text-indent:-2em;margin-left:2em;">Chlormethiazole: May enhance the CNS depressant effect of CNS Depressants. Management: Monitor closely for evidence of excessive CNS depression. The chlormethiazole labeling states that an appropriately reduced dose should be used if such a combination must be used.<i> Risk D: Consider therapy modification</i></p>
<p style="text-indent:-2em;margin-left:2em;">Chlorphenesin Carbamate: May enhance the adverse/toxic effect of CNS Depressants.<i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">Clofazimine: May increase the serum concentration of CYP3A4 Substrates (High risk with Inhibitors).<i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">CNS Depressants: May enhance the CNS depressant effect of Opioid Agonists. Management: Avoid concomitant use of opioid agonists and benzodiazepines or other CNS depressants when possible. These agents should only be combined if alternative treatment options are inadequate. If combined, limit the dosages and duration of each drug.<i> Risk D: Consider therapy modification</i></p>
<p style="text-indent:-2em;margin-left:2em;">CYP3A4 Inducers (Moderate): May decrease the serum concentration of FentaNYL.<i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">CYP3A4 Inducers (Strong): May decrease the serum concentration of FentaNYL.<i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">CYP3A4 Inhibitors (Moderate): May increase the serum concentration of FentaNYL. Management: Consider fentanyl dose reductions when combined with a moderate CYP3A4 inhibitor. Monitor for respiratory depression and sedation. Upon discontinuation of a CYP3A4 inhibitor, consider a fentanyl dose increase; monitor for signs and symptoms of withdrawal.<i> Risk D: Consider therapy modification</i></p>
<p style="text-indent:-2em;margin-left:2em;">CYP3A4 Inhibitors (Strong): May increase the serum concentration of FentaNYL. Management: Consider fentanyl dose reductions when combined with a strong CYP3A4 inhibitor. Monitor for respiratory depression and sedation. Upon discontinuation of a CYP3A4 inhibitor, consider a fentanyl dose increase; monitor for signs and symptoms of withdrawal.<i> Risk D: Consider therapy modification</i></p>
<p style="text-indent:-2em;margin-left:2em;">Dapoxetine: May enhance the serotonergic effect of Serotonergic Agents (High Risk). This could result in serotonin syndrome. Management: Do not use serotonergic agents (high risk) with dapoxetine or within 7 days of serotonergic agent discontinuation. Do not use dapoxetine within 14 days of monoamine oxidase inhibitor use. Dapoxetine labeling lists this combination as contraindicated.<i> Risk X: Avoid combination</i></p>
<p style="text-indent:-2em;margin-left:2em;">Daridorexant: May enhance the CNS depressant effect of CNS Depressants. Management: Dose reduction of daridorexant and/or any other CNS depressant may be necessary. Use of daridorexant with alcohol is not recommended, and the use of daridorexant with any other drug to treat insomnia is not recommended.<i> Risk D: Consider therapy modification</i></p>
<p style="text-indent:-2em;margin-left:2em;">Decongestants: May decrease the serum concentration of FentaNYL.<i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">Desmopressin: Opioid Agonists may enhance the hyponatremic effect of Desmopressin. <i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">DexmedeTOMIDine: CNS Depressants may enhance the CNS depressant effect of DexmedeTOMIDine.  Management: Monitor for increased CNS depression during coadministration of dexmedetomidine and CNS depressants, and consider dose reductions of either agent to avoid excessive CNS depression.<i> Risk D: Consider therapy modification</i></p>
<p style="text-indent:-2em;margin-left:2em;">Dexmethylphenidate-Methylphenidate: May enhance the serotonergic effect of Serotonergic Agents (High Risk). This could result in serotonin syndrome. Management: Monitor for signs and symptoms of serotonin syndrome/serotonin toxicity (eg, hyperreflexia, clonus, hyperthermia, diaphoresis, tremor, autonomic instability, mental status changes) when these agents are combined.<i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">Dextromethorphan: May enhance the serotonergic effect of Serotonergic Agents (High Risk). This could result in serotonin syndrome. Management: Monitor for signs and symptoms of serotonin syndrome/serotonin toxicity (eg, hyperreflexia, clonus, hyperthermia, diaphoresis, tremor, autonomic instability, mental status changes) when these agents are combined.<i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">Difelikefalin: May enhance the CNS depressant effect of CNS Depressants.<i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">Dimethindene (Topical): May enhance the CNS depressant effect of CNS Depressants.<i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">Diuretics: Opioid Agonists may enhance the adverse/toxic effect of Diuretics. Opioid Agonists may diminish the therapeutic effect of Diuretics. <i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">DroPERidol: May enhance the CNS depressant effect of CNS Depressants. Management: Consider dose reductions of droperidol or of other CNS agents (eg, opioids, barbiturates) with concomitant use.<i> Risk D: Consider therapy modification</i></p>
<p style="text-indent:-2em;margin-left:2em;">Eletriptan: May enhance the serotonergic effect of Serotonergic Agents (High Risk). This could result in serotonin syndrome. Management: Monitor for signs and symptoms of serotonin syndrome/serotonin toxicity (eg, hyperreflexia, clonus, hyperthermia, diaphoresis, tremor, autonomic instability, mental status changes) when these agents are combined.<i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">Eluxadoline: Opioid Agonists may enhance the constipating effect of Eluxadoline. <i> Risk X: Avoid combination</i></p>
<p style="text-indent:-2em;margin-left:2em;">Ergot Derivatives: May enhance the serotonergic effect of Serotonergic Agents (High Risk). This could result in serotonin syndrome. Management: Monitor for signs and symptoms of serotonin syndrome/serotonin toxicity (eg, hyperreflexia, clonus, hyperthermia, diaphoresis, tremor, autonomic instability, mental status changes) when these agents are combined.<i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">Etrasimod: May enhance the bradycardic effect of Bradycardia-Causing Agents.<i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">Fexinidazole: Bradycardia-Causing Agents may enhance the arrhythmogenic effect of Fexinidazole. <i> Risk X: Avoid combination</i></p>
<p style="text-indent:-2em;margin-left:2em;">Fexinidazole: May increase the serum concentration of CYP3A4 Substrates (High risk with Inhibitors).<i> Risk X: Avoid combination</i></p>
<p style="text-indent:-2em;margin-left:2em;">Fingolimod: Bradycardia-Causing Agents may enhance the bradycardic effect of Fingolimod.  Management: Consult with the prescriber of any bradycardia-causing agent to see if the agent could be switched to an agent that does not cause bradycardia prior to initiating fingolimod. If combined, perform continuous ECG monitoring after the first fingolimod dose.<i> Risk D: Consider therapy modification</i></p>
<p style="text-indent:-2em;margin-left:2em;">Flunarizine: CNS Depressants may enhance the CNS depressant effect of Flunarizine. <i> Risk X: Avoid combination</i></p>
<p style="text-indent:-2em;margin-left:2em;">Flunitrazepam: CNS Depressants may enhance the CNS depressant effect of Flunitrazepam.  Management: Reduce the dose of CNS depressants when combined with flunitrazepam and monitor patients for evidence of CNS depression (eg, sedation, respiratory depression). Use non-CNS depressant alternatives when available.<i> Risk D: Consider therapy modification</i></p>
<p style="text-indent:-2em;margin-left:2em;">Fusidic Acid (Systemic): May increase the serum concentration of CYP3A4 Substrates (High risk with Inhibitors).<i> Risk X: Avoid combination</i></p>
<p style="text-indent:-2em;margin-left:2em;">Gastrointestinal Agents (Prokinetic): Opioid Agonists may diminish the therapeutic effect of Gastrointestinal Agents (Prokinetic). <i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">Gepirone: May enhance the serotonergic effect of Serotonergic Agents (High Risk). This could result in serotonin syndrome.<i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">HydrOXYzine: May enhance the CNS depressant effect of CNS Depressants. Management: Consider a decrease in the CNS depressant dose, as appropriate, when used together with hydroxyzine. Increase monitoring of signs/symptoms of CNS depression in any patient receiving hydroxyzine together with another CNS depressant.<i> Risk D: Consider therapy modification</i></p>
<p style="text-indent:-2em;margin-left:2em;">Ivabradine: Bradycardia-Causing Agents may enhance the bradycardic effect of Ivabradine. <i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">Ixabepilone: May enhance the CNS depressant effect of CNS Depressants.<i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">Kava Kava: May enhance the CNS depressant effect of CNS Depressants.<i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">Kratom: May enhance the CNS depressant effect of CNS Depressants.<i> Risk X: Avoid combination</i></p>
<p style="text-indent:-2em;margin-left:2em;">Lemborexant: May enhance the CNS depressant effect of CNS Depressants. Management: Dosage adjustments of lemborexant and of concomitant CNS depressants may be necessary when administered together because of potentially additive CNS depressant effects. Close monitoring for CNS depressant effects is necessary.<i> Risk D: Consider therapy modification</i></p>
<p style="text-indent:-2em;margin-left:2em;">Linezolid: May enhance the serotonergic effect of Serotonergic Opioids (High Risk). This could result in serotonin syndrome. Management: Consider alternatives to this drug combination. If combined, monitor for signs and symptoms of serotonin syndrome/serotonin toxicity (eg, hyperreflexia, clonus, hyperthermia, diaphoresis, tremor, autonomic instability, mental status changes).<i> Risk D: Consider therapy modification</i></p>
<p style="text-indent:-2em;margin-left:2em;">Lisuride: May enhance the CNS depressant effect of CNS Depressants.<i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">Lofexidine: May enhance the CNS depressant effect of CNS Depressants.<i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">Lorcaserin (Withdrawn From US Market): May enhance the serotonergic effect of Serotonergic Agents (High Risk). This could result in serotonin syndrome. Management: Monitor for signs and symptoms of serotonin syndrome/serotonin toxicity (eg, hyperreflexia, clonus, hyperthermia, diaphoresis, tremor, autonomic instability, mental status changes) when these agents are combined.<i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">Magnesium Sulfate: May enhance the CNS depressant effect of CNS Depressants.<i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">Meperidine: May enhance the CNS depressant effect of FentaNYL. Meperidine may enhance the serotonergic effect of FentaNYL. This could result in serotonin syndrome. Management: Consider alternatives to this combination. If use is necessary, monitor for signs and symptoms of serotonin syndrome/serotonin toxicity and CNS depression.<i> Risk D: Consider therapy modification</i></p>
<p style="text-indent:-2em;margin-left:2em;">Methotrimeprazine: CNS Depressants may enhance the CNS depressant effect of Methotrimeprazine. Methotrimeprazine may enhance the CNS depressant effect of CNS Depressants.  Management: Reduce the usual dose of CNS depressants by 50% if starting methotrimeprazine until the dose of methotrimeprazine is stable. Monitor patient closely for evidence of CNS depression.<i> Risk D: Consider therapy modification</i></p>
<p style="text-indent:-2em;margin-left:2em;">Methylene Blue: May enhance the serotonergic effect of Serotonergic Opioids (High Risk). This could result in serotonin syndrome. Management: Consider alternatives to this drug combination. If combined, monitor for signs and symptoms of serotonin syndrome/serotonin toxicity (eg, hyperreflexia, clonus, hyperthermia, diaphoresis, tremor, autonomic instability, mental status changes).<i> Risk D: Consider therapy modification</i></p>
<p style="text-indent:-2em;margin-left:2em;">Metoclopramide: May enhance the CNS depressant effect of CNS Depressants.<i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">Metoclopramide: May enhance the serotonergic effect of Serotonergic Agents (High Risk). This could result in serotonin syndrome. Management: Consider monitoring for signs and symptoms of serotonin syndrome/serotonin toxicity (eg, hyperreflexia, clonus, hyperthermia, diaphoresis, tremor, autonomic instability, mental status changes) when these agents are combined.<i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">MetyroSINE: CNS Depressants may enhance the sedative effect of MetyroSINE. <i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">Midodrine: May enhance the bradycardic effect of Bradycardia-Causing Agents.<i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">MiFEPRIStone: May increase the serum concentration of FentaNYL.<i> Risk X: Avoid combination</i></p>
<p style="text-indent:-2em;margin-left:2em;">Minocycline (Systemic): May enhance the CNS depressant effect of CNS Depressants.<i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">Monoamine Oxidase Inhibitors (Antidepressant): FentaNYL may enhance the serotonergic effect of Monoamine Oxidase Inhibitors (Antidepressant). This could result in serotonin syndrome. <i> Risk X: Avoid combination</i></p>
<p style="text-indent:-2em;margin-left:2em;">Monoamine Oxidase Inhibitors (Type B): FentaNYL may enhance the serotonergic effect of Monoamine Oxidase Inhibitors (Type B). This could result in serotonin syndrome. <i> Risk X: Avoid combination</i></p>
<p style="text-indent:-2em;margin-left:2em;">Nabilone: May enhance the CNS depressant effect of CNS Depressants.<i> Risk X: Avoid combination</i></p>
<p style="text-indent:-2em;margin-left:2em;">Nalfurafine: Opioid Agonists may enhance the adverse/toxic effect of Nalfurafine. Opioid Agonists may diminish the therapeutic effect of Nalfurafine. <i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">Nalmefene: May diminish the therapeutic effect of Opioid Agonists. Management: Avoid the concomitant use of oral nalmefene and opioid agonists. Discontinue oral nalmefene 1 week prior to any anticipated use of opioid agonists. If combined, larger doses of opioid agonists will likely be required.<i> Risk D: Consider therapy modification</i></p>
<p style="text-indent:-2em;margin-left:2em;">Naltrexone: May diminish the therapeutic effect of Opioid Agonists. Management: Seek therapeutic alternatives to opioids. See full drug interaction monograph for detailed recommendations.<i> Risk X: Avoid combination</i></p>
<p style="text-indent:-2em;margin-left:2em;">Nefazodone: FentaNYL may enhance the serotonergic effect of Nefazodone. This could result in serotonin syndrome. Nefazodone may increase the serum concentration of FentaNYL.  Management: Consider reducing fentanyl dose. Monitor for signs and symptoms of respiratory depression, sedation, and serotonin syndrome/serotonin toxicity (eg, hyperreflexia, clonus, hyperthermia) when these agents are combined.<i> Risk D: Consider therapy modification</i></p>
<p style="text-indent:-2em;margin-left:2em;">Olopatadine (Nasal): May enhance the CNS depressant effect of CNS Depressants.<i> Risk X: Avoid combination</i></p>
<p style="text-indent:-2em;margin-left:2em;">Ondansetron: May enhance the serotonergic effect of Serotonergic Agents (High Risk). This could result in serotonin syndrome. Management: Monitor for signs and symptoms of serotonin syndrome/serotonin toxicity (eg, hyperreflexia, clonus, hyperthermia, diaphoresis, tremor, autonomic instability, mental status changes) when these agents are combined.<i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">Opioid Agonists: CNS Depressants may enhance the CNS depressant effect of Opioid Agonists.  Management: Avoid concomitant use of opioid agonists and benzodiazepines or other CNS depressants when possible. These agents should only be combined if alternative treatment options are inadequate. If combined, limit the dosages and duration of each drug.<i> Risk D: Consider therapy modification</i></p>
<p style="text-indent:-2em;margin-left:2em;">Opioids (Mixed Agonist / Antagonist): May diminish the analgesic effect of Opioid Agonists. Management: Seek alternatives to mixed agonist/antagonist opioids in patients receiving pure opioid agonists, and monitor for symptoms of therapeutic failure/high dose requirements (or withdrawal in opioid-dependent patients) if patients receive these combinations.<i> Risk X: Avoid combination</i></p>
<p style="text-indent:-2em;margin-left:2em;">Orphenadrine: CNS Depressants may enhance the CNS depressant effect of Orphenadrine. <i> Risk X: Avoid combination</i></p>
<p style="text-indent:-2em;margin-left:2em;">Oxitriptan: Serotonergic Agents (High Risk) may enhance the serotonergic effect of Oxitriptan. This could result in serotonin syndrome.  Management: Monitor for signs and symptoms of serotonin syndrome/serotonin toxicity (eg, hyperreflexia, clonus, hyperthermia, diaphoresis, tremor, autonomic instability, mental status changes) when these agents are combined.<i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">Oxomemazine: May enhance the CNS depressant effect of CNS Depressants.<i> Risk X: Avoid combination</i></p>
<p style="text-indent:-2em;margin-left:2em;">Oxybate Salt Products: CNS Depressants may enhance the CNS depressant effect of Oxybate Salt Products.  Management: Consider alternatives to this combination when possible. If combined, dose reduction or discontinuation of one or more CNS depressants (including the oxybate salt product) should be considered. Interrupt oxybate salt treatment during short-term opioid use<i> Risk D: Consider therapy modification</i></p>
<p style="text-indent:-2em;margin-left:2em;">OxyCODONE: CNS Depressants may enhance the CNS depressant effect of OxyCODONE.  Management: Avoid concomitant use of oxycodone and benzodiazepines or other CNS depressants when possible. These agents should only be combined if alternative treatment options are inadequate. If combined, limit the dosages and duration of each drug.<i> Risk D: Consider therapy modification</i></p>
<p style="text-indent:-2em;margin-left:2em;">Ozanimod: May enhance the adverse/toxic effect of Serotonergic Agents (High Risk).<i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">Ozanimod: May enhance the bradycardic effect of Bradycardia-Causing Agents.<i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">Paraldehyde: CNS Depressants may enhance the CNS depressant effect of Paraldehyde. <i> Risk X: Avoid combination</i></p>
<p style="text-indent:-2em;margin-left:2em;">Pegvisomant: Opioid Agonists may diminish the therapeutic effect of Pegvisomant. <i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">PHENobarbital: May enhance the CNS depressant effect of FentaNYL. PHENobarbital may decrease the serum concentration of FentaNYL. Management: Avoid use of fentanyl and phenobarbital when possible. Monitor for respiratory depression/sedation. Because phenobarbital is also a strong CYP3A4 inducer, monitor for decreased fentanyl efficacy and withdrawal if combined.<i> Risk D: Consider therapy modification</i></p>
<p style="text-indent:-2em;margin-left:2em;">Piribedil: CNS Depressants may enhance the CNS depressant effect of Piribedil. <i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">Ponesimod: Bradycardia-Causing Agents may enhance the bradycardic effect of Ponesimod.  Management: Avoid coadministration of ponesimod with drugs that may cause bradycardia when possible. If combined, monitor heart rate closely and consider obtaining a cardiology consult. Do not initiate ponesimod in patients on beta-blockers if HR is less than 55 bpm.<i> Risk D: Consider therapy modification</i></p>
<p style="text-indent:-2em;margin-left:2em;">Pramipexole: CNS Depressants may enhance the sedative effect of Pramipexole. <i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">Primidone: May enhance the CNS depressant effect of FentaNYL. Primidone may decrease the serum concentration of FentaNYL. Management: Avoid use of fentanyl and primidone when possible. Monitor for respiratory depression/sedation. Because primidone is also a strong CYP3A4 inducer, monitor for decreased fentanyl efficacy and withdrawal if combined.<i> Risk D: Consider therapy modification</i></p>
<p style="text-indent:-2em;margin-left:2em;">Procarbazine: May enhance the CNS depressant effect of CNS Depressants.<i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">Propofol: May enhance the CNS depressant effect of FentaNYL. Management: Consider alternatives to this combination when possible. If the combination is used, monitor more closely for bradycardia, apnea, and excessive CNS depression. Propofol induction dose requirements may be reduced. Pediatric patients may be at greater risk.<i> Risk D: Consider therapy modification</i></p>
<p style="text-indent:-2em;margin-left:2em;">Ramosetron: Opioid Agonists may enhance the constipating effect of Ramosetron. <i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">Ramosetron: May enhance the serotonergic effect of Serotonergic Agents (High Risk). This could result in serotonin syndrome. Management: Monitor for signs and symptoms of serotonin syndrome/serotonin toxicity (eg, hyperreflexia, clonus, hyperthermia, diaphoresis, tremor, autonomic instability, mental status changes) when these agents are combined.<i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">Ropeginterferon Alfa-2b: CNS Depressants may enhance the adverse/toxic effect of Ropeginterferon Alfa-2b. Specifically, the risk of neuropsychiatric adverse effects may be increased.  Management: Avoid coadministration of ropeginterferon alfa-2b and other CNS depressants. If this combination cannot be avoided, monitor patients for neuropsychiatric adverse effects (eg, depression, suicidal ideation, aggression, mania).<i> Risk D: Consider therapy modification</i></p>
<p style="text-indent:-2em;margin-left:2em;">ROPINIRole: CNS Depressants may enhance the sedative effect of ROPINIRole. <i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">Rotigotine: CNS Depressants may enhance the sedative effect of Rotigotine. <i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">Rufinamide: May enhance the adverse/toxic effect of CNS Depressants. Specifically, sleepiness and dizziness may be enhanced.<i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">Samidorphan: May diminish the therapeutic effect of Opioid Agonists.<i> Risk X: Avoid combination</i></p>
<p style="text-indent:-2em;margin-left:2em;">Selective Serotonin Reuptake Inhibitors: Serotonergic Opioids (High Risk) may enhance the serotonergic effect of Selective Serotonin Reuptake Inhibitors. This could result in serotonin syndrome.  Management: Monitor for signs and symptoms of serotonin syndrome/serotonin toxicity (eg, hyperreflexia, clonus, hyperthermia, diaphoresis, tremor, autonomic instability, mental status changes) if these agents are combined.<i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">Serotonergic Agents (High Risk, Miscellaneous): Serotonergic Opioids (High Risk) may enhance the serotonergic effect of Serotonergic Agents (High Risk, Miscellaneous). This could result in serotonin syndrome.  Management: Monitor for signs and symptoms of serotonin syndrome/serotonin toxicity (eg, hyperreflexia, clonus, hyperthermia, diaphoresis, tremor, autonomic instability, mental status changes) if these agents are combined.<i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">Serotonergic Non-Opioid CNS Depressants: May enhance the CNS depressant effect of Serotonergic Opioids (High Risk). Serotonergic Non-Opioid CNS Depressants may enhance the serotonergic effect of Serotonergic Opioids (High Risk). This could result in serotonin syndrome. Management: Consider alternatives to this drug combination. If combined, monitor for signs and symptoms of serotonin syndrome/serotonin toxicity and CNS depression.<i> Risk D: Consider therapy modification</i></p>
<p style="text-indent:-2em;margin-left:2em;">Serotonin 5-HT1D Receptor Agonists (Triptans): May enhance the serotonergic effect of Serotonergic Agents (High Risk). This could result in serotonin syndrome. Management: Monitor for signs and symptoms of serotonin syndrome/serotonin toxicity (eg, hyperreflexia, clonus, hyperthermia, diaphoresis, tremor, autonomic instability, mental status changes) when these agents are combined.<i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">Serotonin/Norepinephrine Reuptake Inhibitors: FentaNYL may enhance the serotonergic effect of Serotonin/Norepinephrine Reuptake Inhibitors. This could result in serotonin syndrome.  Management: Monitor for signs and symptoms of serotonin syndrome/serotonin toxicity (eg, hyperreflexia, clonus, hyperthermia, diaphoresis, tremor, autonomic instability, mental status changes) if these agents are combined.<i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">Sincalide: Drugs that Affect Gallbladder Function may diminish the therapeutic effect of Sincalide.  Management: Consider discontinuing drugs that may affect gallbladder motility prior to the use of sincalide to stimulate gallbladder contraction.<i> Risk D: Consider therapy modification</i></p>
<p style="text-indent:-2em;margin-left:2em;">Siponimod: Bradycardia-Causing Agents may enhance the bradycardic effect of Siponimod.  Management: Avoid coadministration of siponimod with drugs that may cause bradycardia. If combined, consider obtaining a cardiology consult regarding patient monitoring.<i> Risk D: Consider therapy modification</i></p>
<p style="text-indent:-2em;margin-left:2em;">Somatostatin Analogs: Opioid Agonists may diminish the analgesic effect of Somatostatin Analogs. Opioid Agonists may enhance the analgesic effect of Somatostatin Analogs. <i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">St John's Wort: May enhance the serotonergic effect of FentaNYL. This could result in serotonin syndrome. St John's Wort may decrease the serum concentration of FentaNYL. Management: Monitor for signs and symptoms of serotonin syndrome/serotonin toxicity and reduced fentanyl effects (including withdrawal symptoms) when combined. Monitor for increased fentanyl effects if St. John's wort is discontinued.<i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">Succinylcholine: May enhance the bradycardic effect of Opioid Agonists.<i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">Suvorexant: CNS Depressants may enhance the CNS depressant effect of Suvorexant.  Management: Dose reduction of suvorexant and/or any other CNS depressant may be necessary.  Use of suvorexant with alcohol is not recommended, and the use of suvorexant with any other drug to treat insomnia is not recommended.<i> Risk D: Consider therapy modification</i></p>
<p style="text-indent:-2em;margin-left:2em;">Syrian Rue: May enhance the serotonergic effect of Serotonergic Agents (High Risk). This could result in serotonin syndrome. Management: Monitor for signs and symptoms of serotonin syndrome/serotonin toxicity (eg, hyperreflexia, clonus, hyperthermia, diaphoresis, tremor, autonomic instability, mental status changes) when these agents are combined.<i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">Thalidomide: CNS Depressants may enhance the CNS depressant effect of Thalidomide. <i> Risk X: Avoid combination</i></p>
<p style="text-indent:-2em;margin-left:2em;">Tofacitinib: May enhance the bradycardic effect of Bradycardia-Causing Agents.<i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">TraMADol: Serotonergic Opioids (High Risk) may enhance the CNS depressant effect of TraMADol. Serotonergic Opioids (High Risk) may enhance the serotonergic effect of TraMADol. This could result in serotonin syndrome.  Management: Consider alternatives to this drug combination. If combined, monitor for signs and symptoms of serotonin syndrome/serotonin toxicity and CNS depression.<i> Risk D: Consider therapy modification</i></p>
<p style="text-indent:-2em;margin-left:2em;">Tricyclic Antidepressants: May enhance the CNS depressant effect of Serotonergic Opioids (High Risk). Serotonergic Opioids (High Risk) may enhance the serotonergic effect of Tricyclic Antidepressants. This could result in serotonin syndrome. Management: Consider alternatives to this drug combination. If combined, monitor for signs and symptoms of serotonin syndrome/serotonin toxicity and CNS depression.<i> Risk D: Consider therapy modification</i></p>
<p style="text-indent:-2em;margin-left:2em;">Valerian: May enhance the CNS depressant effect of CNS Depressants.<i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">Zolpidem: CNS Depressants may enhance the CNS depressant effect of Zolpidem.  Management: Reduce the Intermezzo brand sublingual zolpidem adult dose to 1.75 mg for  men who are also receiving other CNS depressants. No such dose change is recommended for women. Avoid use with other CNS depressants at bedtime; avoid use with alcohol.<i> Risk D: Consider therapy modification</i></p>
<p style="text-indent:-2em;margin-left:2em;">Zuranolone: May enhance the CNS depressant effect of CNS Depressants. Management: Consider alternatives to the use of zuranolone with other CNS depressants or alcohol. If combined, consider a zuranolone dose reduction and monitor patients closely for increased CNS depressant effects.<i> Risk D: Consider therapy modification</i></p></div>
<div class="block dic drugH1Div" id="F170595"><span class="drugH1">Dietary Considerations</span>
<p style="text-indent:0em;display:inline">Transmucosal lozenge contains 2 g sugar per unit.</p></div>
<div class="block rep_considerations drugH1Div" id="F49306379"><span class="drugH1">Reproductive Considerations</span>
<p style="text-indent:0em;">Chronic opioid use may cause hypogonadism and hyperprolactinemia which may decrease fertility in patients of reproductive potential. Menstrual cycle disorders (including amenorrhea), erectile dysfunction, and impotence have been reported. The incidence of hypogonadism may be increased with the use of opioids in high doses or long-acting opioid formulations. It is not known if the effects on fertility are reversible. Monitor patients on long-term therapy (de Vries 2020; Gadelha 2022).</p>
<p style="text-indent:0em;margin-top:2em;">Consider family planning, contraception, and the effects on fertility prior to prescribing opioids for chronic pain to patients who could become pregnant (ACOG 2017; CDC [Dowell 2022]).</p></div>
<div class="block pri drugH1Div" id="F170593"><span class="drugH1">Pregnancy Considerations</span>
<p style="text-indent:0em;">Fentanyl crosses the placenta (Leuschen 1990). Following epidural use for labor analgesia, fentanyl remained detectable in neonatal urine 24 hours after birth (Moore 2016).</p>
<p style="text-indent:0em;margin-top:2em;">Maternal use of opioids may be associated with poor fetal growth, stillbirth, and preterm delivery (CDC [Dowell 2022]). Opioids used as part of obstetric analgesia/anesthesia during labor and delivery may temporarily affect the fetal heart rate (ACOG 2019b). Transient muscular rigidity has been observed in the neonate following maternal administration of IV fentanyl; symptoms of respiratory or neurological depression were not different than those observed in infants of untreated mothers following IV or epidural use during labor.</p>
<p style="text-indent:0em;margin-top:2em;">Neonatal abstinence syndrome (NAS)/neonatal opioid withdrawal syndrome (NOWS) may occur following prolonged in utero exposure to opioids (CDC [Dowell 2022]). NAS/NOWS may be life-threatening if not recognized and treated and requires management according to protocols developed by neonatology experts. Presentation of symptoms varies by opioid characteristics (eg, immediate release, sustained release), time of last dose prior to delivery, drug metabolism (maternal, placental, and infant), net placental transfer, as well as other factors (AAP [Hudak 2012]; AAP [Patrick 2020]). Clinical signs characteristic of withdrawal following in utero opioid exposure include excessive crying or easily irritable, fragmented sleep (&lt;2 to 3 hours after feeding), tremors, increased muscle tone, or GI dysfunction (hyperphagia, poor feeding, feeding intolerance, watery or loose stools) (Jilani 2022). NAS/NOWS occurs following chronic opioid exposure and would not be expected following the use of opioids at delivery (AAP [Patrick 2020]).</p>
<p style="text-indent:0em;margin-top:2em;">Monitor infants of mothers on long-term/chronic opioid therapy for symptoms of withdrawal. Symptom onset reflects the half-life of the opioid used. Monitor infants for at least 3 days following exposure to immediate-release opioids; monitor for at least 4 to 7 days following exposure to sustained-release opioids (AAP [Patrick 2020]; CDC [Dowell 2022]). Monitor newborns for excess sedation and respiratory depression when opioids are used during labor.</p>
<p style="text-indent:0em;margin-top:2em;">When opioids are needed to treat acute pain in pregnant patients, the lowest effective dose for only the expected duration of pain should be prescribed (CDC [Dowell 2022]).</p>
<p style="text-indent:0em;margin-top:2em;">Fentanyl injection is approved as an adjunct to general or regional anesthesia and as an analgesic during anesthesia. Pregnant patients should not be denied medically necessary surgery, regardless of trimester. If the procedure is elective, it should be delayed until after delivery (ACOG 2019a).</p>
<p style="text-indent:0em;margin-top:2em;">Fentanyl IM and IV injection are commonly used to treat maternal pain during labor and immediately postpartum; the intranasal route has also been studied (ACOG 2019b; Jabalameli 2016). Not all formulations are recommended. Opioid use for pain following vaginal or cesarean delivery should be made as part of a shared decision-making process. A stepwise, multimodal approach to managing postpartum pain is recommended. A low-dose, low-potency, short-acting opioid can be used to treat acute pain associated with delivery when needed (ACOG 2021).</p>
<p style="text-indent:0em;margin-top:2em;">Opioids are not preferred for the treatment of chronic noncancer pain during pregnancy; consider strategies to minimize or avoid opioid use. Advise pregnant patients requiring long-term opioid use of the risk of NAS/NOWS and provide appropriate treatment for the neonate after delivery. NAS/NOWS is an expected and treatable condition following chronic opioid use during pregnancy and should not be the only reason to avoid treating pain with an opioid in pregnant patients (ACOG 2017; CDC [Dowell 2022]). Do not abruptly discontinue opioids during pregnancy; taper prior to discontinuation when appropriate, considering the risks to the pregnant patient and fetus if maternal withdrawal occurs (CDC [Dowell 2022]).</p></div>
<div class="block mopp drugH1Div" id="F53566883"><span class="drugH1">Monitoring Parameters</span>
<p style="text-indent:0em;display:inline">Respiratory rate, blood pressure, heart rate, oxygen saturation, chest wall rigidity (with IV administration), pain relief, level of sedation and mental status; monitor for bowel sounds, abdominal distention, constipation, and urinary retention; signs of misuse, abuse, or substance use disorder; signs or symptoms of hypogonadism or hypoadrenalism (Brennan 2013).</p>
<p style="text-indent:-2em;margin-left:2em;">Transdermal patch: Monitor patient for at least 24 hours after application of first dose.</p>
<p style="text-indent:-2em;margin-left:2em;">Chronic pain (long-term therapy outside of end-of-life or palliative care, active cancer treatment, sickle cell disease, or medication-assisted treatment for opioid use disorder): Evaluate benefits/risks of opioid therapy within 1 to 4 weeks of treatment initiation and with dose increases. Re-evaluate benefits/risks every 3 months during therapy or more frequently in patients at increased risk of overdose or opioid use disorder. Urine drug testing is recommended prior to initiation and re-checking should be considered at least yearly (includes controlled prescription medications and illicit drugs of abuse). State prescription drug monitoring program (PDMP) data should be reviewed by clinicians prior to initiation and periodically during therapy (frequency ranging from every prescription to every 3 months) (Dowell [CDC 2016]).</p></div>
<div class="block pha drugH1Div" id="F170570"><span class="drugH1">Mechanism of Action</span>
<p style="text-indent:0em;display:inline">Binds with stereospecific receptors at many sites within the CNS, increases pain threshold, alters pain reception, inhibits ascending pain pathways</p></div>
<div class="block phk drugH1Div" id="F170589"><span class="drugH1">Pharmacokinetics (Adult Data Unless Noted)</span>
<p style="text-indent:-2em;margin-left:2em;">Onset of action:</p>
<p style="text-indent:-2em;margin-left:4em;">Children 3 to 12 years: Intranasal: 5 to 10 minutes (Borland 2002).</p>
<p style="text-indent:-2em;margin-left:4em;">Adults: Analgesic: IM: 7 to 8 minutes; IV: Almost immediate (maximal analgesic and respiratory depressant effects may not be seen for several minutes); Transdermal patch (initial placement): 6 hours; Transmucosal: 5 to 15 minutes.</p>
<p style="text-indent:-2em;margin-left:2em;">Duration: IM: 1 to 2 hours; IV: 0.5 to 1 hour; Transdermal (removal of patch/no replacement): Related to blood level; some effects may last 72 to 96 hours due to extended half-life and absorption from the skin, fentanyl concentrations decrease by ~50% in 20 to 27 hours; Transmucosal: Related to blood level; respiratory depressant effect may last longer than analgesic effect.</p>
<p style="text-indent:-2em;margin-left:2em;">Absorption:</p>
<p style="text-indent:-2em;margin-left:4em;">Transdermal, patch: Initial application: Drug is released at a nearly constant rate from the transdermal matrix system into the skin, where it accumulates; this results in a depot of fentanyl in the outer layer of skin. Fentanyl is absorbed into systemic circulation from the depot. This results in a gradual increase in serum concentration over the first 12 to 24 hours, followed by fairly constant concentrations for the remainder of the dosing interval. Absorption is decreased in cachectic patients (compared to normal size patients). Exposure to external heat increases drug absorption from patch.</p>
<p style="text-indent:-2em;margin-left:4em;">Transdermal, device: At the activation of each dose, an electrical current is activated for 10 minutes, which moves a dose of fentanyl from the drug-containing reservoir through the skin and into the systemic circulation. Fentanyl concentrations increase slowly with device activation and continue to increase for ~5 minutes after the completion of each 10 minute dose. Absorption of fentanyl from the device increases as a function of time and is independent of frequency of dosing.</p>
<p style="text-indent:-2em;margin-left:4em;">Transmucosal, buccal tablet: Rapid, ~50% from the buccal mucosa; remaining 50% swallowed with saliva and slowly absorbed from GI tract.</p>
<p style="text-indent:-2em;margin-left:4em;">Transmucosal, lozenge: Rapid, ~25% from the buccal mucosa; 75% swallowed with saliva and slowly absorbed from GI tract.</p>
<p style="text-indent:-2em;margin-left:2em;">Distribution: Highly lipophilic, redistributes into muscle and fat; <b>Note:</b> IV fentanyl exhibits a 3-compartment distribution model. Changes in blood pH may alter ionization of fentanyl and affect its distribution between plasma and CNS.</p>
<p style="text-indent:-2em;margin-left:4em;">V<sub>dss</sub>:</p>
<p style="text-indent:-2em;margin-left:6em;">Preterm and term neonates: <b>Note:</b> Volume of distribution is highly variable and significantly influenced by patient weight (Norman 2019; Wu 2022).</p>
<p style="text-indent:-2em;margin-left:8em;">Bolus dose: 5.1 ± 1 L/kg (Koehntop 1986).</p>
<p style="text-indent:-2em;margin-left:6em;">Infants, Children, and Adolescents ≤14 years of age (after long-term continuous infusion): ~15 L/kg (range: 5 to 30 L/kg) (Katz 1993).</p>
<p style="text-indent:-2em;margin-left:6em;">Adults: 4 to 6 L/kg.</p>
<p style="text-indent:-2em;margin-left:2em;">Protein binding: 79% to 87%, primarily to alpha-1 acid glycoprotein; also binds to albumin and erythrocytes; <b>Note:</b> Free fraction increases with acidosis.</p>
<p style="text-indent:-2em;margin-left:2em;">Metabolism: Hepatic, primarily via CYP3A4 by N-dealkylation (to norfentanyl) and hydroxylation to other inactive metabolites.</p>
<p style="text-indent:-2em;margin-left:2em;">Bioavailability: <b>Note:</b> Comparative studies have found the buccal tablet to have a 30% to 50% greater exposure than the transmucosal lozenge.</p>
<p style="text-indent:-2em;margin-left:4em;">Buccal tablet: 65%.</p>
<p style="text-indent:-2em;margin-left:4em;">Lozenge: ~50%.</p>
<p style="text-indent:-2em;margin-left:4em;">Sublingual spray: 76%.</p>
<p style="text-indent:-2em;margin-left:4em;">Sublingual tablet: 54%.</p>
<p style="text-indent:-2em;margin-left:2em;">Half-life elimination:</p>
<p style="text-indent:-2em;margin-left:4em;">IV:</p>
<p style="text-indent:-2em;margin-left:6em;">Preterm and term neonate (PNA ≤14 days): Bolus dose: 5.28 ± 1.17 hours (Koehntop 1986); <b>Note: </b>Half-life may be prolonged (1.5 to 3 times the population mean) in patients with increased intra-abdominal pressure (Koehntop 1986).</p>
<p style="text-indent:-2em;margin-left:6em;">Pediatric patients 5 months to 4.5 years: 2.4 hours.</p>
<p style="text-indent:-2em;margin-left:6em;">Pediatric patients 6 months to 14 years (after long-term continuous infusion): ~21 hours (range: 11 to 36 hours).</p>
<p style="text-indent:-2em;margin-left:6em;">Adults: 2 to 4 hours; when administered as a continuous infusion, the half-life prolongs with infusion duration due to the large volume of distribution (Sessler 2008).</p>
<p style="text-indent:-2em;margin-left:4em;">SUBQ bolus injection: 10 hours (Capper 2010).</p>
<p style="text-indent:-2em;margin-left:4em;">Transdermal device: Terminal: ~16 hours.</p>
<p style="text-indent:-2em;margin-left:4em;">Transdermal patch: 20 to 27 hours (apparent half-life is influenced by continued fentanyl absorption from skin).</p>
<p style="text-indent:-2em;margin-left:4em;">Transmucosal products: 3 to 14 hours (dose dependent).</p>
<p style="text-indent:-2em;margin-left:4em;">Intranasal: 15 to 25 hours (based on a multiple-dose pharmacokinetic study when doses are administered in the same nostril and separated by a 1-, 2-, or 4-hour time lapse).</p>
<p style="text-indent:-2em;margin-left:4em;">Buccal tablet: 100 to 200 mcg: 3 to 4 hours; 400 to 800 mcg: 11 to 12 hours.</p>
<p style="text-indent:-2em;margin-left:2em;">Time to peak:</p>
<p style="text-indent:-2em;margin-left:4em;">Buccal tablet: 20 to 240 minutes (median: 47 minutes).</p>
<p style="text-indent:-2em;margin-left:4em;">Lozenge: 20 to 480 minutes (median: 20 to 40 minutes).</p>
<p style="text-indent:-2em;margin-left:4em;">Intranasal: Median: 15 to 21 minutes.</p>
<p style="text-indent:-2em;margin-left:4em;">SUBQ bolus injection: 10 to 30 minutes (median: 15 minutes) (Capper 2010).</p>
<p style="text-indent:-2em;margin-left:4em;">Sublingual spray: 10 to 120 minutes (median: 90 minutes).</p>
<p style="text-indent:-2em;margin-left:4em;">Sublingual tablet: 15 to 240 minutes (median: 30 to 60 minutes).</p>
<p style="text-indent:-2em;margin-left:4em;">Transdermal patch: 20 to 72 hours; steady state serum concentrations are reached after two sequential 72-hour applications.</p>
<p style="text-indent:-2em;margin-left:2em;">Excretion: Urine 75% (primarily as metabolites, &lt;7% to 10% as unchanged drug); feces ~9%.</p>
<p style="text-indent:-2em;margin-left:4em;">Clearance: Neonates: Clearance rapidly increased based on birthweight and PNA (Wu 2022); one study identified PNA as the most relevant covariate with very low clearance in the first few days after birth and then rapidly increasing until about 10 to 15 days of life (Völler 2019).</p></div>
<div class="block phksp drugH1Div" id="F51192547"><span class="drugH1">Pharmacokinetics: Additional Considerations (Adult Data Unless Noted)</span>
<p style="text-indent:-2em;margin-left:2em;">Altered kidney function: May alter kinetics because of alterations in clearance and plasma proteins.</p>
<p style="text-indent:-2em;margin-left:2em;">Hepatic function impairment: May alter kinetics because of alterations in clearance and plasma proteins.</p>
<p style="text-indent:-2em;margin-left:2em;">Pediatric: Plasma concentrations with transdermal use were approximately twice as high in pediatric patients 1.5 to 5 years of age, who are not opioid-tolerant, compared with adults. Pharmacokinetic parameters in older pediatric patients were similar to those seen in adults.</p>
<p style="text-indent:-2em;margin-left:2em;">Older adult: Reduced clearance and terminal half-life is prolonged (transdermal).</p>
<p style="text-indent:-2em;margin-left:2em;">Sex: Systemic exposure was higher in women after administration of buccal fentanyl (Fentora); this difference was largely attributed to differences in weight.</p>
<p style="text-indent:-2em;margin-left:2em;">Race/ethnicity: Systemic exposure was higher in Japanese subjects after administration of buccal fentanyl (Fentora); this difference was largely attributed to differences in weight.</p>
<p style="text-indent:-2em;margin-left:2em;">Extracorporeal membrane oxygenation (ECMO): Neonates, Infants, Children, and Adolescents: Increases in circulating blood volume and extraction of drug by the ECMO circuit (tubing and/or oxygenator) result in an increased volume of distribution (V<sub>d</sub>) of drugs in patients on ECMO (Raffaeli 2019; Zimmerman 2020). As a result, larger doses/infusion rates may be required to achieve adequate pain control and level of sedation.</p></div>
<div class="list fbnlist drugH1Div drugBrandNames" id="F170596"><span class="drugH1">Brand Names: International</span><div class="ibn-search drugBrandNames"></div>
<div class="collapsible-indication brand-names-accordion drugBrandNames"><span class="collapsible-indication-title">International Brand Names by Country</span><div class="collapsible-indication-wrap-frame drugBrandNames"><div class="collapsible-indication-wrap drugBrandNames">For country code abbreviations (<a class="graphic graphic_table" href="/d/html/116421.html" rel="external">show table</a>)<br xmlns=""/><br/><ul>
<li>
<span class="countryCode">(AE)</span> <span class="country">United Arab Emirates</span><span class="countrySeparator">: </span><span class="drugName">Abstral | Fencino | Fentadur</span>;</li>
<li>
<span class="countryCode">(AR)</span> <span class="country">Argentina</span><span class="countrySeparator">: </span><span class="drugName">Durogesic d trans | Fentanilo celtyc | Fentanilo HLB | Fentora | Sublimaze | Talnur</span>;</li>
<li>
<span class="countryCode">(AT)</span> <span class="country">Austria</span><span class="countrySeparator">: </span><span class="drugName">Actiq | Durogesic | Effentora | Fentabucc akut | Fentamed | Fentanyl | Fentanyl actavis | Fentanyl Genericon | Fentanyl hameln | Fentanyl janssen-cilag ph | Fentanyl sandoz | Fentanyl Stada | Fentanyl torrex pharma | Fentaplast | Fentoron | Instanyl | Ionsys | Lafene | Submena | Vellofent</span>;</li>
<li>
<span class="countryCode">(AU)</span> <span class="country">Australia</span><span class="countrySeparator">: </span><span class="drugName">Abstral | Actiq | Apo fentanyl | Denpax | Durogesic | Fenpatch | Fentanyl | Fentanyl sandoz</span>;</li>
<li>
<span class="countryCode">(BD)</span> <span class="country">Bangladesh</span><span class="countrySeparator">: </span><span class="drugName">Durogesic | Opifen</span>;</li>
<li>
<span class="countryCode">(BE)</span> <span class="country">Belgium</span><span class="countrySeparator">: </span><span class="drugName">Abstral | Durogesic | Effentora | Fentamax | Fentanyl matrix eg | Fentanyl matrix mylan | Fentanyl Matrix Sandoz | Instanyl | Matrifen</span>;</li>
<li>
<span class="countryCode">(BG)</span> <span class="country">Bulgaria</span><span class="countrySeparator">: </span><span class="drugName">Durogesic | Fentadolor | Fentanyl | Instanyl | Sublifen | Vellofent | Victanyl</span>;</li>
<li>
<span class="countryCode">(BR)</span> <span class="country">Brazil</span><span class="countrySeparator">: </span><span class="drugName">Anesfent | Biofent | Citrato de fentanila | Durogesic d trans | Fentanest | Unifental</span>;</li>
<li>
<span class="countryCode">(CH)</span> <span class="country">Switzerland</span><span class="countrySeparator">: </span><span class="drugName">Abstral | Actiq | Durogesic | Effentora | Fentalis | Fentanyl actavis | Fentanyl Cimex TTS | Fentanyl helvepharm tts | Fentanyl Mepha | Fentanyl Sandoz MAT | Fentanyl sintetica | Fentanyl Spirig | Fentanyl spirig hc | Fentanyl zentiva</span>;</li>
<li>
<span class="countryCode">(CL)</span> <span class="country">Chile</span><span class="countrySeparator">: </span><span class="drugName">Durogesic | Fentanila | Fentora</span>;</li>
<li>
<span class="countryCode">(CN)</span> <span class="country">China</span><span class="countrySeparator">: </span><span class="drugName">Durogesic d trans</span>;</li>
<li>
<span class="countryCode">(CO)</span> <span class="country">Colombia</span><span class="countrySeparator">: </span><span class="drugName">Diopal | Durfenta | Durogesic | Fentanex | Fentanilo | Fenyldol</span>;</li>
<li>
<span class="countryCode">(CZ)</span> <span class="country">Czech Republic</span><span class="countrySeparator">: </span><span class="drugName">Adolor | Algogesic | Dolforin | Durogesic | Effentora | Fenroo | Fentalis | Fentalis akut | Fentanyl | Fentanyl ratiopharm | Instanyl | Lunaldin | Menasu | Pecfent | Vellofent</span>;</li>
<li>
<span class="countryCode">(DE)</span> <span class="country">Germany</span><span class="countrySeparator">: </span><span class="drugName">Abstral | Actiq | Durogesic | Durogesic Smat | Effentora | Fentaderm | Fentadolon | Fentamat | Fentanyl | Fentanyl 1 a pharma | Fentanyl AbZ | Fentanyl Actavis | Fentanyl AL | Fentanyl aristo | Fentanyl Awd Matrix | Fentanyl Beta | Fentanyl CT | Fentanyl Dura | Fentanyl Esparma | Fentanyl hameln | Fentanyl hennig | Fentanyl Heumann | Fentanyl hexal | Fentanyl Krewel | Fentanyl mylan | Fentanyl painbreak | Fentanyl puren | Fentanyl q pharm | Fentanyl Riemser TDS | Fentanyl tad | Fentanyl Winthrop | Fentapon | Fentavera | Fenylat | Instanyl | Ionsys | Matrifen | Pecfent</span>;</li>
<li>
<span class="countryCode">(DK)</span> <span class="country">Denmark</span><span class="countrySeparator">: </span><span class="drugName">Instanyl</span>;</li>
<li>
<span class="countryCode">(DO)</span> <span class="country">Dominican Republic</span><span class="countrySeparator">: </span><span class="drugName">Durogesic | Fentanyl</span>;</li>
<li>
<span class="countryCode">(EC)</span> <span class="country">Ecuador</span><span class="countrySeparator">: </span><span class="drugName">Fentanex | Fentanyl</span>;</li>
<li>
<span class="countryCode">(EE)</span> <span class="country">Estonia</span><span class="countrySeparator">: </span><span class="drugName">Actiq | Durogesic | Effentora | Instanyl | Lunaldin | Matrifen</span>;</li>
<li>
<span class="countryCode">(EG)</span> <span class="country">Egypt</span><span class="countrySeparator">: </span><span class="drugName">Durogesic | Fentadur | Fentamat</span>;</li>
<li>
<span class="countryCode">(ES)</span> <span class="country">Spain</span><span class="countrySeparator">: </span><span class="drugName">Abfentiq | Abstral | Actiq | Avaric | Bimbax | Doloxital | Durfenta | Durogesic | Effentora | Fendivia | Fentanilo Actavis | Fentanilo Aristo | Fentanilo Cinfa | Fentanilo kalceks | Fentanilo Kern Pharma | Fentanilo matrix acino | Fentanilo matrix mylan | Fentanilo Matrix Normon | Fentanilo Matrix Sandoz | Fentanilo Stada | Fenticerta | Instanyl | Kaptic | Matrifen | Pecfent</span>;</li>
<li>
<span class="countryCode">(ET)</span> <span class="country">Ethiopia</span><span class="countrySeparator">: </span><span class="drugName">Fentanyl</span>;</li>
<li>
<span class="countryCode">(FI)</span> <span class="country">Finland</span><span class="countrySeparator">: </span><span class="drugName">Abstral | Actiq | Durogesic | Effentora | Fentanyl | Fentanyl actavis | Fentanyl Alpharma | Fentanyl braun | Fentanyl hameln | Fentanyl orion | Fentanyl ratiopharm | Fentanyl sandoz | Fentanyl Stada | Instanyl | Matrifen | Pecfent</span>;</li>
<li>
<span class="countryCode">(FR)</span> <span class="country">France</span><span class="countrySeparator">: </span><span class="drugName">Abstral | Actiq | Durogesic | Effentora | Fentanyl actavis | Fentanyl arrow | Fentanyl Biogaran | Fentanyl biogaran | Fentanyl dakota | Fentanyl EG | Fentanyl janssen | Fentanyl lavipharm hellas | Fentanyl merck | Fentanyl mylan | Fentanyl Nycomed | Fentanyl ranbaxy | Fentanyl ratiopharm | Fentanyl sandoz | Fentanyl Teva | Fentanyl Winthrop | Instanyl | Matrifen | Pecfent | Recivit</span>;</li>
<li>
<span class="countryCode">(GB)</span> <span class="country">United Kingdom</span><span class="countrySeparator">: </span><span class="drugName">Abstral | Actiq | Cynril | Durogesic d trans | Fencino | Fenhuma | Fentalis Resevoir | Fentanyl | Instanyl | Ionsys | Mezolar | Mylafent | Opiodur | Osmanil | Pecfent | Recivit | Victanyl | Yemex</span>;</li>
<li>
<span class="countryCode">(GR)</span> <span class="country">Greece</span><span class="countrySeparator">: </span><span class="drugName">Abstral | Actiq | Demogyl | Dolfen | Durogesic | Fentadur | Fentanyl orion | Fentanyl sandoz | Fentanyl/mylan | Instanyl | Matrifen | Myfene | Pecfent | Vellofent</span>;</li>
<li>
<span class="countryCode">(HK)</span> <span class="country">Hong Kong</span><span class="countrySeparator">: </span><span class="drugName">Durogesic | Fentora</span>;</li>
<li>
<span class="countryCode">(HR)</span> <span class="country">Croatia</span><span class="countrySeparator">: </span><span class="drugName">Durogesic | Fentagesic | Fentanil M | Fentanyl | Matrifen</span>;</li>
<li>
<span class="countryCode">(HU)</span> <span class="country">Hungary</span><span class="countrySeparator">: </span><span class="drugName">Dolforin | Durogesic | Fentanyl | Fentanyl Pliva | Fentanyl ratiopharm | Instanyl | Lunaldin | Matrifen</span>;</li>
<li>
<span class="countryCode">(ID)</span> <span class="country">Indonesia</span><span class="countrySeparator">: </span><span class="drugName">Durogesic</span>;</li>
<li>
<span class="countryCode">(IE)</span> <span class="country">Ireland</span><span class="countrySeparator">: </span><span class="drugName">Abstral | Actiq | Durogesic | Effentora | Fentadur | Fental | Instanyl | Matrifen | Pecfent</span>;</li>
<li>
<span class="countryCode">(IL)</span> <span class="country">Israel</span><span class="countrySeparator">: </span><span class="drugName">Actiq | Beatryl | Durogesic | Fenta | Fentanyl</span>;</li>
<li>
<span class="countryCode">(IN)</span> <span class="country">India</span><span class="countrySeparator">: </span><span class="drugName">Durogesic | Fenstud | Finrid</span>;</li>
<li>
<span class="countryCode">(IT)</span> <span class="country">Italy</span><span class="countrySeparator">: </span><span class="drugName">Abstral | Actiq | Alghedon | Dogetic | Durfenta | Durogesic | Effentora | Fenroo | Fentalgon | Fentanest | Fentanil Ratiopharm | Fentanil sandoz | Fentanyl | Fentanyl Lavipharm | Fenticer | Fenvel | Ifyltan | Instanyl | Pecfent | Sublifen | Vellofent</span>;</li>
<li>
<span class="countryCode">(JP)</span> <span class="country">Japan</span><span class="countrySeparator">: </span><span class="drugName">Abstral | Durotep | Durotep dainippon | Durotep sankyo | Durotep shionogi | Durotep takeda | Durotep tanabe | E fen | Fentanest sankyo | Fentanest shionogi | Fentanest tanabe | Fentanyl | Fentanyl 3 day | Fentanyl 3 day hmt | Fentanyl tape for 1 day meiji | Fentanyl tape for 3 days towa | Fentos</span>;</li>
<li>
<span class="countryCode">(KE)</span> <span class="country">Kenya</span><span class="countrySeparator">: </span><span class="drugName">Durogesic | Fenstud | Fentavera</span>;</li>
<li>
<span class="countryCode">(KR)</span> <span class="country">Korea, Republic of</span><span class="countrySeparator">: </span><span class="drugName">Abstral | Actic | Durogesic d trans | Fentaderm | Fentadur | Fentakhan | Fentamax Mat | Fentarix | Fentas | Fentavera | Fentora | Instanyl | Matrifen | Myungmoon fentanyl | Narco | Pecfent</span>;</li>
<li>
<span class="countryCode">(KW)</span> <span class="country">Kuwait</span><span class="countrySeparator">: </span><span class="drugName">Abstral | Durogesic</span>;</li>
<li>
<span class="countryCode">(LB)</span> <span class="country">Lebanon</span><span class="countrySeparator">: </span><span class="drugName">Abstral | Durogesic</span>;</li>
<li>
<span class="countryCode">(LT)</span> <span class="country">Lithuania</span><span class="countrySeparator">: </span><span class="drugName">Dolforin | Durogesic | Effentora | Instanyl | Lunaldin | Matrifen</span>;</li>
<li>
<span class="countryCode">(LU)</span> <span class="country">Luxembourg</span><span class="countrySeparator">: </span><span class="drugName">Durogesic | Fentanyl janssen | Fentanyl matrix eg | Instanyl | Matrifen</span>;</li>
<li>
<span class="countryCode">(LV)</span> <span class="country">Latvia</span><span class="countrySeparator">: </span><span class="drugName">Actiq | Dolforin | Durogesic | Effentora | Fentanyl | Instanyl | Lunaldin | Matrifen | Phentanyl</span>;</li>
<li>
<span class="countryCode">(MA)</span> <span class="country">Morocco</span><span class="countrySeparator">: </span><span class="drugName">Abstral | Durogesic | Fentanyl</span>;</li>
<li>
<span class="countryCode">(MT)</span> <span class="country">Malta</span><span class="countrySeparator">: </span><span class="drugName">Instanyl</span>;</li>
<li>
<span class="countryCode">(MX)</span> <span class="country">Mexico</span><span class="countrySeparator">: </span><span class="drugName">Durogesic d trans | Fentanest | Filtaten</span>;</li>
<li>
<span class="countryCode">(MY)</span> <span class="country">Malaysia</span><span class="countrySeparator">: </span><span class="drugName">Abstral | Durogesic | Fen touch | Fentanyl hexal</span>;</li>
<li>
<span class="countryCode">(NL)</span> <span class="country">Netherlands</span><span class="countrySeparator">: </span><span class="drugName">Abstral | Actiq | Durogesic | Effentora | Fentanyl | Fentanyl actavis | Fentanyl Apotex | Fentanyl aurobindo | Fentanyl glenmark | Fentanyl matrix | Fentanyl pch | Fentanyl ratiopharm | Fentanyl sandoz | Instanyl | Ionsys | Pecfent | Recivit</span>;</li>
<li>
<span class="countryCode">(NO)</span> <span class="country">Norway</span><span class="countrySeparator">: </span><span class="drugName">Abstral | Actiq | Actiq teva | Durogesic | Effentora | Fentanyl ratiopharm | Fentanyl sandoz | Instanyl | Ionsys | Leptanal | Pecfent</span>;</li>
<li>
<span class="countryCode">(NZ)</span> <span class="country">New Zealand</span><span class="countrySeparator">: </span><span class="drugName">Biomed Fentanyl Citrat | Durogesic | Fentalis | Fentanyl | Fentanyl sandoz | Sublimaze</span>;</li>
<li>
<span class="countryCode">(PE)</span> <span class="country">Peru</span><span class="countrySeparator">: </span><span class="drugName">Durogesic d trans</span>;</li>
<li>
<span class="countryCode">(PH)</span> <span class="country">Philippines</span><span class="countrySeparator">: </span><span class="drugName">Abstral | Durogesic | Fendermal | Fentyn</span>;</li>
<li>
<span class="countryCode">(PK)</span> <span class="country">Pakistan</span><span class="countrySeparator">: </span><span class="drugName">Fentanyl sandoz | Fentavera</span>;</li>
<li>
<span class="countryCode">(PL)</span> <span class="country">Poland</span><span class="countrySeparator">: </span><span class="drugName">Aurofena | Dolforin | Durogesic | Effentora | Fenta MX | Fentagesic | Fentanyl | Fentanyl actavis | Fentanyl ratiopharm | Fentanyl Torrex | Instanyl | Lunaldin | Matrifen | Pecfent | Vellofent</span>;</li>
<li>
<span class="countryCode">(PR)</span> <span class="country">Puerto Rico</span><span class="countrySeparator">: </span><span class="drugName">Abstral | Actiq | Duragesic | Fentanyl | Fentanyl Cit | Fentora | Lazanda | Subsys</span>;</li>
<li>
<span class="countryCode">(PT)</span> <span class="country">Portugal</span><span class="countrySeparator">: </span><span class="drugName">Abstral | Actiq | Durogesic | Fentanilo | Fentanilo ardicat | Fentanilo Ciclum | Fentanilo Matrifen | Fentanilo Mylan | Fentanilo sandoz | Fentanilo Wynn | Fentanilo zentiva | Instanyl | Nilfene | Pecfent | Vellofent</span>;</li>
<li>
<span class="countryCode">(PY)</span> <span class="country">Paraguay</span><span class="countrySeparator">: </span><span class="drugName">Durogesic | Fenium | Fentanilo interlabo</span>;</li>
<li>
<span class="countryCode">(QA)</span> <span class="country">Qatar</span><span class="countrySeparator">: </span><span class="drugName">Abstral | Durogesic | Sublimaze | Talinat</span>;</li>
<li>
<span class="countryCode">(RO)</span> <span class="country">Romania</span><span class="countrySeparator">: </span><span class="drugName">Algogesic | Dolforin | Durogesic | Effentora | Fentanyl actavis | Fentanyl TTS Sandoz | Instanyl | Lunaldin</span>;</li>
<li>
<span class="countryCode">(RU)</span> <span class="country">Russian Federation</span><span class="countrySeparator">: </span><span class="drugName">Dolforin | Durogesic | Fendivia | Fentadol matrix | Fentanyl | Instanil | Lunaldin</span>;</li>
<li>
<span class="countryCode">(SA)</span> <span class="country">Saudi Arabia</span><span class="countrySeparator">: </span><span class="drugName">Abstral | Durogesic | Fencino | Fentanyl | Pecfent</span>;</li>
<li>
<span class="countryCode">(SE)</span> <span class="country">Sweden</span><span class="countrySeparator">: </span><span class="drugName">Abstral | Actiq | Durogesic | Effentora | Fentanyl 2care4 | Fentanyl actavis | Fentanyl Alpharma | Fentanyl B Braun | Fentanyl hameln | Fentanyl hexal | Fentanyl Lavipharm | Fentanyl mylan | Fentanyl orion | Fentanyl ratiopharm | Fentanyl sandoz | Instanyl | Leptanal | Matriban | Matrifen | Pecfent | Submena</span>;</li>
<li>
<span class="countryCode">(SG)</span> <span class="country">Singapore</span><span class="countrySeparator">: </span><span class="drugName">Abstral | Durogesic | Fantamax | Fentanyl</span>;</li>
<li>
<span class="countryCode">(SI)</span> <span class="country">Slovenia</span><span class="countrySeparator">: </span><span class="drugName">Abstral | Durogesic | Effentora | Epufen | Fentanyl | Instanyl | Matrifen | Victanyl</span>;</li>
<li>
<span class="countryCode">(SK)</span> <span class="country">Slovakia</span><span class="countrySeparator">: </span><span class="drugName">Dolforin | Durogesic | Effentora | Fentanyl | Fentanyl actavis | Instanyl | Lunaldin | Submena | Vellofent</span>;</li>
<li>
<span class="countryCode">(TH)</span> <span class="country">Thailand</span><span class="countrySeparator">: </span><span class="drugName">Durogesic | Fentanyl GPO | Fentanyl hexal</span>;</li>
<li>
<span class="countryCode">(TN)</span> <span class="country">Tunisia</span><span class="countrySeparator">: </span><span class="drugName">Durogesic | Fentanyl</span>;</li>
<li>
<span class="countryCode">(TR)</span> <span class="country">Turkey</span><span class="countrySeparator">: </span><span class="drugName">Abstral | Durogesic | Effentora | Fentanyl | Fentanyl mercury</span>;</li>
<li>
<span class="countryCode">(TW)</span> <span class="country">Taiwan</span><span class="countrySeparator">: </span><span class="drugName">Durogesic | Fentanyl fresenius | Fentanyl Hpq | Fentora</span>;</li>
<li>
<span class="countryCode">(UA)</span> <span class="country">Ukraine</span><span class="countrySeparator">: </span><span class="drugName">Durogesic | Fentanyl | Fentanyl m | Fentavera | Matrifen</span>;</li>
<li>
<span class="countryCode">(UY)</span> <span class="country">Uruguay</span><span class="countrySeparator">: </span><span class="drugName">Durogesic | Fentanilo | Fentivo</span>;</li>
<li>
<span class="countryCode">(VE)</span> <span class="country">Venezuela, Bolivarian Republic of</span><span class="countrySeparator">: </span><span class="drugName">Durogesic</span>;</li>
<li>
<span class="countryCode">(ZA)</span> <span class="country">South Africa</span><span class="countrySeparator">: </span><span class="drugName">Adco tenyl | Durogesic | Fendermal</span></li></ul></div>
</div>
</div>
</div>
</div><div class="headingAnchor" id="references"><ol id="reference">
<li>
<div class="reference" id="lexi-content-ref-37139824">
<a name="37139824"></a>2023 American Geriatrics Society Beers Criteria Update Expert Panel. American Geriatrics Society 2023 updated AGS Beers Criteria for potentially inappropriate medication use in older adults. <i>J Am Geriatr Soc</i>. 2023;71(7):2052-2081. doi:10.1111/jgs.18372<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/fentanyl-pediatric-drug-information/abstract-text/37139824/pubmed" id="37139824" target="_blank">37139824</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-Abstral.1">
<a name="Abstral.1"></a>Abstral (fentanyl) [prescribing information]. Solana Beach, CA: Sentynl Therapeutics Inc; October 2019.</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-Abstral.2">
<a name="Abstral.2"></a>Abstral (fentanyl) [product monograph]. St-Laurent, Quebec, Canada: Paladin Labs Inc; March 2018.</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-Actiq.1">
<a name="Actiq.1"></a>Actiq (fentanyl) [prescribing information]. Parsippany, NJ: Teva Pharmaceuticals USA Inc; December 2023.</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-Alexander.1">
<a name="Alexander.1"></a>Alexander JC. Perioperative uses of intravenous opioids: specific agents. Post TW, ed. UpToDate. Waltham, MA: UpToDate Inc. <a href="http://www.uptodate.com" target="_blank">http://www.uptodate.com</a>. Accessed March 21, 2023.</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-30915997">
<a name="30915997"></a>Algera MH, Kamp J, van der Schrier R, et al. Opioid-induced respiratory depression in humans: a review of pharmacokinetic-pharmacodynamic modelling of reversal. <i>Br J Anaesth</i>. 2019;122(6):e168-e179. doi:10.1016/j.bja.2018.12.023<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/fentanyl-pediatric-drug-information/abstract-text/30915997/pubmed" id="30915997" target="_blank">30915997</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-9024461">
<a name="9024461"></a>American Academy of Pediatrics Committee on Drugs. "Inactive" ingredients in pharmaceutical products: update (subject review). <i>Pediatrics</i>. 1997;99(2):268-278.<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/fentanyl-pediatric-drug-information/abstract-text/9024461/pubmed" id="9024461" target="_blank">9024461</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-26810788">
<a name="26810788"></a>American Academy of Pediatrics (AAP) Committee on Fetus and Newborn and Section on Anesthesiology and Pain Medicine. Prevention and management of procedural pain in the neonate: an update. <i>Pediatrics</i>. 2016;137(2):e20154271. doi:10.1542/peds.2015-4271<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/fentanyl-pediatric-drug-information/abstract-text/26810788/pubmed" id="26810788" target="_blank">26810788</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-30913200">
<a name="30913200"></a>American College of Obstetricians and Gynecologists (ACOG). ACOG Committee Opinion No. 775: Nonobstetric surgery during pregnancy. <i>Obstet Gynecol</i>. 2019a;133(4):e285-e286.<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/fentanyl-pediatric-drug-information/abstract-text/30913200/pubmed" id="30913200" target="_blank">30913200</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-30801474">
<a name="30801474"></a>American College of Obstetricians and Gynecologists (ACOG). ACOG Practice Bulletin No. 209: Obstetric analgesia and anesthesia. <i>Obstet Gynecol</i>. 2019b;133(3):e208-e225.<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/fentanyl-pediatric-drug-information/abstract-text/30801474/pubmed" id="30801474" target="_blank">30801474</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-34412076">
<a name="34412076"></a>American College of Obstetricians and Gynecologists’ (ACOG) Committee on Clinical Consensus–Obstetrics. Pharmacologic stepwise multimodal approach for postpartum pain management: ACOG clinical consensus no. 1. <i>Obstet Gynecol.</i> 2021;138(3):507-517. doi:10.1097/AOG.0000000000004517<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/fentanyl-pediatric-drug-information/abstract-text/34412076/pubmed" id="34412076" target="_blank">34412076</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-28742676">
<a name="28742676"></a>American College of Obstetricians and Gynecologists’ (ACOG) Committee on Clinical Consensus–Obstetrics. Committee opinion no. 711: opioid use and opioid use disorder in pregnancy. <i>Obstet Gynecol</i>. 2017;130(2):e81-e94. doi:10.1097/AOG.0000000000002235<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/fentanyl-pediatric-drug-information/abstract-text/28742676/pubmed" id="28742676" target="_blank">28742676</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-APS.1">
<a name="APS.1"></a>American Pain Society (APS). <i>Principles of Analgesic Use in the Treatment of Acute Pain and Cancer Pain</i>. 6th ed. Glenview, IL: American Pain Society; 2008.</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-APS.2">
<a name="APS.2"></a>American Pain Society (APS).<i> Principles of Analgesic Use in the Treatment of Acute Pain and Cancer Pain</i>. 7th ed. Glenview, IL: American Pain Society; 2016.</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-ASHP.2">
<a name="ASHP.2"></a>American Society of Health-System Pharmacists (ASHP). Pediatric continuous infusion standards. Available at https://www.ashp.org/-/media/assets/pharmacy-practice/s4s/docs/Pediatric-Infusion-Standards.ashx. Updated September 2023. Accessed October 30, 2023.</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-11177093">
<a name="11177093"></a>Anand KJ and International Evidence-Based Group for Neonatal Pain. Consensus Statement for the Prevention and Management of Pain in the Newborn. <i>Arch Pediatr Adolesc Med. </i>2001;155(2):173-180.<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/fentanyl-pediatric-drug-information/abstract-text/11177093/pubmed" id="11177093" target="_blank">11177093</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-23582138">
<a name="23582138"></a>Ancora G, Lago P, Garetti E, et al. Efficacy and safety of continuous infusion of fentanyl for pain control in preterm newborns on mechanical ventilation. <i>J Pediatr</i>. 2013;163(3):645-51.e1. doi:10.1016/j.jpeds.2013.02.039<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/fentanyl-pediatric-drug-information/abstract-text/23582138/pubmed" id="23582138" target="_blank">23582138</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-30290021">
<a name="30290021"></a>Ancora G, Lago P, Garetti E, et al. Evidence-based clinical guidelines on analgesia and sedation in newborn infants undergoing assisted ventilation and endotracheal intubation. <i>Acta Paediatr</i>. 2019;108(2):208-217. doi:10.1111/apa.14606<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/fentanyl-pediatric-drug-information/abstract-text/30290021/pubmed" id="30290021" target="_blank">30290021</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-15122000">
<a name="15122000"></a>Anderson SL, Shreve ST. Continuous subcutaneous infusion of opiates at end-of-life. <i>Ann Pharmacother</i>. 2004;38(6):1015-1023. doi:10.1345/aph.1D395<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/fentanyl-pediatric-drug-information/abstract-text/15122000/pubmed" id="15122000" target="_blank">15122000</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-27729502">
<a name="27729502"></a>Anton-Martin P, Modem V, Taylor D, Potter D, Darnell-Bowens C. A retrospective study of sedation and analgesic requirements of pediatric patients on extracorporeal membrane oxygenation (ECMO) from a single-center experience. <i>Perfusion</i>. 2017;32(3):183-191. doi:10.1177/0267659116670483<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/fentanyl-pediatric-drug-information/abstract-text/27729502/pubmed" id="27729502" target="_blank">27729502</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-1919898">
<a name="1919898"></a>Arnold JH, Truog RD, Scavone JM, et al. Changes in the pharmacodynamics response to fentanyl in neonates during continuous infusion. <i>Journal of Pediatrics</i>. 1991;119:639-643.<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/fentanyl-pediatric-drug-information/abstract-text/1919898/pubmed" id="1919898" target="_blank">1919898</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-Arnold.2019">
<a name="Arnold.2019"></a>Arnold RM, Childers JW. Management of acute pain in the patient chronically using opioids. Post TW, ed. UpToDate. Waltham, MA: UpToDate Inc. <a href="http://www.uptodate.com" target="_blank">http://www.uptodate.com</a>. Accessed November 11, 2019.</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-Aronoff.1">
<a name="Aronoff.1"></a>Aronoff GR, Bennett WM, Berns JS, et al. <i>Drug Prescribing in Renal Failure: Dosing Guidelines for Adults and Children</i>. 5th ed. American College of Physicians; 2007.</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-APA.1">
<a name="APA.1"></a>Association of Paediatric Anaesthetists of Great Britain and Ireland (APA). Good practice in postoperative and procedural pain management, 2nd edition. <i>Paediatr Anaesth</i>. 2012;22(Suppl 1):1-79.</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-15829394">
<a name="15829394"></a>Bahn EL, Holt KR. Procedural sedation and analgesia: a review and new concepts. <i>Emerg Med Clin North Am</i>. 2005;23(2):503-517. doi:10.1016/j.emc.2004.12.013<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/fentanyl-pediatric-drug-information/abstract-text/15829394/pubmed" id="15829394" target="_blank">15829394</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-28259526">
<a name="28259526"></a>Bailey AM, Baum RA, Horn K, et al. Review of intranasally administered medications for use in the emergency department. <i>J Emerg Med</i>. 2017;53(1):38-48. doi:10.1016/j.jemermed.2017.01.020<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/fentanyl-pediatric-drug-information/abstract-text/28259526/pubmed" id="28259526" target="_blank">28259526</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-Barash.1">
<a name="Barash.1"></a>Barash PG, Cullen BF, Stoelting RK, et al, eds. <i>Clinical Anesthesia.</i> 6th ed. Lippincott Williams &amp; Wilkins; 2009.</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-23269131">
<a name="23269131"></a>Barr J, Fraser GL, Puntillo K, et al; American College of Critical Care Medicine. Clinical practice guidelines for the management of pain, agitation, and delirium in adult patients in the intensive care unit. <i>Crit Care Med</i>. 2013;41(1):263-306. doi:10.1097/CCM.0b013e3182783b72<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/fentanyl-pediatric-drug-information/abstract-text/23269131/pubmed" id="23269131" target="_blank">23269131</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-9430910">
<a name="9430910"></a>Bastani B, Jamal JA. Removal of morphine but not fentanyl during haemodialysis. <i>Nephrol Dial Transplant</i>. 1997;12(12):2802-2804. doi:10.1093/ndt/12.12.2802<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/fentanyl-pediatric-drug-information/abstract-text/9430910/pubmed" id="9430910" target="_blank">9430910</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-21338400">
<a name="21338400"></a>Beathard GA, Urbanes A, Litchfield T, Weinstein A. The risk of sedation/analgesia in hemodialysis patients undergoing interventional procedures. <i>Semin Dial</i>. 2011;24(1):97-103. doi:10.1111/j.1525-139X.2011.00844.x<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/fentanyl-pediatric-drug-information/abstract-text/21338400/pubmed" id="21338400" target="_blank">21338400</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-Bennett.1">
<a name="Bennett.1"></a>Bennett MR, Adams AP. Postoperative respiratory complications of opiates. <i>Clin Anaesthesiol.</i> 1983;1:41-56.</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-12362012">
<a name="12362012"></a>Berde CB, Sethna NF. Analgesics for the treatment of pain in children. <i>N Engl J Med</i>. 2002;347(14):1094-1103.<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/fentanyl-pediatric-drug-information/abstract-text/12362012/pubmed" id="12362012" target="_blank">12362012</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-4057297">
<a name="4057297"></a>Billmire DA, Neale HW, Gregory RO. Use of I.V. Fentanyl in the Outpatient Treatment of Pediatric Facial Trauma. <i>J Trauma.</i> 1985;25(11):1079-1080.<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/fentanyl-pediatric-drug-information/abstract-text/4057297/pubmed" id="4057297" target="_blank">4057297</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-32199668">
<a name="32199668"></a>Bluthenthal RN, Simpson K, Ceasar RC, Zhao J, Wenger L, Kral AH. Opioid withdrawal symptoms, frequency, and pain characteristics as correlates of health risk among people who inject drugs. <i>Drug Alcohol Depend</i>. 2020;211:107932. doi:10.1016/j.drugalcdep.2020.107932<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/fentanyl-pediatric-drug-information/abstract-text/32199668/pubmed" id="32199668" target="_blank">32199668</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-22747535">
<a name="22747535"></a>Boom M, Niesters M, Sarton E, Aarts L, Smith TW, Dahan A. Non-analgesic effects of opioids: opioid-induced respiratory depression. <i>Curr Pharm Des</i>. 2012;18(37):5994-6004. doi:10.2174/138161212803582469<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/fentanyl-pediatric-drug-information/abstract-text/22747535/pubmed" id="22747535" target="_blank">22747535</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-17067720">
<a name="17067720"></a>Borland M, Jacobs I, King B, et al. A Randomized Controlled Trial Comparing Intranasal Fentanyl to Intravenous Morphine for Managing Acute Pain in Children in the Emergency Department. <i>Ann Emerg Med. </i>2007;49(3):335-340.<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/fentanyl-pediatric-drug-information/abstract-text/17067720/pubmed" id="17067720" target="_blank">17067720</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-16005154">
<a name="16005154"></a>Borland ML, Bergesio R, Pascoe EM, et al. Intranasal Fentanyl Is an Equivalent Analgesic to Oral Morphine in Paediatric Burns Patients for Dressing Changes: A Randomised Double Blind Crossover Study. <i>Burns.</i> 2005;31(7):831-837.<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/fentanyl-pediatric-drug-information/abstract-text/16005154/pubmed" id="16005154" target="_blank">16005154</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-12487045">
<a name="12487045"></a>Borland ML, Jacobs I, Geelhoed G. Intranasal fentanyl reduces acute pain in children in the emergency department: a safety and efficacy study. <i>Emerg Med (Fremantle)</i>. 2002;14(3):275-280.<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/fentanyl-pediatric-drug-information/abstract-text/12487045/pubmed" id="12487045" target="_blank">12487045</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-Bravenec.1">
<a name="Bravenec.1"></a>Bravenec B. General anesthesia: Intravenous induction agents. Post TW, ed. UpToDate. Waltham, MA: UpToDate Inc. <a href="http://www.uptodate.com" target="_blank">http://www.uptodate.com</a>. Accessed August 21, 2019.</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-23414717">
<a name="23414717"></a>Brennan MJ. The effect of opioid therapy on endocrine function. <i>Am J Med</i>. 2013;126(3)(suppl 1):S12-S18. doi:10.1016/j.amjmed.2012.12.001<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/fentanyl-pediatric-drug-information/abstract-text/23414717/pubmed" id="23414717" target="_blank">23414717</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-Buys.1">
<a name="Buys.1"></a>Buys MJ. Use of opioids for postoperative pain control. Post TW, ed. UpToDate. Waltham, MA: UpToDate Inc. <a href="http://www.uptodate.com" target="_blank">http://www.uptodate.com</a>. Accessed March 21, 2023.</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-9559604">
<a name="9559604"></a>Cammarano WB, Pittet JF, Weitz S, Schlobohm RM, Marks JD. Acute withdrawal syndrome related to the administration of analgesic and sedative medications in adult intensive care unit patients. <i>Crit Care Med</i>. 1998;26(4):676-684. doi:10.1097/00003246-199804000-00015<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/fentanyl-pediatric-drug-information/abstract-text/9559604/pubmed" id="9559604" target="_blank">9559604</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-19918182">
<a name="19918182"></a>Capper SJ, Loo S, Geue JP, et al. Pharmacokinetics of fentanyl after subcutaneous administration in volunteers. <i>Eur J Anaesthesiol</i>. 2010;27(3):241-246. doi:10.1097/EJA.0b013e328331a361<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/fentanyl-pediatric-drug-information/abstract-text/19918182/pubmed" id="19918182" target="_blank">19918182</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-22300860">
<a name="22300860"></a>Caraceni A, Hanks G, Kaasa S, et al; European Palliative Care Research Collaborative (EPCRC); European Association for Palliative Care (EAPC). Use of opioid analgesics in the treatment of cancer pain: evidence-based recommendations from the EAPC. <i>Lancet Oncol</i>. 2012;13(2):e58-e68. doi:10.1016/S1470-2045(12)70040-2<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/fentanyl-pediatric-drug-information/abstract-text/22300860/pubmed" id="22300860" target="_blank">22300860</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-Caro.2019">
<a name="Caro.2019"></a>Caro D. Pretreatment medications for rapid sequence intubation in adults for emergency medicine and critical care. Post TW, ed. UpToDate. Waltham, MA: UpToDate Inc. <a href="http://www.uptodate.com" target="_blank">http://www.uptodate.com</a>. Accessed May 31, 2023.</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-CDC.1">
<a name="CDC.1"></a>Centers for Disease Control and Prevention (CDC). Common elements in guidelines for prescribing opioids for chronic pain. <a href="https://www.cdc.gov/drugoverdose/pdf/common_elements_in_guidelines_for_prescribing_opioids-a.pdf" target="_blank">https://www.cdc.gov/drugoverdose/pdf/common_elements_in_guidelines_for_prescribing_opioids-a.pdf</a>. Published 2015. Accessed November 22, 2019.</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-35295509">
<a name="35295509"></a>Cheng C, Tabbara N, Cheng C, Shah V. Intranasal fentanyl for procedural analgesia in preterm infants. <i>Front Pain Res (Lausanne)</i>. 2022;2:815014. doi:10.3389/fpain.2021.815014<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/fentanyl-pediatric-drug-information/abstract-text/35295509/pubmed" id="35295509" target="_blank">35295509</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-26827847">
<a name="26827847"></a>Chou R, Gordon DB, de Leon-Casasola OA, et al. Management of postoperative pain: a clinical practice guideline from the American Pain Society, the American Society of Regional Anesthesia and Pain Medicine, and the American Society of Anesthesiologists' Committee on Regional Anesthesia, Executive Committee, and Administrative Council. <i>J Pain</i>. 2016;17(2):131-157. doi:10.1016/j.jpain.2015.12.008<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/fentanyl-pediatric-drug-information/abstract-text/26827847/pubmed" id="26827847" target="_blank">26827847</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-20180109">
<a name="20180109"></a>Chung S, Lim R, Goldman RD. Intranasal Fentanyl Versus Placebo for Pain in Children During Catheterization for Voiding Cystourethrography. <i>Pediatr Radiol.</i> 2010;40(7):1236-1240.<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/fentanyl-pediatric-drug-information/abstract-text/20180109/pubmed" id="20180109" target="_blank">20180109</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-Cloherty.1">
<a name="Cloherty.1"></a>Cloherty JP, Eichenwald EC, Stark AR, eds. <i>Manual of Neonatal Care</i>. 7th ed. Philadelphia, PA: Lippincott Williams &amp; Wilkins; 2012.</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-19286842">
<a name="19286842"></a>Cohen RS. Fentanyl transdermal analgesia during pregnancy and lactation. <i>J Hum Lact</i>. 2009;25(3):359-361.<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/fentanyl-pediatric-drug-information/abstract-text/19286842/pubmed" id="19286842" target="_blank">19286842</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-19840089">
<a name="19840089"></a>Cole J, Shepherd M, Young P. Intranasal Fentanyl in 1-3-Year-Olds: A Prospective Study of the Effectiveness of Intranasal Fentanyl as Acute Analgesia. <i>Emerg Med Australas. </i>2009;21(5):395-400.<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/fentanyl-pediatric-drug-information/abstract-text/19840089/pubmed" id="19840089" target="_blank">19840089</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-22732639">
<a name="22732639"></a>Cramton RE, Gruchala NE. Managing procedural pain in pediatric patients. <i>Curr Opin Pediatr</i>. 2012;24(4):530-538.<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/fentanyl-pediatric-drug-information/abstract-text/22732639/pubmed" id="22732639" target="_blank">22732639</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-Cravero.1">
<a name="Cravero.1"></a>Cravero JP, Kaplan RF, Landrigan-Ossar M, Coté CJ. Sedation for diagnostic and therapeutic procedures outside the operating room. In: Coté CJ, Lerman J, Anderson B, eds. <i>A Practice of Anesthesia for Infants and Children</i>. 6th ed. Elsevier; 2019:chap. 48.</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-20152004">
<a name="20152004"></a>Crellin D, Ling RX, Babl F. Does the Standard Intravenous Solution of Fentanyl (50 microg/mL) Administered Intranasally Have Analgesic Efficacy? <i>Emerg Med Australas.</i> 2010;22(1):62-67.<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/fentanyl-pediatric-drug-information/abstract-text/20152004/pubmed" id="20152004" target="_blank">20152004</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-20010421">
<a name="20010421"></a>Dahan A, Aarts L, Smith TW. Incidence, reversal, and prevention of opioid-induced respiratory depression. <i>Anesthesiology</i>. 2010;112(1):226-238. doi:10.1097/ALN.0b013e3181c38c25<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/fentanyl-pediatric-drug-information/abstract-text/20010421/pubmed" id="20010421" target="_blank">20010421</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-Darby.2019">
<a name="Darby.2019"></a>d'Arby Toledano R, Leffert L. Neuraxial analgesia for labor and delivery (including instrumented delivery). Post TW, ed. UpToDate. Waltham, MA: UpToDate Inc. <a href="http://www.uptodate.com" target="_blank">http://www.uptodate.com</a>. Accessed December 5, 2019.</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-30833302">
<a name="30833302"></a>Davison SN. Clinical pharmacology considerations in pain management in patients with advanced kidney failure. <i>Clin J Am Soc Nephrol</i>. 2019;14(6):917-931. doi:10.2215/CJN.05180418<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/fentanyl-pediatric-drug-information/abstract-text/30833302/pubmed" id="30833302" target="_blank">30833302</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-24517512">
<a name="24517512"></a>Davison SN, Koncicki H, Brennan F. Pain in chronic kidney disease: a scoping review. <i>Semin Dial</i>. 2014;27(2):188-204. doi:10.1111/sdi.12196<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/fentanyl-pediatric-drug-information/abstract-text/24517512/pubmed" id="24517512" target="_blank">24517512</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-15504625">
<a name="15504625"></a>Dean M. Opioids in renal failure and dialysis patients. <i>J Pain Symptom Manage. </i>2004;28(5):497-504. doi:10.1016/j.jpainsymman.2004.02.021<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/fentanyl-pediatric-drug-information/abstract-text/15504625/pubmed" id="15504625" target="_blank">15504625</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-21243342">
<a name="21243342"></a>Debono M, Chan S, Rolfe C, Jones TH. Tramadol-induced adrenal insufficiency. <i>Eur J Clin Pharmacol</i>. 2011;67(8):865-867. doi:10.1007/s00228-011-0992-9<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/fentanyl-pediatric-drug-information/abstract-text/21243342/pubmed" id="21243342" target="_blank">21243342</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-31511863">
<a name="31511863"></a>de Vries F, Bruin M, Lobatto DJ, et al. Opioids and their endocrine effects: a systematic review and meta-analysis. <i>J Clin Endocrinol Metab</i>. 2020;105(3):1020-1029. doi:10.1210/clinem/dgz022<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/fentanyl-pediatric-drug-information/abstract-text/31511863/pubmed" id="31511863" target="_blank">31511863</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-30113379">
<a name="30113379"></a>Devlin JW, Skrobik Y, Gélinas C, et al. Clinical practice guidelines for the prevention and management of pain, agitation/sedation, delirium, immobility, and sleep disruption in adult patients in the ICU. <i>Crit Care Med</i>. 2018;46(9):e825-e873. doi:10.1097/CCM.0000000000003299<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/fentanyl-pediatric-drug-information/abstract-text/30113379/pubmed" id="30113379" target="_blank">30113379</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-11433853">
<a name="11433853"></a>Dionne RA, Yagiela JA, Moore PA, et al. Comparing Efficacy and Safety of Four Intravenous Sedation Regimens in Dental Outpatients. <i>Am Dent Assoc.</i> 2001;132(6):740-751.<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/fentanyl-pediatric-drug-information/abstract-text/11433853/pubmed" id="11433853" target="_blank">11433853</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-Domonoske.1">
<a name="Domonoske.1"></a>Domonoske C. Appendix A: Common neonatal intensive care unit (NICU) medication guidelines. In: Eichenwald EC, Hansen AR, Martin CR, Stark AR. <i>Cloherty and Stark's Manual of Neonatal Care</i>. 8th edition. Lippincott Williams &amp; Wilkins; 2017.</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-36327391">
<a name="36327391"></a>Dowell D, Ragan KR, Jones CM, Baldwin GT, Chou R. CDC clinical practice guideline for prescribing opioids for pain - United States, 2022. <i>MMWR Recomm Rep</i>. 2022;71(3):1-95. doi:10.15585/mmwr.rr7103a1<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/fentanyl-pediatric-drug-information/abstract-text/36327391/pubmed" id="36327391" target="_blank">36327391</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-Duragesic.1">
<a name="Duragesic.1"></a>Duragesic (fentanyl) [prescribing information]. Titusville, NJ: Janssen Pharmaceuticals Inc; April 2022.</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-Duragesic.2">
<a name="Duragesic.2"></a>Duragesic (fentanyl) [product monograph]. Toronto, Ontario, Canada: Janssen Inc; December 2019.</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-34334427">
<a name="34334427"></a>Elliott M, Burnsed J, Heinan K, et al. Effect of dexmedetomidine on heart rate in neonates with hypoxic ischemic encephalopathy undergoing therapeutic hypothermia. <i>J Neonatal Perinatal Med</i>. 2022;15(1):47-54. doi:10.3233/NPM-210737<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/fentanyl-pediatric-drug-information/abstract-text/34334427/pubmed" id="34334427" target="_blank">34334427</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-37196592">
<a name="37196592"></a>Engstrom K, Brown CS, Mattson AE, Lyons N, Rech MA. Pharmacotherapy optimization for rapid sequence intubation in the emergency department. <i>Am J Emerg Med</i>. 2023;70:19-29. doi:10.1016/j.ajem.2023.05.004<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/fentanyl-pediatric-drug-information/abstract-text/37196592/pubmed" id="37196592" target="_blank">37196592</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-32513237">
<a name="32513237"></a>Erstad BL, Barletta JF. Drug dosing in the critically ill obese patient-a focus on sedation, analgesia, and delirium. <i>Crit Care</i>. 2020;24(1):315. doi:10.1186/s13054-020-03040-z<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/fentanyl-pediatric-drug-information/abstract-text/32513237/pubmed" id="32513237" target="_blank">32513237</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-Expert.DOO">
<a name="Expert.DOO"></a>Expert opinion. Senior Obesity Editorial Team: Jeffrey F. Barletta, PharmD, FCCM; Manjunath P. Pai, PharmD, FCP; Jason A. Roberts, PhD, BPharm (Hons), B App Sc, FSHP, FISAC.</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-Expert.DOR">
<a name="Expert.DOR"></a>Expert opinion. Senior Renal Editorial Team: Bruce Mueller, PharmD, FCCP, FASN, FNKF; Jason A. Roberts, PhD, BPharm (Hons), B App Sc, FSHP, FISAC; Michael Heung, MD, MS.</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-30788113">
<a name="30788113"></a>Farmer AD, Drewes AM, Chiarioni G, et al. Pathophysiology and management of opioid-induced constipation: European expert consensus statement. <i>United European Gastroenterol J</i>. 2019;7(1):7-20. doi:10.1177/2050640618818305. Erratum in: <i>United European Gastroenterol J</i>. 2019;7(2):178.<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/fentanyl-pediatric-drug-information/abstract-text/30788113/pubmed" id="30788113" target="_blank">30788113</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-Hikma.1">
<a name="Hikma.1"></a>Fentanyl citrate injection [prescribing information]. Berkely Heights, NJ: Hikma Pharmaceuticals USA Inc; November 2020.</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-Akorn.2">
<a name="Akorn.2"></a>Fentanyl citrate injection [prescribing information]. Lake Forest, IL: Hospira Inc; December 2023.</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-Akorn.1">
<a name="Akorn.1"></a>Fentanyl citrate injection preservative free [prescribing information]. Lake Forest, IL: Akorn Inc; October 2019.</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-Jamp.1">
<a name="Jamp.1"></a>Fentanyl citrate injection [product monograph]. Boucherville, Quebec, Canada: Jamp Pharma Corporation; October 2020.</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-Telip.1">
<a name="Telip.1"></a>Fentanyl citrate injection, USP [Canadian product monograph]. Buena, NJ: Telip LLC; September 2021.</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-Mylan.1">
<a name="Mylan.1"></a>Fentanyl transdermal patch [prescribing information]. Morgantown, WV: Mylan Pharmaceuticals Inc; September 2023.</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-Fentora.3">
<a name="Fentora.3"></a>Fentora (fentanyl) [prescribing information]. Parsippany, NJ: Teva Pharmaceuticals USA Inc; December 2023.</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-Fentora.2">
<a name="Fentora.2"></a>Fentora (fentanyl) [product monograph]. Toronto, Ontario, Canada: Teva Canada Limited; June 2023.</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-20385685">
<a name="20385685"></a>Finn M, Harris D. Intranasal Fentanyl for Analgesia in the Paediatric Emergency Department. <i>Emerg Med J.</i> 2010;27(4):300-301.<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/fentanyl-pediatric-drug-information/abstract-text/20385685/pubmed" id="20385685" target="_blank">20385685</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-28646524">
<a name="28646524"></a>Fox LM, Hoffman RS, Vlahov D, Manini AF. Risk factors for severe respiratory depression from prescription opioid overdose. <i>Addiction</i>. 2018;113(1):59-66. doi:10.1111/add.13925<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/fentanyl-pediatric-drug-information/abstract-text/28646524/pubmed" id="28646524" target="_blank">28646524</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-Frank.2019">
<a name="Frank.2019"></a>Frank RL. Procedural sedation in adults: Medication selection, dosing, and discharge criteria. Post TW, ed. UpToDate. Waltham, MA: UpToDate Inc. <a href="http://www.uptodate.com" target="_blank">http://www.uptodate.com</a>. Accessed January 3, 2023.</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-30592476">
<a name="30592476"></a>Frey TM, Florin TA, Caruso M, Zhang N, Zhang Y, Mittiga MR. Effect of intranasal ketamine vs fentanyl on pain reduction for extremity injuries in children: The PRIME randomized clinical trial. <i>JAMA Pediatr</i>. 2019;173(2):140-146. doi:10.1001/jamapediatrics.2018.4582<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/fentanyl-pediatric-drug-information/abstract-text/30592476/pubmed" id="30592476" target="_blank">30592476</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-35066756">
<a name="35066756"></a>Gadelha MR, Karavitaki N, Fudin J, Bettinger JJ, Raff H, Ben-Shlomo A. Opioids and pituitary function: expert opinion. <i>Pituitary</i>. 2022;25(1):52-63. doi:10.1007/s11102-021-01202-y<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/fentanyl-pediatric-drug-information/abstract-text/35066756/pubmed" id="35066756" target="_blank">35066756</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-32236681">
<a name="32236681"></a>Gai N, Naser B, Hanley J, Peliowski A, Hayes J, Aoyama K. A practical guide to acute pain management in children. <i>J Anesth</i>. 2020;34(3):421-433. doi:10.1007/s00540-020-02767-x<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/fentanyl-pediatric-drug-information/abstract-text/32236681/pubmed" id="32236681" target="_blank">32236681</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-20547520">
<a name="20547520"></a>Gallagher R. Killing the symptom without killing the patient. <i>Can Fam Physician</i>. 2010;56(6):544-546, e210-212.<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/fentanyl-pediatric-drug-information/abstract-text/20547520/pubmed" id="20547520" target="_blank">20547520</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-18454213">
<a name="18454213"></a>Goma HM, Said RN, El-Ela AM. Study of the newborn feeding behaviors and fentanyl concentration in colostrum after an analgesic dose of epidural and intravenous fentanyl in cesarean section. <i>Saudi Med J</i>. 2008;29(5):678-682.<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/fentanyl-pediatric-drug-information/abstract-text/18454213/pubmed" id="18454213" target="_blank">18454213</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-16334492">
<a name="16334492"></a>Grass JA. Patient-controlled analgesia. <i>Anesth Analg</i>. 2005 Nov;101(5)(suppl):S44-S61.<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/fentanyl-pediatric-drug-information/abstract-text/16334492/pubmed" id="16334492" target="_blank">16334492</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-29413725">
<a name="29413725"></a>Groth CM, Acquisto NM, Khadem T. Current practices and safety of medication use during rapid sequence intubation. <i>J Crit Care</i>. 2018;45:65-70. doi:10.1016/j.jcrc.2018.01.017<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/fentanyl-pediatric-drug-information/abstract-text/29413725/pubmed" id="29413725" target="_blank">29413725</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-29120929">
<a name="29120929"></a>Gupta K, Prasad A, Nagappa M, Wong J, Abrahamyan L, Chung FF. Risk factors for opioid-induced respiratory depression and failure to rescue: a review. <i>Curr Opin Anaesthesiol</i>. 2018;31(1):110-119. doi:10.1097/ACO.0000000000000541<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/fentanyl-pediatric-drug-information/abstract-text/29120929/pubmed" id="29120929" target="_blank">29120929</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-18245435">
<a name="18245435"></a>Hegenbarth MA. Preparing for pediatric emergencies: drugs to consider. <i>Pediatrics</i>. 2008;121:433-443.<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/fentanyl-pediatric-drug-information/abstract-text/18245435/pubmed" id="18245435" target="_blank">18245435</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-19682022">
<a name="19682022"></a>Herd D, Borland M. Intranasal Fentanyl Paediatric Clinical Practice Guidelines.<i> Emerg Med Australas.</i> 2009;21(4):335.<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/fentanyl-pediatric-drug-information/abstract-text/19682022/pubmed" id="19682022" target="_blank">19682022</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-28267689">
<a name="28267689"></a>Hill MV, Stucke RS, McMahon ML, Beeman JL, Barth RJ Jr. An educational intervention decreases opioid prescribing after general surgical operations. <i>Ann Surg</i>. 2018;267(3):468-472. doi:10.1097/SLA.0000000000002198<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/fentanyl-pediatric-drug-information/abstract-text/28267689/pubmed" id="28267689" target="_blank">28267689</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-31499594">
<a name="31499594"></a>Hill R, Santhakumar R, Dewey W, Kelly E, Henderson G. Fentanyl depression of respiration: Comparison with heroin and morphine. <i>Br J Pharmacol</i>. 2020;177(2):254-266. doi:10.1111/bph.14860<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/fentanyl-pediatric-drug-information/abstract-text/31499594/pubmed" id="31499594" target="_blank">31499594</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-22291123">
<a name="22291123"></a>Hudak ML, Tan RC, Committee On Drugs, et al. Neonatal Drug Withdrawal. <i>Pediatrics.</i> 2012;129(2):e540-e560.<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/fentanyl-pediatric-drug-information/abstract-text/22291123/pubmed" id="22291123" target="_blank">22291123</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-29273520">
<a name="29273520"></a>Imam MZ, Kuo A, Ghassabian S, Smith MT. Progress in understanding mechanisms of opioid-induced gastrointestinal adverse effects and respiratory depression. <i>Neuropharmacology</i>. 2018;131:238-255. doi:10.1016/j.neuropharm.2017.12.032<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/fentanyl-pediatric-drug-information/abstract-text/29273520/pubmed" id="29273520" target="_blank">29273520</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-ISMP.1">
<a name="ISMP.1"></a>Institute for Safe Medication Practice (ISMP). <i>ISMP Targeted Medication Safety Best Practices for Hospitals</i>. https://ismp.org/guidelines/best-practices-hospitals. Published February 21, 2020. Accessed August 4, 2020.</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-ISMP.2">
<a name="ISMP.2"></a>Institute for Safe Medication Practice (ISMP); Vermont Oxford Network. Standard Concentrations of Neonatal Drug Infusions. 2011. https://www.ismp.org/Tools/PediatricConcentrations.pdf.</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-ISMP.3">
<a name="ISMP.3"></a>Institute for Safe Medication Practices (ISMP). Beware of basal opioid infusions with PCA therapy. https://www.ismp.org/resources/beware-basal-opioid-infusions-pca-therapy. Published March 12, 2009. Accessed December 16, 2019.</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-Eichenwald.1">
<a name="Eichenwald.1"></a>Intubation sedation guidelines. In: Eichenwald EC, Hansen AR, Martin CR, Stark AR. <i>Cloherty and Stark's Manual of Neonatal Care</i>. 8th edition. Lippincott Williams &amp; Wilkins; 2017.</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-Ionsys.1">
<a name="Ionsys.1"></a>Ionsys (fentanyl transdermal system) [prescribing information]. Parsippany, NJ: The Medicines Company; January 2017.</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-28217636">
<a name="28217636"></a>Jabalameli M, Talakoub R, Abedi B, et al. A randomized controlled trial comparing the effect of intravenous, subcutaneous, and intranasal fentanyl for pain management in patients undergoing cesarean section. <i>Adv Biomed Res.</i> 2016;5:198. doi:10.4103/2277-9175.190989<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/fentanyl-pediatric-drug-information/abstract-text/28217636/pubmed" id="28217636" target="_blank">28217636</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-11902253">
<a name="11902253"></a>Jacobi J, Fraser GL, Coursin DB, et al; Task Force of the American College of Critical Care Medicine (ACCM) of the Society of Critical Care Medicine (SCCM), American Society of Health-System Pharmacists (ASHP), American College of Chest Physicians. Clinical practice guidelines for the sustained use of sedatives and analgesics in the critically ill adult. <i>Crit Care Med</i>. 2002;30(1):119-141. doi:10.1097/00003246-200201000-00020<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/fentanyl-pediatric-drug-information/abstract-text/11902253/pubmed" id="11902253" target="_blank">11902253</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-16176118">
<a name="16176118"></a>Janmahasatian S, Duffull SB, Ash S, Ward LC, Byrne NM, Green B. Quantification of lean bodyweight. <i>Clin Pharmacokinet</i>. 2005;44(10):1051-1065. doi:10.2165/00003088-200544100-00004<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/fentanyl-pediatric-drug-information/abstract-text/16176118/pubmed" id="16176118" target="_blank">16176118</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-9459269">
<a name="9459269"></a>Joh J, Sila MK, Bastani B. Nondialyzability of fentanyl with high-efficiency and high-flux membranes. <i>Anesth Analg</i>. 1998;86(2):447. doi:10.1097/00000539-199802000-00049<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/fentanyl-pediatric-drug-information/abstract-text/9459269/pubmed" id="9459269" target="_blank">9459269</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-34942181">
<a name="34942181"></a>Jilani SM, Jones HE, Grossman M, et al. Standardizing the clinical definition of opioid withdrawal in the neonate. <i>J</i>
<i>Pediatr</i>. 2022;243:33-39.e1. doi:10.1016/j.jpeds.2021.12.021<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/fentanyl-pediatric-drug-information/abstract-text/34942181/pubmed" id="34942181" target="_blank">34942181</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-29740192">
<a name="29740192"></a>Kasirer Y, Shah V, Yoon EW, Bromiker R, Mcnair C, Taddio A. Safety of fentanyl for peripherally inserted central catheter in non-intubated infants in the neonatal intensive care unit. <i>J Perinatol</i>. 2018;38(5):526-529. doi:10.1038/s41372-018-0101-3<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/fentanyl-pediatric-drug-information/abstract-text/29740192/pubmed" id="29740192" target="_blank">29740192</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-8319480">
<a name="8319480"></a>Katz R, Kelly HW. Pharmacokinetics of continuous infusions of fentanyl in critically ill children. <i>Crit Care Med</i>. 1993;21(7):995-1000. doi:10.1097/00003246-199307000-00012<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/fentanyl-pediatric-drug-information/abstract-text/8319480/pubmed" id="8319480" target="_blank">8319480</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-8181283">
<a name="8181283"></a>Katz R, Kelly HW, Hsi A. Prospective Study on the Occurrence of Withdrawal in Critically Ill Children Who Receive Fentanyl by Continuous Infusion. <i>Crit Care Med. </i>1994;22(5):763-767.<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/fentanyl-pediatric-drug-information/abstract-text/8181283/pubmed" id="8181283" target="_blank">8181283</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-32214447">
<a name="32214447"></a>Kaushal S, Placencia JL, Maffei SR, Chumpitazi CE. Intranasal fentanyl use in neonates. <i>Hosp Pharm</i>. 2020;55(2):126-129. doi:10.1177/0018578719828335<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/fentanyl-pediatric-drug-information/abstract-text/32214447/pubmed" id="32214447" target="_blank">32214447</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-32925318">
<a name="32925318"></a>Khanna AK, Bergese SD, Jungquist CR, et al; PRediction of Opioid-induced respiratory Depression In patients monitored by capnoGraphY (PRODIGY) Group Collaborators. Prediction of opioid-induced respiratory depression on inpatient wards using continuous capnography and oximetry: An international prospective, observational trial. <i>Anesth Analg</i>. 2020;131(4):1012-1024. doi:10.1213/ANE.0000000000004788<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/fentanyl-pediatric-drug-information/abstract-text/32925318/pubmed" id="32925318" target="_blank">32925318</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-3954090">
<a name="3954090"></a>Koehntop DE, Rodman JH, Brundage DM, Hegland MG, Buckley JJ. Pharmacokinetics of fentanyl in neonates. <i>Anesth Analg</i>. 1986;65(3):227-232.<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/fentanyl-pediatric-drug-information/abstract-text/3954090/pubmed" id="3954090" target="_blank">3954090</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-27881247">
<a name="27881247"></a>Koncicki HM, Unruh M, Schell JO. Pain management in CKD: a guide for nephrology providers. <i>Am J Kidney Dis.</i> 2017;69(3):451-460. doi:10.1053/j.ajkd.2016.08.039<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/fentanyl-pediatric-drug-information/abstract-text/27881247/pubmed" id="27881247" target="_blank">27881247</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-11753984">
<a name="11753984"></a>Kornick CA, Santiago-Palma J, Khojainova N, Primavera LH, Payne R, Manfredi PL. A safe and effective method for converting cancer patients from intravenous to transdermal fentanyl. <i>Cancer</i>. 2001;92(12):3056-3061.<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/fentanyl-pediatric-drug-information/abstract-text/11753984/pubmed" id="11753984" target="_blank">11753984</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-30701615">
<a name="30701615"></a>Kosten TR, Baxter LE. Review article: Effective management of opioid withdrawal symptoms: A gateway to opioid dependence treatment. <i>Am J Addict</i>. 2019;28(2):55-62. doi:10.1111/ajad.12862<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/fentanyl-pediatric-drug-information/abstract-text/30701615/pubmed" id="30701615" target="_blank">30701615</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-16517277">
<a name="16517277"></a>Krauss B, Green SM. Procedural sedation and analgesia in children. <i>Lancet</i>. 2006;367(9512):766-780.<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/fentanyl-pediatric-drug-information/abstract-text/16517277/pubmed" id="16517277" target="_blank">16517277</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-30562908">
<a name="30562908"></a>Ku LC, Simmons C, Smith PB, et al. Intranasal midazolam and fentanyl for procedural sedation and analgesia in infants in the neonatal intensive care unit. <i>J Neonatal Perinatal Med</i>. 2019;12(2):143-148. doi:10.3233/NPM-17149<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/fentanyl-pediatric-drug-information/abstract-text/30562908/pubmed" id="30562908" target="_blank">30562908</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-20176672">
<a name="20176672"></a>Kumar P, Denson SE, Mancuso TJ. Clinical report – premedication for nonemergency endotracheal intubation in the neonate.<i> Pediatrics</i>. 2010;125:608-615.<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/fentanyl-pediatric-drug-information/abstract-text/20176672/pubmed" id="20176672" target="_blank">20176672</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-Lazanda.1">
<a name="Lazanda.1"></a>Lazanda (fentanyl) [prescribing information]. Northbrook, IL: West Therapeutic Development LLC; March 2021.</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-9262751">
<a name="9262751"></a>Lee HA, Anderson PO. Giving Partial Doses of Transdermal Patches. <i>Am J Health Syst Pharm.</i> 1997;54(15):1759-1760.<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/fentanyl-pediatric-drug-information/abstract-text/9262751/pubmed" id="9262751" target="_blank">9262751</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-Lemus.1">
<a name="Lemus.1"></a>Lemus-Varela ML, Villaseñor-Chávez DA, Gómez-Meda BC, Martínez-Ruezgas ME, Gallegos-Arreola MP, Torres-Mendoza BM. Efficacy and safety of multimodal analgesic therapy to prevent pain during screening for retinopathy of prematurity. <i>J Pediatr Neonatal</i>. 2022;4(2):1-6.</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-8487566">
<a name="8487566"></a>Leuschen MP, Willett LD, Hoie EB, et al. Plasma Fentanyl Levels in Infants Undergoing Extracorporeal Membrane Oxygenation. <i>J Thorac Cardiovasc Surg.</i> 1993;105(5):885-891.<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/fentanyl-pediatric-drug-information/abstract-text/8487566/pubmed" id="8487566" target="_blank">8487566</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-2350936">
<a name="2350936"></a>Leuschen MP, Wolf LJ, Rayburn WF. Fentanyl excretion in breast milk. <i>Clin Pharm</i>. 1990;9(5):336-337.<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/fentanyl-pediatric-drug-information/abstract-text/2350936/pubmed" id="2350936" target="_blank">2350936</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-12662124">
<a name="12662124"></a>Liu LL, Gropper MA. Postoperative Analgesia and Sedation in the Adult Intensive Care Unit. <i>Drugs.</i> 2003;63(8):755-767.<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/fentanyl-pediatric-drug-information/abstract-text/12662124/pubmed" id="12662124" target="_blank">12662124</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-26254837">
<a name="26254837"></a>López J, Botrán M, García A, et al. Constipation in the critically ill child: frequency and related factors. <i>J Pediatr</i>. 2015;167(4):857-861.e1. doi:10.1016/j.jpeds.2015.06.046<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/fentanyl-pediatric-drug-information/abstract-text/26254837/pubmed" id="26254837" target="_blank">26254837</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-34486466">
<a name="34486466"></a>Lugli L, Spada C, Garetti E, et al. Fentanyl analgesia in asphyxiated newborns treated with therapeutic hypothermia. <i>J Matern Fetal Neonatal Med</i>. 2022;35(25):7764-7770. doi:10.1080/14767058.2021.1937106<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/fentanyl-pediatric-drug-information/abstract-text/34486466/pubmed" id="34486466" target="_blank">34486466</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-Mandel.1">
<a name="Mandel.1"></a>Mandel L, Carunchio MJ. Rampant caries from oral transmucosal fentanyl citrate lozenge abuse. <i>J Am Dent Assoc.</i> 2011;142(4):406-409.</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-21606825">
<a name="21606825"></a>Manion SC, Brennan TJ. Thoracic epidural analgesia and acute pain management. <i>Anesthesiology</i>. 2011;115(1):181-188. doi: 10.1097/ALN.0b013e318220847c.<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/fentanyl-pediatric-drug-information/abstract-text/21606825/pubmed" id="21606825" target="_blank">21606825</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-29595994">
<a name="29595994"></a>Martin E, Vickers B, Landau R, Reece-Stremtan S. ABM clinical protocol #28, peripartum analgesia and anesthesia for the breastfeeding mother. <i>Breastfeed Med</i>. 2018;13(3):164-171.<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/fentanyl-pediatric-drug-information/abstract-text/29595994/pubmed" id="29595994" target="_blank">29595994</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-McClain.1">
<a name="McClain.1"></a>McClain CD, Soriano SG. Pediatric neurosurgical anesthesia. In: Coté CJ, Lerman J, Anderson B, eds. <i>A Practice of Anesthesia for Infants and Children</i>. 6th ed. Elsevier; 2019:chap. 26.</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-15153834">
<a name="15153834"></a>McMillan SC. Assessing and managing opiate-induced constipation in adults with cancer. <i>Cancer Control</i>. 2004;11(3 Suppl):3-9. doi:10.1177/10732748040110S302<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/fentanyl-pediatric-drug-information/abstract-text/15153834/pubmed" id="15153834" target="_blank">15153834</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-30842699">
<a name="30842699"></a>McNair C, Graydon B, Taddio A. A cohort study of intranasal fentanyl for procedural pain management in neonates. <i>Paediatr Child Health</i>. 2018;23(8):e170-e175. doi:10.1093/pch/pxy060<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/fentanyl-pediatric-drug-information/abstract-text/30842699/pubmed" id="30842699" target="_blank">30842699</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-McPherson.1">
<a name="McPherson.1"></a>McPherson ML. <i>Demystifying Conversion Calculations: A Guide for Effective Dosing.</i> 2nd ed. Bethesda, MD: American Society of Health-System Pharmacists; 2016.</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-35921640">
<a name="35921640"></a>Meek JY, Noble L; Section on Breastfeeding. Policy statement: breastfeeding and the use of human milk. <i>Pediatrics</i>. 2022;150(1):e2022057988. doi:10.1542/peds.2022-057988<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/fentanyl-pediatric-drug-information/abstract-text/35921640/pubmed" id="35921640" target="_blank">35921640</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-Miller.1">
<a name="Miller.1"></a>Miller RD. <i>Miller’s Anesthesia.</i> 7th ed, Philadelphia PA: Churchill Livingstone; 2010.</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-8703661">
<a name="8703661"></a>Miller RS, Peterson GM, Abbott F, Maddocks I, Parker D, McLean S. Plasma concentrations of fentanyl with subcutaneous infusion in palliative care patients. <i>Br J Clin Pharmacol</i>. 1995;40(6):553-556.<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/fentanyl-pediatric-drug-information/abstract-text/8703661/pubmed" id="8703661" target="_blank">8703661</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-32640456">
<a name="32640456"></a>Mitra S, Babadagli ME, Hatfield T, et al. Effect of fentanyl boluses on cerebral oxygenation and hemodynamics in preterm infants: a prospective observational study. <i>Neonatology</i>. 2020;117(4):480-487. doi:10.1159/000508555<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/fentanyl-pediatric-drug-information/abstract-text/32640456/pubmed" id="32640456" target="_blank">32640456</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-26701799">
<a name="26701799"></a>Moore A, el-Bahrawy A, Hatzakorzian R, Li-Pi-Shan W. Maternal epidural fentanyl administered for labor analgesia is found in neonatal urine 24 hours after birth. <i>Breastfeed Med</i>. 2016;11(1):40-41.<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/fentanyl-pediatric-drug-information/abstract-text/26701799/pubmed" id="26701799" target="_blank">26701799</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-28034973">
<a name="28034973"></a>Müller-Lissner S, Bassotti G, Coffin B, et al. Opioid-induced constipation and bowel dysfunction: A clinical guideline. <i>Pain Med</i>. 2017;18(10):1837-1863. doi:10.1093/pm/pnw255<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/fentanyl-pediatric-drug-information/abstract-text/28034973/pubmed" id="28034973" target="_blank">28034973</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-16898102">
<a name="16898102"></a>Murtagh FE, Addington-Hall JM, Donohoe P, Higginson IJ. Symptom management in patients with established renal failure managed without dialysis. <i>EDTNA ERCA J</i>. 2006;32(2):93-98. doi:10.1111/j.1755-6686.2006.tb00459.x<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/fentanyl-pediatric-drug-information/abstract-text/16898102/pubmed" id="16898102" target="_blank">16898102</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-35558346">
<a name="35558346"></a>Naveed M, Bondi DS, Shah PA. Dexmedetomidine versus fentanyl for neonates with hypoxic ischemic encephalopathy undergoing therapeutic hypothermia. <i>J Pediatr Pharmacol Ther</i>. 2022;27(4):352-357. doi:10.5863/1551-6776-27.4.352<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/fentanyl-pediatric-drug-information/abstract-text/35558346/pubmed" id="35558346" target="_blank">35558346</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-31740092">
<a name="31740092"></a>Nazemian N, Torabi M, Mirzaee M. Atomized intranasal vs intravenous fentanyl in severe renal colic pain management: a randomized single-blinded clinical trial. <i>Am J Emerg Med</i>. 2020;38(8):1635-1640. doi:10.1016/j.ajem.2019.158483<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/fentanyl-pediatric-drug-information/abstract-text/31740092/pubmed" id="31740092" target="_blank">31740092</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-26136838">
<a name="26136838"></a>Nelson AD, Camilleri M. Chronic opioid induced constipation in patients with nonmalignant pain: challenges and opportunities. <i>Therap Adv Gastroenterol</i>. 2015;8(4):206-220. doi:10.1177/1756283X15578608<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/fentanyl-pediatric-drug-information/abstract-text/26136838/pubmed" id="26136838" target="_blank">26136838</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-Nelson.1">
<a name="Nelson.1"></a>Nelson WE, Behrman RE, Kliegman RM, et al, eds. <i>Nelson Textbook of Pediatrics</i>. 15th ed. WB Saunders Company; 1996: 2058-2078.</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-Nemecek.1">
<a name="Nemecek.1"></a>Nemecek BD, Hammond DA. <i>Demystifying drug dosing in renal dysfunction</i>. American Society of Health-System Pharmacists; 2019.</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-25950621">
<a name="25950621"></a>Nightingale CE, Margarson MP, Shearer E, et al; Association of Anaesthetists of Great Britain; Ireland Society for Obesity and Bariatric Anaesthesia. Peri-operative management of the obese surgical patient 2015: Association of Anaesthetists of Great Britain and Ireland Society for Obesity and Bariatric Anaesthesia. <i>Anaesthesia</i>. 2015;70(7):859-876. doi:10.1111/anae.13101<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/fentanyl-pediatric-drug-information/abstract-text/25950621/pubmed" id="25950621" target="_blank">25950621</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-20041843">
<a name="20041843"></a>Niscola P, Scaramucci L, Vischini G, et al. The use of major analgesics in patients with renal dysfunction. <i>Curr Drug Targets</i>. 2010;11(6):752-758. doi:10.2174/138945010791170879<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/fentanyl-pediatric-drug-information/abstract-text/20041843/pubmed" id="20041843" target="_blank">20041843</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-16765143">
<a name="16765143"></a>Nitsun M, Szokol JW, Saleh HJ, et al. Pharmacokinetics of midazolam, propofol, and fentanyl transfer to human breast milk. <i>Clin Pharmacol Ther</i>. 2006;79(6):549-557.<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/fentanyl-pediatric-drug-information/abstract-text/16765143/pubmed" id="16765143" target="_blank">16765143</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-30721546">
<a name="30721546"></a>Norman E, Kindblom JM, Rane A, et al. Individual variations in fentanyl pharmacokinetics and pharmacodynamics in preterm infants. <i>Acta Paediatr</i>. 2019;108(8):1441-1446. doi:10.1111/apa.14744<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/fentanyl-pediatric-drug-information/abstract-text/30721546/pubmed" id="30721546" target="_blank">30721546</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-30186671">
<a name="30186671"></a>O'Mara K, Weiss MD. Dexmedetomidine for sedation of neonates with HIE undergoing therapeutic hypothermia: a single-center experience. <i>AJP Rep</i>. 2018;8(3):e168-e173.<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/fentanyl-pediatric-drug-information/abstract-text/30186671/pubmed" id="30186671" target="_blank">30186671</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-26762381">
<a name="26762381"></a>Oosten AW, Abrantes JA, Jönsson S, et al. Treatment with subcutaneous and transdermal fentanyl: results from a population pharmacokinetic study in cancer patients. <i>Eur J Clin Pharmacol</i>. 2016;72(4):459-467. doi: 10.1007/s00228-015-2005-x.<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/fentanyl-pediatric-drug-information/abstract-text/26762381/pubmed" id="26762381" target="_blank">26762381</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-8628593">
<a name="8628593"></a>Paix A, Coleman A, Lees J, et al. Subcutaneous fentanyl and sufentanil infusion substitution for morphine intolerance in cancer pain management. <i>Pain</i>. 1995;63(2):263-269. doi: 10.1016/0304-3959(95)00084-6.<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/fentanyl-pediatric-drug-information/abstract-text/8628593/pubmed" id="8628593" target="_blank">8628593</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-Pandharipande.2019">
<a name="Pandharipande.2019"></a>Pandharipande P, McGrane S. Pain control in the critically ill adult patient. Post TW, ed. UpToDate. Waltham, MA: UpToDate Inc. <a href="http://www.uptodate.com" target="_blank">http://www.uptodate.com</a>. Accessed February 13, 2023.</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-9553237">
<a name="9553237"></a>Pang WW, Huang S, Chung YT, et al. Comparison of Intravenous Retention of Fentanyl and Lidocaine on Local Analgesia in Propofol Injection Pain. <i>Acta Anaesthesiol Sin.</i> 1997;35(4):217-221.<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/fentanyl-pediatric-drug-information/abstract-text/9553237/pubmed" id="9553237" target="_blank">9553237</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-33106341">
<a name="33106341"></a>Patrick SW, Barfield WD, Poindexter BB; Committee on Fetus and Newborn; Committee on Substance Use and Prevention. Neonatal opioid withdrawal syndrome. <i>Pediatrics</i>. 2020;146(5):e2020029074. doi:10.1542/peds.2020-029074<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/fentanyl-pediatric-drug-information/abstract-text/33106341/pubmed" id="33106341" target="_blank">33106341</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-9952166">
<a name="9952166"></a>Peng PW, Sandler AN. A review of the use of fentanyl analgesia in the management of acute pain in adults. <i>Anesthesiology</i>. 1999;90(2):576-599.<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/fentanyl-pediatric-drug-information/abstract-text/9952166/pubmed" id="9952166" target="_blank">9952166</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-Portenoy.2">
<a name="Portenoy.2"></a>Portenoy RK, Broglio K. Approximate dose conversions for commonly used opioids. Post TW, ed. UpToDate. Waltham, MA: UpToDate Inc. <a href="http://www.uptodate.com" target="_blank">http://www.uptodate.com</a>. Accessed July 15, 2019a.</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-Portenoy.1">
<a name="Portenoy.1"></a>Portenoy RK, Mehta Z, Ahmed E. Cancer pain management with opioids: Optimizing analgesia. Post TW, ed. UpToDate. Waltham, MA: UpToDate Inc. <a href="http://www.uptodate.com" target="_blank">http://www.uptodate.com</a>. Accessed May 12, 2023.</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-32925317">
<a name="32925317"></a>Prielipp RC, Fulesdi B, Brull SJ. Postoperative opioid-induced respiratory depression: 3 steps forward. <i>Anesth Analg</i>. 2020;131(4):1007-1011. doi:10.1213/ANE.0000000000005098<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/fentanyl-pediatric-drug-information/abstract-text/32925317/pubmed" id="32925317" target="_blank">32925317</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-30045355">
<a name="30045355"></a>Quinn K, Kriss S, Drapkin J, et al. Analgesic efficacy of intranasal ketamine versus intranasal fentanyl for moderate to severe pain in children: a prospective, randomized, double-blind study. <i>Pediatr Emerg Care</i>. 2021;37(5):250-254. doi:10.1097/PEC.0000000000001556<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/fentanyl-pediatric-drug-information/abstract-text/30045355/pubmed" id="30045355" target="_blank">30045355</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-31552205">
<a name="31552205"></a>Raffaeli G, Pokorna P, Allegaert K, et al. Drug disposition and pharmacotherapy in neonatal ECMO: from fragmented data to integrated knowledge. <i>Front Pediatr</i>. 2019;7:360. doi:10.3389/fped.2019.00360<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/fentanyl-pediatric-drug-information/abstract-text/31552205/pubmed" id="31552205" target="_blank">31552205</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-29624435">
<a name="29624435"></a>Reece-Stremtan S, Campos M, Kokajko L; Academy of Breastfeeding Medicine. ABM clinical protocol #15: analgesia and anesthesia for the breastfeeding mother, revised 2017. <i>Breastfeed Med</i>. 2017;12(9):500-506.<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/fentanyl-pediatric-drug-information/abstract-text/29624435/pubmed" id="29624435" target="_blank">29624435</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-manu.1">
<a name="manu.1"></a>Refer to US manufacturer's labeling.</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-manu.2">
<a name="manu.2"></a>Refer to Canadian manufacturer's labeling.</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-28926159">
<a name="28926159"></a>Reynolds SL, Bryant KK, Studnek JR, et al. Randomized controlled feasibility trial of intranasal ketamine compared to intranasal fentanyl for analgesia in children with suspected extremity fractures. <i>Acad Emerg Med</i>. 2017;24(12):1430-1440. doi:10.1111/acem.13313<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/fentanyl-pediatric-drug-information/abstract-text/28926159/pubmed" id="28926159" target="_blank">28926159</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-Roberts.2019">
<a name="Roberts.2019"></a>Roberts JR, ed. <i>Roberts and Hedges' Clinical Procedures in Emergency Medicine and Acute Care</i>. 7th ed. Elsevier; 2019.</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-Rosero.2019">
<a name="Rosero.2019"></a>Rosero EB. Monitored anesthesia care in adults. Post TW, ed. UpToDate. Waltham, MA: UpToDate Inc. <a href="http://www.uptodate.com" target="_blank">http://www.uptodate.com</a>. Accessed September 21, 2020.</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-30778756">
<a name="30778756"></a>Rossi M, Casale G, Badiali D, et al. Opioid-induced bowel dysfunction: suggestions from a multidisciplinary expert Board. <i>Support Care Cancer</i>. 2019;27(11):4083-4090. doi:10.1007/s00520-019-04688-2<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/fentanyl-pediatric-drug-information/abstract-text/30778756/pubmed" id="30778756" target="_blank">30778756</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-1841826">
<a name="1841826"></a>Roth B, Schlunder C, Houben F, et al. Analgesia and Sedation in Neonatal Intensive Care Using Fentanyl by Continuous Infusion. <i>Dev Pharmacol Ther</i>. 1991;17(3-4):121-127.<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/fentanyl-pediatric-drug-information/abstract-text/1841826/pubmed" id="1841826" target="_blank">1841826</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-23979084">
<a name="23979084"></a>Sachs HC, Committee On Drugs. The transfer of drugs and therapeutics into human breast milk: an update on selected topics. <i>Pediatrics</i>. 2013;132(3):e796-e809.<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/fentanyl-pediatric-drug-information/abstract-text/23979084/pubmed" id="23979084" target="_blank">23979084</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-1952204">
<a name="1952204"></a>Salomäki TE, Laitinen JO, Nuutinen LS. A randomized double-blind comparison of epidural versus intravenous fentanyl infusion for analgesia after thoracotomy. <i>Anesthesiology</i>. 1991;75(5):790-795.<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/fentanyl-pediatric-drug-information/abstract-text/1952204/pubmed" id="1952204" target="_blank">1952204</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-21175512">
<a name="21175512"></a>Saunders M, Adelgais K, Nelson D. Use of Intranasal Fentanyl for the Relief of Pediatric Orthopedic Trauma Pain. <i>Acad Emerg Med</i>. 2010;17(11):1155-1161.<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/fentanyl-pediatric-drug-information/abstract-text/21175512/pubmed" id="21175512" target="_blank">21175512</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-7862469">
<a name="7862469"></a>Schechter NL, Weisman SJ, Rosenblum M, et al. The Use of Oral Transmucosal Fentanyl Citrate for Painful Procedures in Children. <i>Pediatrics</i>. 1995;95(3):335-339.<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/fentanyl-pediatric-drug-information/abstract-text/7862469/pubmed" id="7862469" target="_blank">7862469</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-18252923">
<a name="18252923"></a>Sessler CN, Varney K. Patient-Focused Sedation and Analgesia in the ICU. <i>Chest.</i> 2008;133(2):552-565.<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/fentanyl-pediatric-drug-information/abstract-text/18252923/pubmed" id="18252923" target="_blank">18252923</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-Sevarino.2019">
<a name="Sevarino.2019"></a>Sevarino KA. Opioid withdrawal in adults: clinical manifestations, course, assessment, and diagnosis. Post TW, ed. UpToDate. Waltham, MA: UpToDate Inc. <a href="http://www.uptodate.com" target="_blank">http://www.uptodate.com</a>. Accessed July 16, 2019.</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-19188870">
<a name="19188870"></a>Shehab N, Lewis CL, Streetman DD, Donn SM. Exposure to the pharmaceutical excipients benzyl alcohol and propylene glycol among critically ill neonates. <i>Pediatr Crit Care Med</i>. 2009;10(2):256-259.<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/fentanyl-pediatric-drug-information/abstract-text/19188870/pubmed" id="19188870" target="_blank">19188870</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-31871244">
<a name="31871244"></a>Shenoi RP, Timm N; Committee on Drugs; Committee on Pediatric Emergency Medicine. Drugs used to treat pediatric emergencies. <i>Pediatrics</i>. 2020;145(1):e20193450. doi:10.1542/peds.2019-3450<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/fentanyl-pediatric-drug-information/abstract-text/31871244/pubmed" id="31871244" target="_blank">31871244</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-15329584">
<a name="15329584"></a>Shibutani K, Inchiosa MA Jr, Sawada K, Bairamian M. Accuracy of pharmacokinetic models for predicting plasma fentanyl concentrations in lean and obese surgical patients: derivation of dosing weight ("pharmacokinetic mass"). <i>Anesthesiology</i>. 2004;101(3):603-613. doi:10.1097/00000542-200409000-00008<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/fentanyl-pediatric-drug-information/abstract-text/15329584/pubmed" id="15329584" target="_blank">15329584</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-16024584">
<a name="16024584"></a>Shibutani K, Inchiosa MA Jr, Sawada K, Bairamian M. Pharmacokinetic mass of fentanyl for postoperative analgesia in lean and obese patients. <i>Br J Anaesth</i>. 2005;95(3):377-383. doi:10.1093/bja/aei195<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/fentanyl-pediatric-drug-information/abstract-text/16024584/pubmed" id="16024584" target="_blank">16024584</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-32054982">
<a name="32054982"></a>Sindhur M, Balasubramanian H, Srinivasan L, Kabra NS, Agashe P, Doshi A. Intranasal fentanyl for pain management during screening for retinopathy of prematurity in preterm infants: a randomized controlled trial. <i>J Perinatol</i>. 2020;40(6):881-887. doi:10.1038/s41372-020-0608-2<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/fentanyl-pediatric-drug-information/abstract-text/32054982/pubmed" id="32054982" target="_blank">32054982</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-15537367">
<a name="15537367"></a>Skaer TL. Practice guidelines for transdermal opioids in malignant pain. <i>Drugs</i>. 2004;64(23):2629-2638.<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/fentanyl-pediatric-drug-information/abstract-text/15537367/pubmed" id="15537367" target="_blank">15537367</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-35119438">
<a name="35119438"></a>Smith HAB, Besunder JB, Betters KA, et al. 2022 Society of Critical Care Medicine clinical practice guidelines on prevention and management of pain, agitation, neuromuscular blockade, and delirium in critically ill pediatric patients with consideration of the ICU environment and early mobility. <i>Pediatr Crit Care Med</i>. 2022;23(2):e74-e110. doi:10.1097/PCC.0000000000002873<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/fentanyl-pediatric-drug-information/abstract-text/35119438/pubmed" id="35119438" target="_blank">35119438</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-35231912">
<a name="35231912"></a>Snyers D, Tribolet S, Rigo V. Intranasal analgosedation for infants in the neonatal intensive care unit: a systematic review. <i>Neonatology</i>. 2022;119(3):273-284. doi:10.1159/000521949<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/fentanyl-pediatric-drug-information/abstract-text/35231912/pubmed" id="35231912" target="_blank">35231912</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-10937472">
<a name="10937472"></a>Spigset O, Hagg S. Analgesics and Breast-feeding: Safety Considerations. <i>Paediatr Drugs</i>. 2000;2(3):223-238.<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/fentanyl-pediatric-drug-information/abstract-text/10937472/pubmed" id="10937472" target="_blank">10937472</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-1551153">
<a name="1551153"></a>Steer PL, Biddle CJ, Marley WS, Lantz RK, Sulik PL. Concentration of fentanyl in colostrum after an analgesic dose. <i>Can J Anaesth</i>. 1992;39(3):231-235.<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/fentanyl-pediatric-drug-information/abstract-text/1551153/pubmed" id="1551153" target="_blank">1551153</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-24259635">
<a name="24259635"></a>Stollings JL, Diedrich DA, Oyen LJ, Brown DR. Rapid-sequence intubation: a review of the process and considerations when choosing medications. <i>Ann Pharmacother</i>. 2014;48(1):62-76. doi:10.1177/1060028013510488<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/fentanyl-pediatric-drug-information/abstract-text/24259635/pubmed" id="24259635" target="_blank">24259635</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-Sublimaze.1">
<a name="Sublimaze.1"></a>Sublimaze [package insert]. Lake Forest, IL; Akorn: January 2012.</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-Subsys.1">
<a name="Subsys.1"></a>Subsys (fentanyl) [prescribing information]. Lakewood, NJ: Renaissance Lakewood LLC; April 2021.</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-17087429">
<a name="17087429"></a>Swegle JM, Logemann C. Management of common opioid-induced adverse effects. <i>Am Fam Physician</i>. 2006;74(8):1347-1354.<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/fentanyl-pediatric-drug-information/abstract-text/17087429/pubmed" id="17087429" target="_blank">17087429</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-30275061">
<a name="30275061"></a>Tucker C, Tucker L, Brown K. The intranasal route as an alternative method of medication administration.<i> Crit Care Nurse</i>. 2018;38(5):26-31. doi:10.4037/ccn2018836<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/fentanyl-pediatric-drug-information/abstract-text/30275061/pubmed" id="30275061" target="_blank">30275061</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-FDA.1">
<a name="FDA.1"></a>US Food and Drug Administration (FDA). FDA drug safety communication: FDA updates prescribing information for all opioid pain medicines to provide additional guidance for safe use. <a href="https://www.fda.gov/drugs/drug-safety-and-availability/fda-updates-prescribing-information-all-opioid-pain-medicines-provide-additional-guidance-safe-use" target="_blank">https://www.fda.gov/drugs/drug-safety-and-availability/fda-updates-prescribing-information-all-opioid-pain-medicines-provide-additional-guidance-safe-use</a>. Published April 13, 2023. Accessed April 17, 2023.</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-20097932">
<a name="20097932"></a>Van Nimmen NF, Poels KL, Menten JJ, et al. Fentanyl transdermal absorption linked to pharmacokinetic characteristics in patients undergoing palliative care. <i>J Clin Pharmacol.</i> 2010;50(6):667-678. doi:10.1177/0091270009347872<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/fentanyl-pediatric-drug-information/abstract-text/20097932/pubmed" id="20097932" target="_blank">20097932</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-31589332">
<a name="31589332"></a>Varga AG, Reid BT, Kieffer BL, Levitt ES. Differential impact of two critical respiratory centres in opioid-induced respiratory depression in awake mice. <i>J Physiol</i>. 2020;598(1):189-205. doi:10.1113/JP278612<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/fentanyl-pediatric-drug-information/abstract-text/31589332/pubmed" id="31589332" target="_blank">31589332</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-30855724">
<a name="30855724"></a>Velázquez Rivera I, Velázquez Clavarana L, García Velasco P, Melero Ramos C. Opioid-induced constipation in chronic pain: Experience with 180 patients. <i>J Opioid Manag</i>. 2019;15(1):69-76. doi:10.5055/jom.2019.0487<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/fentanyl-pediatric-drug-information/abstract-text/30855724/pubmed" id="30855724" target="_blank">30855724</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-VON.1">
<a name="VON.1"></a>Vermont Oxford Network (VON). Neonatal drug concentrations. https://public.vtoxford.org/wp-content/uploads/2022/11/Neonatal-Drug-Concentrations-Updated-November-2022.pdf. Updated November 2022. Accessed August 15, 2023.</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-31498775">
<a name="31498775"></a>Völler S, Flint RB, Andriessen P, et al. Rapidly maturing fentanyl clearance in preterm neonates. <i>Arch Dis Child Fetal Neonatal Ed</i>. 2019;104(6):F598-F603. doi:10.1136/archdischild-2018-315920<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/fentanyl-pediatric-drug-information/abstract-text/31498775/pubmed" id="31498775" target="_blank">31498775</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-Walker.1">
<a name="Walker.1"></a>Walker BJ, Polaner DM, Berde CB. Acute pain. In: Coté CJ, Lerman J, Anderson B, eds. <i>A Practice of Anesthesia for Infants and Children</i>. 6th ed. Elsevier; 2019:chap. 44.</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-28866754">
<a name="28866754"></a>Wang PP, Huang E, Feng X, et al. Opioid-associated iatrogenic withdrawal in critically ill adult patients: a multicenter prospective observational study. <i>Ann Intensive Care</i>. 2017;7(1):88. doi:10.1186/s13613-017-0310-5<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/fentanyl-pediatric-drug-information/abstract-text/28866754/pubmed" id="28866754" target="_blank">28866754</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-WHO.1">
<a name="WHO.1"></a>World Health Organization (WHO). Breastfeeding and maternal medication, recommendations for drugs in the Eleventh WHO Model List of Essential Drugs. 2002. https://apps.who.int/iris/handle/10665/62435.</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-23720867">
<a name="23720867"></a>World Health Organization (WHO). <i>WHO guidelines on the pharmacological treatment of persisting pain in children with medical illnesses</i>. 2012.<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/fentanyl-pediatric-drug-information/abstract-text/23720867/pubmed" id="23720867" target="_blank">23720867</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-34773609">
<a name="34773609"></a>Wu Y, Völler S, Flint RB, et al. Pre- and postnatal maturation are important for fentanyl exposure in preterm and term newborns: a pooled population pharmacokinetic study. <i>Clin Pharmacokinet</i>. 2022;61(3):401-412. doi:10.1007/s40262-021-01076-0<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/fentanyl-pediatric-drug-information/abstract-text/34773609/pubmed" id="34773609" target="_blank">34773609</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-21903538">
<a name="21903538"></a>Wynn RL The sugar-loaded fentanyl lollipop (Actiq) and the risk of tooth decay. <i>Gen Den.</i> 2011;59(3):168-170.<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/fentanyl-pediatric-drug-information/abstract-text/21903538/pubmed" id="21903538" target="_blank">21903538</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-2216645">
<a name="2216645"></a>Zeltzer LK, Altman A, Cohen D, et al. Report of the Subcommittee on the Management of Pain Associated With Procedures in Children With Cancer. <i>Pediatrics</i>. 1990;86(5, pt 2):826-831.<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/fentanyl-pediatric-drug-information/abstract-text/2216645/pubmed" id="2216645" target="_blank">2216645</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-Zeltzer.2020">
<a name="Zeltzer.2020"></a>Zeltzer LK, Krane EJ, Levy RL. Pediatric pain management. In: Kliegman RM, St. Geme J, eds. <i>Nelson Textbook of Pediatrics</i>. 21st ed. Elsevier; 2020:chap. 76.</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-33214778">
<a name="33214778"></a>Zimmerman KO, Dallefeld SH, Hornik CP, Watt KM. Sedative and analgesic pharmacokinetics during pediatric ECMO. <i>J Pediatr Pharmacol Ther</i>. 2020;25(8):675-688. doi:10.5863/1551-6776-25.8.675<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/fentanyl-pediatric-drug-information/abstract-text/33214778/pubmed" id="33214778" target="_blank">33214778</a>]</span>
</div>
</li></ol></div><div id="topicVersionRevision">Topic 13298 Version 634.0</div></div>
</div>
</div>

</section>

</section>
<!-- End Main Menu Area -->
<!-- Start Search Popup Area -->


<!-- End Footer Area -->
<!-- Back to top -->

<a class="scrolltop" href="#top"><i class="icofont-hand-drawn-up"></i></a>
<!-- End Back to top -->
<!-- jQuery Min JS -->

<!-- Prpper JS -->

<!-- Bootstrap Min JS -->

<!-- Classy Nav Min Js -->

<!-- Owl Carousel Min Js -->

<!-- Magnific Popup JS -->

<!-- CounterUp JS -->

<!-- Waypoints JS -->

<!-- Form Validator Min JS -->

<!-- Contact Form Min JS -->

<!-- Main JS -->

<!-- Global site tag (gtag.js) - Google Analytics -->






</body>
</html>
